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Chapter 1
General introduction

The largest organ of the human body is the 
skin, which main function is to serve as a barrier. 
This barrier function plays a role in protection 
against pathogenic exogenous factors (e.g. invading 
micro-organisms and radiation) and in homeostasis 
of endogenous processes (e.g. water and tempera­
ture retention).
The skin exists of two layers: epidermis and 
dermis (Figure 1). The epidermis consists mainly of 
upward differentiating keratinocytes finally
NORMAL SKIN AN D  THE MELANOCYTE forming and constantly renewing the stratum 
corneum. Other cell types present in the epidermis 
are Langerhans cells (4%), melanocytes (3%), and 
Merkel cells (<1%). A  basement membrane sepa­
rates the epidermal from the dermal layer. This 
basement membrane is responsible for the 
epidermal-dermal attachment and serves as a 
macro-molecular filter. The dermis is less rich in 
cells compared to the epidermis and consists 
mainly of collagen fibers, produced by fibroblasts, 
and small blood and lymph vessels. It also contains 
the cutaneous adnexa (e.g. hair follicles, sweat
Langerhans cell
Keratinocyte
Melanocyte
Elastic fiber
PAPILLARY
DERMIS
RETICULAR
DERMIS
SUBCUTIS
Artery
Figure 1.
Sim plified microscopical anatomy of 
the normal skin (adapted from [1])
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glands). Beneath the dermis lies a layer of fatty 
tissue.
The melanocyte, a dendritic cell of neuroecto­
dermal origin, is present in the basal layer of the 
epidermis. Melanocytes are responsible for skin 
color and UV-protection. Each melanocyte supplies 
about 36 keratinocytes with melanin pigment by 
transporting melanosomes via its dendrites.
Melanosomes are unique lysosome-related 
organelles that synthesize and store melanin 
pigment. Melanin, either the black eumelanin or 
the brown/red pheomelanin, is formed from 
modified and polymerised tyrosines [2]. This 
pigment absorbs invading light and protects the 
(DN A  of) keratinocytes against the mutagenic 
effects of UV-radiation.
M EL A N O M A  
Facts, classification and staging
Malignant neoplasia of the pigment producing 
melanocyte in the skin are called cutaneous 
melanomas. The incidence of melanoma is 
increasing steadily. In Western Europe 80 per 
1.000.000 people annually are diagnosed for this 
aggressive type of skin cancer, accounting for about 
3 percent of all new cancer cases [3]. Since 
melanomas are earlier detected than in the past the
Table I.
C lark's classification of human cutaneous melanoma
Clark level Extension of the tumor
mortality is not rising as fast as the incidence. 
Compared to other types of cancer melanoma 
affects a much younger population [4]. The etiopa- 
thogenesis of melanoma is related to UV-radiation 
(excessive sun exposure and childhood sunburns) 
and is most common in people with fair skin, light 
hair and large number of atypical nevi. Another 
risk factor is a family history of melanoma. Though 
about 10% of melanomas are familial, this does not 
imply direct heredity [5]. One of the settings in 
which familial melanoma occurs is the Dysplastic 
Nevus Syndrome (DNS) [4].
The therapy of choice for melanoma is surgical 
removal of the primary tumor. Once a melanoma 
has spread beyond the skin treatment is difficult 
and mortality rates steeply increase. Next to skin 
and lymph node, the most common sites for 
metastatic spreading of melanoma are lung, liver, 
brain, bone and small intestine [4]. Tumor thick­
ness, measured as Breslow thickness [6,7], is the 
most important prognostic factor. Presence of 
ulceration and number of mitotic figures are also 
important prognosticators.
Human cutaneous melanoma can be divided 
into four major types:
- Superficial spreading melanoma (70% of cases): 
usually flat and irregular in shape and color and 
can occur at any site. However in males they are
I confined to the epidermis
II invading the papillary layer, but not extending to the reticular layer
III filling and expanding the papillary layer, not invading the reticular layer
IV  penetrating into the reticular layer
V  invading the hypodermic fat
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most often found at the back, while the highest 
frequency in females is observed at the lower 
extremities.
Nodular melanoma (20%): starts usually as a 
raised lesion and can lack color.
Lentigo maligna melanoma (5%): usually large 
and flat and most frequent in the elderly.
Acral lentigineous melanoma (5%): occurs at the 
hands and feet.
Almost parallel with the Breslow thickness
another classification system for cutaneous mela­
noma was introduced based on the level of 
invasion into the dermis [8,9]. This classification 
according to Clark levels is divided into five stages 
(Table I).
Since 1988 the most widely used staging 
system for cutaneous melanoma is that proposed 
by the American Joint Committee on Cancer 
(AJCC). This system, several times modified, makes 
use of a TN M  staging whereby the T stages at first
Table II.
A JC C  T N M  classification for human cutaneous melanoma
T classification Thickness Ulceration status
T1 < 1 mm a: without ulceration 
b: with ulceration
T2 1-2 mm a: without ulceration 
b: with ulceration
T3 2-4 mm a: without ulceration 
b: with ulceration
T4 > 4 mm a: without ulceration 
b: with ulceration
N  classification No. of metastatic nodes Nodal metastatic mass
N1 1 a: micro metastases 
b: macro metastases
N2 2-3 a: micro metastases 
b: macro metastases 
c: in-transit or satellite
N3 > 4
M  classification Site of metastasis Serum lactate dehydrogenase
M1 Skin Normal
M2 Lung Normal
M3 Other visceral sites Normal
Any distant metastasis Elevated
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were mainly based on Breslow thickness and Clark 
level [10,11]. Based on more recent insights, novel 
techniques and retrospective evaluations several 
critical reports have been published which implica­
tions have led to the release of a revised TNM  
classification system for cutaneous melanoma by 
the A JCC (Table II) [11-15]. This classification 
reflects and focusses upon a limited number of 
independent significant prognostic factors like 
primary tumor thickness, ulceration, number of 
tumor-containing lymph nodes, micrometastatic 
disease based upon sentinel lymph node mapping, 
site of metastasis and serum level of lactate 
dehydrogenase (LDH). The Clark level of invasion 
was replaced by the tumor thickness as best 
prognostic variable in predicting survival. Previous 
reports already indicated that the Breslow 
thickness was a more reproducible and reliable 
prognostic factor compared to the Clark level 
[6,16].
As an alternative for the previous classification 
based on Breslow thickness and Clark level, they 
also propose a pathological staging of the primary 
melanoma making use of the TNM  classification 
(Table III).
This newly introduced system better reflects 
the prognostic factors of clinical outcome and is 
easier in use, probably leading to a better repro­
ducibility [17]. However, we should realize that 
future developments and molecular insights will 
surely lead to adjustments. A  major contribution 
can be expected from profiling of melanoma stages 
based on their molecular fingerprint [18].
Melanocytic tumor progression
Progression of human cutaneous melanoma 
passes through several sequential stages, which 
have been defined based on clinical and pathologic 
observations [9]. To surpass all these stages 
melanocytic cells acquire several switch point
Table I II .
A JC C  pathological staging for human cutaneous melanoma. 1 melanoma in situ
Stage T classification N  classification M  classification
0 Tis 1 N0 M0
IA T1a N0 M0
IB T1b-2a N0 M0
IIA T2b-3a N0 M0
IIB T3b-4a N0 M0
IIC T4b N0 M0
IIIA T1-4a N1a or N2a M0
IIIB T1-4a N1b or N2b M0
T1-4b N1a or N2a M0
T1-4b N2c M0
IIIC T1-4b N1b or N2b M0
Any T N3 M0
IV Any T Any N Any M1
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PROGRESSION STAGE BIOLOGICAL KEY FEATURE
melanocyte
common nevus
atypical nevus
primary melanoma RGP
primary melanoma VGP
melanoma metastasis
induction of proliferation 
genomic instability 
uncontrolled proliferation 
invasive potential
distant outgrowth
Figure 2.
Sequential stages of melanoma 
progression and corresponding 
biological features
features representing biological alterations (Figure 
2) [19].
In Figure 3 these stages of progression are 
shown in a cartoon, including the steps required 
for successful spreading to and outgrowth at 
distant sites [20]. Induction of proliferation by a 
certain factor (e.g. UV-radiation) can cause melano­
cytes to form common acquired nevi. By genetic 
instability these nevus cells sometimes may escape 
from their normal differentiation pathway (Figure 
3A). Via alternative differentiation pathways 
proliferation of these melanocytes can result in 
benign lesions showing melanocytic dysplasia. 
These so-called atypical nevi are considered to be 
the precursor lesion of cutaneous melanoma [5].
The majority of melanocytic nevi are terminal 
lesions that do not progress further. However, 
based upon additional genetic damage, some can 
switch to a state of uncontrolled proliferation and 
become a melanoma. A t first these primary mela­
nomas exhibit a radial (or horizontal) growth phase 
(RGP), whereby they grow in the epidermis (Figure 
3B), but also can pass the basement membrane 
(Figure 3C) and extend in the papillary dermis 
(Figure 3D).
From here the so called vertical growth phase
(VGP) starts, which heralds metastatic potential. 
These cells subsequently invade into the reticular 
dermis (Figure 3E). V G P  cells often form a new 
population within the melanoma rather than an 
expansion of the cells from the pre-existing RGP. 
When these invasive cells reach and enter a blood 
or lymph vessel they are able to spread throughout 
the body (Figure 3F).
Having successfully invaded the dermal 
stroma some cells may reach the lymphatic or 
blood vessels. Of these cells only very few are 
finally able to complete the highly selective 
multistep process of metastasis and form distant 
metastases [20]. The first step of metastasis is the 
entrance of a vessel, whereby a cell must break 
though and pass the vessel-wall (Figure 3G). Once 
detached from the inside of that vessel-wall the 
tumor cells are in the circulation. Here the vast 
majority is rapidly destroyed by the unfavorable 
mechanical, chemical and cellular microenviron­
ment to which they are subjected (Figure 3H). 
Having survived the bloodstream some are able to 
attach to the vessel-wall, thereby 'homing' to the 
site of metastasis (Figure 3I).
The preferential site of metastatic outgrowth is 
determined by specific properties of both the
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A B C D E F
G H
Figure 3.
Progression from melanocyte to melanoma metastasis
I J
spreading tumor cell and the host tissue [21]. 
Alternatively, tumor cells can aggregate and form 
tumor emboli. These clumps of tumor cells can be 
trapped by physical arrest in certain capillaries. 
Additional advantage for the formation of emboli 
is that the tumor cells in the center of the aggregate 
are better protected from harmful environmental 
factors [22]. Once arrested real metastatic tumor 
cells need to again break and pass the vessel-wall 
(Figure 3J) and invade the distant tissue stroma 
(Figure 3K). Under the right stroma-tumor environ­
ment [23] and interactions the melanoma cell
finally might be able to expand at the metastatic 
site (Figure 3L).
O R IG IN  A N D  R EG U LA T IO N  OF 
D IFFER EN T IA L  G EN E  EX PR ESS IO N
In order to successfully evolve through all the 
stages of progression and finally metastasize tumor 
cells need to acquire a number of essential 
properties. These so-called hallmarks of cancer, 
excellently reviewed by Hanahan and Weinberg 
[24], are:
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1: self-sufficiency in growth signals 
This allows cell proliferation in the absence of 
growth stimulatory signal and can be induced by 
oncogene activation (e.g. Ras T).
2: insensitivity to antigrowth stimuli 
Escape from signals that regulate tissue 
homeostasis is achieved in many cancers by loss 
of tumor suppressor function (e.g. pRb i) .
3: evasion of apoptosis 
Overruling programmed cell death by induction 
of anti-apoptotic factors (e.g. IGF T).
4: unlimited replicative potential 
The number of maximal population doublings is 
extended limitless in most tumors by restoring 
telomere length and reversing the loss of 
telomeric repeats (e.g. hTERT T).
5: sustained angiogenesis 
If a tumor grows beyond a certain size the inner 
part cannot sufficiently be supplied of oxygen 
and nutrients by surrounding blood vessels. New 
tumor infiltrating vessels can be formed by 
production of angiogenic factors (e.g. VEG F T).
6: tissue invasion and metastatic potential 
To finally spread and form new colonies 
throughout the body tumor cells have to detach 
from the primary tumor and effectuate 
migration. (e.g. E-cadherin i) .
To achieve all these crucial capabilities tumor 
cells need to dramatically shift and regulate their 
pool of expressed proteins. Ways in which different 
expression of proteins can be managed are present 
at all levels from genomic D N A  via m RNA to pro­
tein [25]. A  summary of the regulating processes in­
volved (with key references), though undoubtedly 
incomplete, is given in Figure 4.
T EC H N IQ U ES  TO STU D Y  D IFFER EN T IA L  
m RN A  EX PR ESS IO N
Among the 3 x 109 base pairs of the haploid 
human genome an estimate of 40,000 genes reside. 
Of these genes only a fraction is expressed in each 
of the roughly 250 different cell types in the human 
body. A  single cell is estimated to contain about 
20,000 distinct m RNA transcripts. About 99% of the 
mRNAs are rare (only one or several copies 
present) and represent half of the total messages. 
The remaining 50% is formed by a small number of 
highly abundant mRNAs [45]. The mRNAs present 
are believed to give rise to about 5,000 different 
proteins together with their modified variants. Up 
to 80% of all proteins in vertebrate cells are 
expressed in almost all cell types since they are
Figure 4.
Regulation of gene expression
D N A :
aberration: double strand breaks [26]
chromosome segregation [27] 
loss of heterozygosity [28] 
accessib ility: nuclear organization [29] 
packaging [30-32]
> m ethylation [33-35]
m RN A :
transcription: initiation [36] 
elongation [37] 
processing: splicing [38]
5'-capping [37] 
3'-polyadenylation [39] 
stab ility  [40,41] 
silencing  [42] 
transport [25]
Protein:
translation [43]
posttranslational m odification [44]
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needed for essential processes. The remaining 
proteins are used to generate the specific features 
of certain cell types [45].
In a comparison between normal and neoplas­
tic cell of one tissue type more than 300,000 
transcripts derived from 45,000 different genes 
were analyzed [46]. More than 500 transcripts were 
found to be expressed at a significantly different 
level between these two samples, indicating that 
the level of gene expression changes during 
tumorigenesis.
Though not a perfect predictor of protein 
expression, generally the m RNA population 
roughly represents the changes in effective gene 
expression. Because it is much easier to compare 
m RNA pools of certain cell populations than pro­
tein pools, several techniques to study differential 
m RNA expression have been developed over the 
last decades (Figure 5). These techniques can be 
subdivided based on their qualitative or 
quantitative approach.
Differential display of m RN A  (DD)
Comparing m RNA populations of different 
samples by DD was first introduced in the early 
nineties [51]. This approach is based on the 
comparison of radiolabeled cDNA fragments 
generated by PCR and separated on a sequencing 
gel (Figure 6). The first step is reverse transcription 
with an anchored oligo-dT primer (e.g. dT 12V N ) in 
which cDNA is made starting at the 3'-polyA-tail 
of a subpopulation of the messenger RNAs. The
Qualitative
Message display based
Differential display (DD)
Arbitrary primed PCR (AP-PCR)
cDNA-amplified fragment length polymorphism (cDNA-AFLP)
Subtraction based
Representational difference analysis (RDA)
Suppression subtractive hybridization (SSH)
Quantitative
Sequencing based
Expressed sequence tags (ESTs) "Ì Electronic subtraction
Serial analysis of gene expression (SAGE) J  and display
Array based
Macro array/reversed Northern 
Micro array 
cDNA micro array 
Oligo micro array
Figure 5.
Approaches to study differential m RNA 
expression [45, 47-50]
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following PCR step uses, in addition to the same 
dT12VN, an arbitrary 10-mer resulting in a number 
of PCR  fragments (about 50-100 products of 200­
300 bp in length) suitable for separation on a 
sequencing gel. Using several combinations of
dT 12V N  and arbitrary oligomers a good representa­
tion can be formed of the original m RNA pool. 
Comparing corresponding PCR  combinations for 
different samples directly visualizes up- or 
downregulated messages between the samples.
□ A BA A A A A A AA A A A A
Reverse transcription I Reverse transcriptase dN TPsT 12V N  (e.g. T 12V A )
C
□ CBA A AA A A A AA A A A
□ G BA AA A A A AA A A AA
□ T B  AAAAAAAAAAAA
□ TBA AA A A A AA A A A A
□ A V T T T T T T T T T T T T
Second strand synthesis
Taq  polym erase 
d N T Ps; 32P-dA TP
A rb itrary decam er (e.g. AG CCAG CG AA)
A G C C A G C G A A [
A V T T T T T T T T T T T T
AGCCAGCGAA
A G C C AG C G A A [
A V T T T T T T T T T T T T
A V T T T T T T T T T T T T
PC R  amplification 
and
size separation
Taq  polym erase 
d N T Ps; 32P-dA TP 
T12VA
A rb itrary decam er (e.g. AG CCAG CG AA)
A B  C D
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These cDNA fragments can be isolated from the gel 
and used for further analyses.
Since the introduction of DD many studies 
have been published describing all kinds of 
variations and improvements of the technique [52­
56]. The technique can readily be used, even in less 
well-equipped laboratories and needs no prior 
sequence information. Moreover, it does not 
require large amounts of starting material and is 
suitable for simultaneous comparison of multiple 
samples. Drawbacks are the high level of false 
positives (usually >50%), labor intensity when 
analyzing multiple fragments and generation of 
only 3' information [56]. The technique also has a 
bias towards high abundant transcripts and often 
fails to identify transcripts with an abundance less 
than 1% [57]. Nevertheless, it is one of the most 
w idely applied techniques for differential expres­
sion analysis and has also successfully been used in 
melanoma research [58-60].
Arbitrary primed PC R  (AP-PCR)
Very similar to DD, AP-PCR also makes use of 
a gel-based display of cDNA fragments generated 
by PCR [61]. The main difference is that in AP-PCR 
both primers are random oligomers. The generated 
products therefore represent all parts of the 
mRNAs and are not 3'-restricted as in DD. A  
second difference is that the first cycles of PCR are 
performed at low stringency followed by a series of 
high stringency cycles.
cDNA amplified restriction fragment length 
polymorphism (cDNA-AFLP)
A  third DD-like protocol, adapted from a PCR- 
based technology for mapping of genomic D N A  
[62], is called cDNA-AFLP [63]. To minimize
redundancy in the amplified cDNA sequences a 
restriction step is incorporated (compared to DD). 
After reverse transcription, the cDNA is cleaved 
with an appropriate restriction enzyme. Adapters 
are then ligated to the fragments and by a PCR 
with adapter primers these cDNA fragments are 
amplified. Finally the products are separated on gel 
and visualized. The advantage of this technique is 
that it yields cDNA products representing more 
central parts of the m RNA and therefore are more 
likely to include open reading frame information 
[48].
Representational difference analysis (RDA)
While display methods amplify fragments of 
all m RNA species present, subtractive cloning 
approaches eliminate mRNAs present in both 
populations resulting in a population-specific end 
product. A ll currently used hybridization-based 
technologies are modifications of a standard sub­
tractive hybridization protocol [64]. In general 
these techniques are used to compare a m RNA 
pool of a certain situation of interest (called 
"tester") with a reference m RNA pool (called 
"driver").
RDA  was originally developed for comparison 
of the genomes of two cell populations [65]. Later 
on this technique was adapted and suited for 
comparison of transcriptomes [66]. After reverse 
transcription the cDNA is treated with an enzyme 
cutting the cDNA to fragments of 200-300 base 
pairs called representations. The representations of 
the tester population are then ligated to an adapter. 
In the next step denatured single stranded tester 
cDNAs are hybridized with an excess of 
(adapterless) denatured driver cDNA. After hy­
bridization tester-specific double stranded cDNAs
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are exponentially amplified by PCR with adapter- 
specific primers. The resulting tester-specific 
representation can be cloned and used for further 
analyses. RD A  has successfully been used in tumor 
profiling [67].
Suppression subtractive hybridization (SSH )
A  similar hybridization-based differential gene 
expression approach is SSH [68]. In this somewhat 
more complex technique, schematically shown in
Figure 7, next to subtraction also a normalization 
and a suppression step have been included. After 
cDNA production and cleavage the tester popula­
tion is divided in two batches and to each batch a 
different adapter of about 40 base pairs (1-tester-1 
and 2-tester-2) is ligated. In two rounds of hybridi­
zation these tester populations are hybridized and 
thus subtracted with excess of denatured driver 
cDNA. In the first round the tester cDNAs are 
denatured, while this is not the case in the
Tester DNA
Driver DNA
Alu I digestion ]
Ligate adaptor |  Ligate adaptor
Tester DNA w ith Adaptor 1 Driver DNA (in e x ce ss)  Tester DNA w ith  Adaptor 2
{
Second hybridization
(also a, b, c, & d)
I Fill ends
{
1
Add primers i 
PCR amplify
a, d IMo amplification
and
No amplification 
Linear amplification
e Exponential am plification
Figure 7.
Suppression subtractive hybridization [68]
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subsequent second round of subtraction whereby 
the 1-tester-1 and 2-tester-2 populations are mixed. 
In this procedure the normalization, equaling high 
and low abundant cDNAs, is based on the faster 
annealing of homohybrids.
The last step is the amplification of the tester- 
specific fragments by suppression PCR with 20-mer 
internal adapter primers. Only tester-cDNA frag­
ments with two different adapters at the 3' and 5' 
(1-tester-2 or 2-tester-1) w ill be exponentially 
amplified. In this PCR cDNAs with the same 
adapters at both sides w ill be suppressed based on 
the annealing of both adapters into so-called 
panhandle-like structures (Figure 7; molecule b), 
thereby reducing the redundancy of the end prod­
uct. Again the tester-specific products represent the 
total difference in mRNAs between the two pools 
and can be cloned and further analyzed. SSH  has 
been widely used, also in melanoma research with 
cell lines [69] and tumor specimen [70]. In combina­
tion with reverse Northern SSH  can even be used 
in a relative high throughput setting [71].
Expressed sequence tags (ESTs)
Expressed sequence tags are end-sequences of 
transcripts determined by single sequence reads 
from both ends of cDNAs present in a certain li­
brary [72]. These ESTs, containing several hundred 
base pairs, are representative for the expression of 
their corresponding genes. Since the first EST 
approach on a larger scale [73] many commercial as 
well as non-profit projects (e.g. Merck-WashU EST 
project) have led to exponentially grown data on 
ESTs derived from all kinds of tissue and cell types. 
A ll these data have been deposited in the dbEST 
database (>3.7 million ESTs) curated and made 
publicly available by the National Center for
Biotechnology Information (NCBI) [74]. These data 
are shared and exchanged daily with those of the 
cooperating European (EM BL) and Asian (DDBJ) 
databases to ensure a comprehensive worldwide 
collection of data [75].
Cloned ESTs of interest can be obtained from 
the I.M.A.G.E. (Integrated Molecular Analysis of 
Genomes and their Expression) consortium [76]. 
Depending on the wish for quantitative or qualitive 
results EST sequencing can be performed on either 
normalized or non-normalized cDNA libraries. The 
dbEST can and has widely been used for exploring 
gene-family members, positional cloning of genes 
and disease-associated gene mutations [77].
Serial analysis of gene expression (SAGE)
A  second sequencing-based strategy is SAGE 
[78]. This technique is essentially an accelerated 
version of EST sequencing. SAGE is based on the 
principle that the combination of 10 base pairs of 
sequence, called tag, together with its position 
adjacent to a certain restriction site can specifically 
identify a transcript. After reverse transcription the 
cDNAs are cut with a specific restriction enzyme. 
Adapters containing the recognition site for the 
type-IIS endonuclease (cutting several base pairs 
away from this site in the transcript) are then 
ligated to the restricted cDNA. The following type­
IIS restriction results in the formation of specific 
tags. After ditag formation and amplification by 
PCR, these are then concatenated and cloned for 
subsequent analysis.
The major advantage over EST sequencing is 
that multiple tags are ligated and cloned 
simultaneously in a vector, allowing the analysis of 
up to 50 tags in a single sequencing reaction.
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In such a way large amounts of information on 
the expression of genes are generated. As for ESTs 
these ever growing numbers of data are assembled 
into a database, called SAGEmap [79]. Currently 
this database contains over 4 million tags [74].
Electronic subtraction and display
In analyzing and working with the huge 
amount of expression data publicly available pro­
grams for sequence comparisons and conversions 
(e.g. BLAST  [80] and the BCM  Search Launcher 
[81]) are indispensable for the research community. 
Moreover, the ever growing treasure of sequence 
information has led to the development of elec­
tronically-based approaches of differential 
expression analysis. Digital DD [82] and the 
previously mentioned SAGEmap can display and 
subtract expression data of and between cDNA 
libraries. In such a way even virtual Northern blots 
can be compiled.
Many initiatives and programs have been 
launched to create a structured organization for the 
expression databases. Two examples are the CGAP 
(Cancer Genome Anatomy Program) initiative and 
the Unigene database. CG A P couples large 
amounts of expression data, both ESTs and SAGE 
tags, to normal or cancerous stages of all kinds of 
cell types [83]. So far, however, not all types of 
tissues are analyzed extensively enough to result in 
representative data. A  major step in the compre­
hensiveness of all expression data came from the 
Unigene database [84]. By clustering of ESTs 
belonging to a unique gene the redundancy of the 
data was reduced about 20-fold to 84,000 sequence 
clusters [84]. This Unigene collection is the source 
of choice for assembly of gene-sets in gene-array 
technologies described below.
Macroarray/reversed Northern
cDNA membrane arrays are nylon membranes 
on which up to several hundred denatured cDNAs 
samples are spotted for subsequent differential 
hybridization experiments. A  set of identical filters 
are hybridized with labeled (for radioactive or 
chemoluminescent detection) reversed transcribed 
m RNA (or total RNA ) of several samples of 
interest. The intensity of the obtained signals 
correlate with the level of transcription of the 
corresponding gene in the analyzed sample. 
Quantitation of the signals can be performed with 
image processing software [85].
Microarray
Based on the macroarray principle several 
technological advances have been utilized in gener­
ating a more systematic differential hybridization 
approach on micro scale [86]. The major advance of 
microarrays comes from the use of high-density 
spotting robots. Several thousand cDNAs, mostly 
prepared by PCR amplification of cDNAs or EST 
clones, can be spotted on glass or silicon chips. In 
the subsequent hybridization step fluorescently 
labeled cDNA is incubated with the spotted 
cDNAs. When using two different fluorophores 
(red and green) two probes can be hybridized 
simultaneously. The spot-color (various mixtures of 
red and green) w ill then depend on the level of 
expression of the corresponding transcript in the 
applied samples. Finally high standard recording 
technology and software are used to collect, 
quantify and compare the obtained signals.
Though extremely powerful in high 
throughput applications, these cDNA arrays are 
costly and based on known and available ESTs or 
gene-sequences. Besides cDNA arrays also other
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type of arrays are developed. In oligonucleotide 
arrays nuc leotide sequences are either previously 
prepared oligos spotted on the array [87] or oli­
gonucleotides that are photochemically synthe­
sized on the chip itself [88]. In this way comprehen­
sive transcriptome-covering arrays can be made in 
less time and without the need to physically 
maintain and produce large cDNA libraries.
Microarray technologies have already been 
used in research of melanoma cell lines [89] and 
fresh melanocytic tumor samples [18]. Most studies 
so far have used a gene-by-gene analysis of the 
obtained data. A  new development comes from 
clustering analysis of genes with similar patterns of 
expression [90]. Such a broad picture view of 
expression data can give more insight in pathways 
and genes with similar function. Cluster analysis of 
gene expression can also be helpful in molecular 
classification of cancer types or subgroups [91].
Selection of the method of differential gene 
expression analysis
Selecting an approach for differential gene 
expression analysis from the scala of techniques 
available is a serious and difficult process, which 
w ill influence the type of data obtained. First of all 
this selection w ill have to be based on the budget, 
manpower and facilities present at the lab. 
Secondly it w ill depend on the type and amount of 
materials available. Finally, the technique of choice 
w ill be adapted to the type of interest one has with 
the experiment. If an overview of gene expression 
in a profiling experiment is wished then a quantita­
tive approach is most suitable. On the other hand if 
cloning of (a few) new differentially expressed 
genes is the main interest then a qualitive approach 
seems more suited.
In Table IV  a list of features is given for four of 
the most widely used techniques, representing all 
different types of approaches. These features w ill 
be helpful in selecting the best-suited technique. In 
the literature some studies have compared two or 
more techniques in parallel experiments [92-94]. 
Overall there is no best technique. Probably a 
combination of techniques w ill give the most 
reliable results in profiling all differentially 
expressed genes, both rare and abundant as well as 
known and novel.
Whatever technique chosen, there are several 
aspects to keep in mind when planning an 
experiment. One of these is sample purity and 
comparability. The use of cell lines guarantees a 
pure cell type, but might not lead to in-vivo 
relevant results. On the other hand use of freshly 
harvested tissue gives a better picture of the in-vivo 
situation, but the amount of material could be too 
less, or contaminated with unwanted cell types. 
When comparing fresh lesions, like normal and 
tumor for a certain tissue type, these should ideally 
be from the same patient to minimize genetically- 
based variations in gene expression. If the sample is 
contaminated with unwanted cell types or when 
studying sample heterogeneity, laser-assisted mi­
crodissection can be helpful. W ith this technique it 
is possible to select or remove single cells or groups 
of cells from a section of a specimen [95-97]. If the 
amount of isolated R N A  is too less there is always 
the possibility of linear amplification of the 
obtained m RNA prior to gene profiling [98].
Regardless of the approach the expression 
status of the genes isolated or identified as being 
differentially expressed should be checked. Next to 
the Northern blot analysis, consuming large 
amounts of R N A  but also giving size information,
24 Chapter 1
M ain features of methods for differential gene expression analysis (based on [45,47,48,50,93,104-107])
Table IV.
Qualitative Quantitative
Display-based Subtraction-based Sequencing-based Array-based
Feature D D SSH SA G E Microarray
m RN A  input 10-100 ng 10-100 ng £-51 1-5 mg
Reproducibility Low Medium High High
Gains/losses Gains and losses Gains or losses Gains and losses Gains and losses
Equipment cost Low Low Medium High
Effort High Medium High Medium
No.genes/exp Low Medium Medium High
No.samples/exp Multiple Two One One/Two
Reusable data No No Yes Yes/No
Prior sequence info No No No Yes
Physical cloning Yes Yes No No
Limitations Only 3' info Subtle changes are Difficult to make Difficult for rare
missed good libraries messages
Other advantages Isolation of new 
genes
A ll differentials in 
hand
real-time quantitative PCR can be used for 
validation [99]. One should also keep in mind that 
differences in m RNA level do not always lead to 
differences in protein expression. Though techni­
cally demanding, techniques like 2D-protein 
analysis and subsequent protein sequencing are 
needed to evaluate differences in protein 
expression or modification [45,100-102]. In the near 
future even the use of protein biochips seems 
feasible [103].
In conclusion, profiles of m RNA expression can 
give a clue about genes involved in the phenotypi­
cal differences between the subjected samples. A  
large number of approaches are currently used in 
determining these differences in gene expression. 
However, with the completion of the human 
genome and transcriptome sequencing efforts the 
balance will shift towards the use of microarray- 
based analysis.
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OUTLINE OF THE THESIS
Melanoma tumor progression is known to 
evolve through several stages. For diagnostic, 
prognostic and therapeutic purposes it would be 
important to have target genes that can help to 
distinguish between these stages. Therefore, the 
main goal at the start of the research described in 
this thesis was to identify genes that are 
differentially expressed between the different 
stages of melanocytic tumor progression.
At first we performed m RNA differential 
display comparing human melanoma cell lines 
with different metastatic capacities after subcuta­
neous injection into nude mice. From these 
experiments we identified two novel genes: 
TM7XN1 and CTp11. TM7XN1, described in 
chapter 2 is a member of the seven transmembrane 
receptor subfamily with long N-terminal extracel­
lular domains. Downregulation of TM7XN1 expres­
sion correlated with increasing metastatic capacity 
of the human melanoma cell line panel used. 
However, fresh samples from all stages of the 
melanocytic progression were positive. Chapter 3 
describes the isolation and differential expression 
of CTp11. Expression of CTp11 in the human 
melanoma cell line panel was restricted to the 
highly metastatic cell lines, while in normal tissues 
it could only be detected in testis. During 
melanoma progression it was only found in the 
malignant stages. Based on identification of ho­
mologous testis-specific genes, CTp11 was later on 
renamed as SPANXC. An outline of the SPANX 
family of X-linked cancer/testis-associated genes 
(CTAs) is given in chapter 4.
Another attempt to isolate clinically relevant 
differentially expressed genes during melanoma 
progression was done with fresh human 
melanocytic lesions. Using suppression subtractive 
hybridization we compared m RNA expression 
between nevocellular nevi and melanoma 
metastases. From the metastases fraction subtracted 
with the nevi fraction we isolated another tran­
script with a cancer/testis-associated expression: 
XAGE-1b (chapter 5). XAGE-1b was only expressed 
in metastatic lesions during melanoma tumor 
progression. Previously identified in Ewing's 
sarcoma the XAGE-1 gene is a member of a larger 
family of X-linked genes with homology to GAGE 
and PA G E CTAs as shown in chapter 6.
To investigate the potential clinical use of CTAs 
we compared the expression profile of eight CTAs 
with those of three melanoma differentiation 
antigens (chapter 7). A  literature review on CTAs, 
their expression in melanoma and testis as well as 
their putative use in immunotherapy is given in 
chapter 8. Finally, the general discussion (chapter 
9) summarizes functional data on CTAs and 
speculates on the function of SPAN X and XAG E 
proteins.
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Chapter 2
TM7XN1
TM7XN1, A NOVEL HUMAN EGF-TM7-LIKE cDNA, 
DETECTED WITH mRNA DIFFERENTIAL DISPLAY 
USING HUMAN MELANOMA CELL LINES WITH 
DIFFERENT METASTATIC POTENTIAL
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We have identified a novel 3845 
bp cDNA differentially expressed in a hum an m elanom a 
metastasis model. N orthern blot analysis show ed expression in 
the poorly and interm ediately m etastasizing cell lines and a 
m arked dow nregulation in  the highly m etastatic cell lines. Using 
RT-PCR expression was also seen in  several other tum or cell lines 
and norm al cell types of hum an origin. cDNA sequence analysis 
revealed an ORF of 687 amino acids containing seven putative 
transm em brane dom ains C-term inally and a long N-term inus. The 
gene was m apped to 16q13. H ighest hom ology was observed w ith 
mem bers of the EGF-TM7 subfam ily of the secretin/calcitonin 
receptor family. We propose the delineation of a subfamily of TM7 
proteins, LN-TM7, containing seven transm em brane proteins w ith 
a long N-term inal extracellular part.
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INTRODUCTION MATERIALS AND METHODS
Several genes or gene-products have been 
identified which are differentially expressed during 
melanocytic tumor progression [108]. To identify 
differentially expressed genes various methods 
have been used both on D N A , m RNA and protein 
level. Among the strategies used differential 
hybridization, subtractive hybridization, m RNA 
Differential Display and Serial Analysis of Gene 
Expression [78] are the most common. In onco- 
biology these techniques have been successfully 
used in the identification and subsequent isolation 
of differentially expressed genes in several types of 
tumors [46,58,109-114].
To pick-up possible human melanocytic tumor 
progression markers we performed m RNA 
Differential Display [51], comparing two human 
melanoma cell lines: 1F6 and a spontaneous mutant 
of this cell line, 1F6m. Whereas 1F6 only sporadi­
cally gives rise to metastases after s.c. inoculation 
into nude mice, 1F6m metastasizes very frequently 
and quickly [115].
Here we describe a new cDNA, TM7XN1, 
which inversely correlates with the metastatic 
potential in a panel of human melanoma cell lines. 
Sequence analysis and database searching showed 
highest homology towards members of the EGF- 
TM7 (seven transmembrane molecules containing 
epidermal growth factor-like domains) subfamily 
of the secretin peptide hormone receptor family 
[116].
Based on extensive sequence and homology 
searching, we argue for the delineation of a novel 
subfamily of seven transmembrane receptors, 
named LN-TM7 (Long N-terminus), including the 
novel TM7XN1 and the EGF-TM7 molecules.
Melanoma cell lines
Twenty-three human melanoma cell lines were 
used. A  panel of eight melanoma cell lines contain­
ing 530, 1F6, MV1, M14, Mel57, BLM , MV3, and 
1F6m was described earlier [115]. In this panel of 
cell lines 530 and 1F6 are poorly metastatic, while 
MV3 and BLM  are highly metastatic cell lines. 
MV1, M14, and Mel57 are cell lines with an inter­
mediate metastatic capacity. 1F6m, a metastatic 
subline of 1F6, can be placed between the 
intermediate and highly metastatic cell lines. A ll 
other human melanoma and non-melanoma cell 
lines used are listed in Table I [115,117-123].
A ll cell lines were grown in Dulbecco's 
modified Eagle's medium as described earlier [117]. 
Cultured pericytes, smooth muscle cells and 
endothelial cells were a kind gift from Dr. M. 
Verbeek [124]. Cell line U2OS, as well as dendritic 
cells were a generous gift from Dr. F. Hartgers 
(Dept. of Tumor Immunology, UM C St Radboud, 
Nijmegen, The Netherlands). Keratinocytes, 
melanocytes and nevus cells were cultured as 
described previously [125]. Fibroblasts were grown 
on Eagle's Minimum Essential Medium (Bio- 
Whittaker, Walkersville, MD) supplemented with 
20% human serum , 10% FCS, and antibiotics.
Human tissues
Lesions from all stages of melanocytic tumor 
progression (common nevi, atypical nevi, primary 
melanoma and melanoma metastases) were excised 
from patients at the UM C St Radboud, Nijmegen, 
The Netherlands. As normal human tissues we 
used disease-free samples from surgically removed 
tissues or from autopsies with post-mortem delays
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shorter than 4 hours. Tissue samples were snapfro- 
zen in liquid nitrogen and stored at -80°C until use.
R N A  Isolation
From cultured cells total R N A  was isolated 
using the RNeasy kit (Qiagen, Hilden, Germany) 
following the manufacturers protocol. From tissue 
samples total R N A  was isolated (following 
manufacturers protocol) by disrupting about 25 
frozen sections of 20 |am thickness in 1 ml RNA- 
zolB™ (Campro, Veenendaal, The Netherlands) 
using a pestle. The RNAzolB™  method was 
followed by an additional RNeasy cleaning step of 
the RNA.
m RN A  Differential Display
Before starting Differential Display PCR, 
DNaseI treatment was performed on the RN A  
samples using the Message-Clean™ kit 
(GenHunter Corporation, Brookline, USA). For Dif­
ferential Display the RNAm ap™ protocol 
(GenHunter) was used with some minor 
modifications. Differing from the original protocol, 
we used [32P]-dATP instead of [35S]-dATP. For the 
PCR, combinations of the four T12M N  primers 
together with six arbitrary primers, APu^zn and 12, 
[53] were used.
Northern blot analysis
Ten micrograms of total R N A  were treated 
with glyoxal/DMSO or with formaldehyde [126], 
separated on a 1.2% agarose gel and blotted onto a 
Hybond N+ membrane (Amersham, Aylesbury, 
UK). cDNA probes were radiolabeled by [32P]- 
dATP incorporation using a random-primed DNA  
labelling kit (Roche Diagnostics GmbH, Penzberg, 
Germany). Membranes were hybridized overnight
with the radiolabeled probes at 65°C in a hybridi­
zation mix (0.25 M  sodium phosphate buffer pH 
7.2, 7% SDS, 1% BSA, 1 mM EDTA, 0.1 mg/ml 
single stranded salmon sperm DNA). Afterwards 
membranes were washed at 65°C with wash 
buffers containing decreasing amounts of salt (1% 
SDS, 1 mM ED TA and 0.25-0.05 M  sodium 
phosphate pH 7.2), and autoradiographed using 
Kodak Xomat-S films.
cDNA library screening, sequencing and 
homology searching
cDNA probes were labelled as described before 
and hybridized [126] to a ÀZAP cDNA library of 
human melanoma cell line 530, kindly provided by 
Dr. G. Swart, Department of Biochemistry, Univer­
sity of Nijmegen, The Netherlands. After isolation 
of the full length cDNA, sequencing on both 
strands was performed by Roche Diagnostics 
GmbH, Penzberg, Germany. Homology searches 
were performed using BLAST  [80] and software on 
all kinds of public servers of D N A  and protein 
databases on Internet:
http://www.genome.ad.jp/;
http://www.ncbi.nlm.nih.gov/;
http://expasy.hcuge.ch/;
http://dot.imgen.bcm.tmc.edu:9331/;
http://www.genome.wi.mit.edu/.
RT-PCR
Synthesis of cDNA (10' at 25°C, followed by 59' 
at 42°C) was performed on 0.5 - 1.0 ^g of total RN A  
using the A M V  RT kit (Roche Diagnostics GmbH, 
Penzberg, Germany). The reaction mixture was 
supplemented with 0.04 U  of random hexa- 
deoxynucleotide primers, 2 |al 25 mM MgCk, 1 |al 
10 mM dNTPs, 1 |al of RT buffer (100 mM Tris/HCl
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pH 8.3, 500 |aM KCl), 25 U  RNasin, 10 U  A M V  
reverse transcriptase and water to a final volume of 
10 |al. For amplification one tenth of the cDNA was 
supplemented with 2.5 |al of PCR-buffer (200 mM 
(N H 4)2SO4, 750 mM Tris/HCl pH 9, 0.1% Tween), 5 
|al 1M dNTPs, 10 pmoles of each primer, 2.5 |al 15 
mM MgCl2, 0.15 U  of Thermoperfectplus™ D N A  
polymerase (Integro, Zaandam, The Netherlands) 
and water to a final volume of 25 |al.
PCR conditions were 45" at 94°C, 1' at 59°C and 
1'30" at 72°C for 30 cycles. These cycles were 
preceded by 3 min. denaturation at 94°C and 
followed by a 5 min. elongation step at 72°C. 
Primer combinations and PCR product lengths 
were:
ß2-Microglobulin (136 bp):
sense: 5'-CTCGCGCTACTCTCTCTTTCT-3'
antisense: 5'-TGTCGGATTGATGAAACCCAG-3'
TM7XN1 cDNA (474 bp):
sense: 5'-CCATCTTTCTGGTGACGC-3'
antisense: 5'-GAGCTGATGGGGAGCCTG-3'
D N A  molecular weight markers were from 
Roche Diagnostics GmbH, Penzberg, Germany.
Chromosomal localization
Chromosomal localization of the correspond­
ing gene was determined by genomic PCR on a 
panel of hamster/human and mouse/human hybrid 
cell lines [127]. D N A  of these cell lines, each 
specific for one human chromosome, was kindly 
provided by Dr. A. Simons, Department of Human 
Genetics, UM C St Radboud, Nijmegen, The 
Netherlands. PCR conditions were the same as 
used for the cDNA primer combinations described 
above. Intronspanning primers and product length 
were:
TM7XN1 D N A  (526 bp):
sense: 5'-GCTCTGTCTCTCGTGGTC-3'
antisense: 5'-GCATGGTCCACAGTTCTTG-3'
R ESU LT S  A N D  D ISC U SS IO N  
Isolation and cloning of TM7XN1 cDNA
With m RNA Differential Display, using primer 
combination T 12M G and AP7, we detected a 250 bp 
cDNA (clone 25) abundantly present in 1F6 and 
almost absent in 1F6m (not shown). Using this 250 
bp cDNA clone as a probe a Northern blot, contain­
ing R N A  from a panel of human melanoma cell 
lines with varying metastatic potential, revealed 
two bands at 4.2 kb and 1.0 kb (Figure 1A). Marked 
expression of the 4.2 kb transcript was only seen in 
the poorly and intermediate metastatic cell lines 
530, 1F6, MV1 and M14. No expression could be 
detected in the highly metastatic cell lines MV3 and 
BLM . Very weak expression was seen in 1F6m cells.
To investigate the specificity of the 1.0 kb band 
we did Northern blot analysis of one poorly (530), 
one intermediate (MV1) and two highly (MV3, 
BLM ) metastatic cell lines with three different PCR 
probes throughout the full length cDNA. The 
probes represented the N-terminal part of the open 
reading frame (ORF) (bp 351-979), the seven 
transmembrane region (bp 1878-2352) and the 3'- 
UTR (untranslated region; bp 3339-3689). With all 
three probes we could not detect the 1 kb band 
anymore, while the 4.2 kb band showed the same 
expression pattern. As an example we show the 
results for the probe corresponding to the 3'-UTR 
(Figure 1B). From these results we concluded that 
the 1 kb signal was a background hybridization of 
clone 25, the 250 bp probe (corresponding to the 
last part of the 3'-UTR and part of the poly-A tail).
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Figure 1.
Northern blot analysis of clone 25 on a panel of human 
melanoma cell lines w ith different metastatic capacity after 
subcutaneous inoculation into nude mice [115].
(A ) glyoxal/DMSO blot hybridized w ith clone 25, the 250 bp 
D ifferential D isplay cDNA. Lane 1: 530; lane 2: 1F6; lane 3: 
MV1; lane 4: M14; lane 5: MV3; lane 6: BLM ; lane 7: 1F6m.
(B ) formaldehyde blot hybridized w ith PC R  fragment corre­
sponding to the 3'-UTR (bp 3339-3689) of the full-length 
cDNA. Lane 1: 530; lane 2: MV1; lane 3: MV3; lane 4: BLM .
(C ) 28S and 18S rRN A  bands of ethidium-stained formalde­
hyde gel.
Using the 250 bp cDNA clone as a probe we 
screened a ÀZAP cDNA library of human mela­
noma cell line 530, in which marked expression of 
the 4.2 kb transcript was detected on Northern blot. 
W e isolated a 3845 bp cDNA and sequenced this 
clone (EMBL: AJ011001). The original 250 bp clone 
matched completely with the 3' part of the full 
length cDNA. A  variable poly-A tail can be the 
explanation for the difference in length of the 
estimated 4.2 kb on Northern and the 3845 bp 
cloned cDNA.
The cDNA contains an ORF resulting in a 
protein of 687 amino acids (Figure 2) including 
seven putative C-terminal transmembrane domains 
(a.a. 405-656) and a N-terminal signal peptide (a.a. 
1-25). The protein has a very high leucine and 
serine content of respectively 14.8 and 11.1%. Using 
M O TIFFIN D ER (http://www.motif.genome.ad.jp) 
we found, besides several phosphorylation sites, 
seven potential N-glycosylation sites in the N- 
terminal part. The short C-terminus contains some 
phosphorylation sites and a putative AMP-binding 
domain (a.a. 675-686) which, together with a 
potential tyrosine kinase phosphorylation site (a.a. 
546) between TM4 and TM5, may be indicative for 
interaction with signalling components. It also has 
a microbodies C-terminal targeting site (a.a. 685­
687). This site is normally involved in guidance of 
proteins towards single membraned organelles. 
PSORT II (http://psort.nibb.ac.jp) predicted 
TM7XN1 to be present in the membrane of the 
endoplasmatic reticulum or in the plasma mem­
brane. Determination of the specific localization of 
TM7XN1-protein needs further studies.
Homology search
Homology and domain searches revealed a
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Figure 2.
Protein sequence of TM7XN1. Indicated are the signal peptide (arrow), potential glycosylation 
sites (N  w ith asterisk), cysteine box (shaded black) and transmembrane regions (shaded gray).
perfect homology with a lot of human ESTs from 
several types of both normal and tumor tissues. No 
functional clues from homology to known domains 
were found in the long N-terminal part. W e could 
place the gene in the secretin/calcitonin receptor 
family because of its strong C-terminal homology, 
especially towards members of the recently 
described EGF-TM7 subfamily [116] and other non- 
classical TM7 proteins. Next to the 30% identity in 
the C-terminal seven transmembrane part it also 
had a long N-terminal part, though it lacked the 
EGF-like domains which characterize the EGF-TM7 
family. Based on these finding we named the 
molecule TM7XN1, in which the X represents the 
lack of known domains (no EGF-like domains) and
unclear function of the long N-terminal part of the 
protein.
TM7XN1 expression
Expression of TM7XN1 was tested on a great 
number of human cell types and tumor cell lines 
using RT-PCR. On a melanoma cell line panel with 
known metastatic behavior, we found a clear 
expression in the low and intermediate metastatic 
cell lines 530, 1F6, MV1 and Mel57 (Figure 3). 
Expression in M14 and 1F6m is somewhat lower. 
Though Northern blot was negative for MV3 and 
BLM  (Figure 1) using the more sensitive RT-PCR 
we could detect some weak expression in these 
highly metastatic cell lines (Figure 3). Expression in
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Figure 3.
Expression of TM7XN1
(A ) in human melanoma cell lines w ith differ­
ent metastatic potential using RT-PCR. Lane 1: 
D N A  molecular weight marker X IV  (100 bp 
ladder); lane 2: water control; lane 3: 530; lane 
4: 1F6; lane 5: MV1; lane 6: M14; lane 7: Mel57; 
lane 8: 1F6m; lane 9: MV3; lane 10: BLM .
(B ) ß2-Microglobulin control RT-PCR.
1F6m is higher then we expected on basis of the 
expression detected with the more quantitative 
Northern blot. W e think this is due to instability of 
the 1F6m cell line, as the R N A  used for the RT-PCR 
was isolated from 1F6m cells of a much later 
passage then the one used for Differential Display 
and Northern blot. Based on the Northern blot 
results with the melanoma cell line panel TM7XN1 
expression inversely correlates with the metastatic 
potential after s.c. inoculation into nude mice. RT- 
PCR on R N A  isolated from corresponding xeno­
grafts of the cell line panel matched completely 
with the results of the cultured cells (not shown).
RT-PCR results on expression of TM7XN1 in a 
great number of other cultured normal human cells 
and cell lines are shown in Table I. A ll other human 
melanoma cell lines showed TM7XN1 expression, 
being weak in only four of all melanoma cell lines 
tested (MV3, SK-mel-28, BLM  and its parental cell 
line BRO). Most cell lines derived from other tumor 
types also expressed TM7XN1. In primary cell 
cultures strong expression was observed in 
keratinocytes, melanocytes, nevus cells and 
endothelial cells (Table I), while weak expression
was found in fibroblasts, smooth muscle cells, 
pericytes, and peripheral blood mononuclear cells 
(PBMCs). Dendritic cells (non-stimulated) were 
negative. In normal human tissues clear expression 
was seen in kidney, prostate and testis, weak 
expression in bladder, brain, lung, uterus and 
thyroid glands and no expression in bone marrow, 
colon, hart, ileum, liver, lymph node, pancreas, 
spleen, and stomach. W e also studied TM7XN1 
m RNA expression in fresh human melanocytic 
lesions with RT-PCR. TM7XN1 expression was de­
tected in all stages of melanocytic tumor pro­
gression (not shown). Since not only melanocytic 
cells but also other cell types present in these 
lesions (keratinocytes, fibroblasts, endothelial cells) 
may express TM7XN1 (see Table I) we need 
additional studies to determine whether there are 
differences in expression between melanocytic cells 
in the different stages of tumor progression. For 
this purpose we are currently in the process of 
raising antibodies against TM7XN1 to be able to 
study expression of the corresponding protein on 
the single cell level.
Our data indicate that TM7XN1 is widely
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Table I.
Expression of TM7XN1 in human tumor cell lines, prim ary cell cultures and organ tissues determined by RT-PCR. 
A ll samples had a positive control PCR (ß 2M ); 1 cell lines from the Am erican Type Culture Collection (Rockville, 
M D ); 2 PBM C  = Periphere Blood Mononuclear Cells
strong moderate weak negative
melanoma 1F6 [115]; 451Lu [122]; 518A2 1F6m [115]; E10 BLM  [115]; BRO
cell lines [117];
530 [115]; 603 [117]; A375m 1 ; 
A375p 1 ; Bowes 1 ; M24met 
[117]; Mel57 [115]; M KR  [123]; 
MV1 [115]; OCM1 [120];
[117]; M14 [115]; 
ZKR  [123]
[119]; MV3 [115]; 
SK-Mel-28 1
other tumor A4311; CaCo2 1; HT29 [118]; Hep/G2 [118]; U2OS [118] Daudi 1; Jurkat 1 ;
cell lines Molt41; Umscc2 [117] HT1080 [118] K562 [118]; U937 
[118]
primary cell 
cultures
keratinocytes; nevus cells; 
endothelial cells; melanocytes
fibroblasts PBMCs 2; pericytes; 
smooth muscle 
cells
dendritic cells
organ tissue kidney; prostate; 
testis
bladder; brain; 
lungs; thyroid 
gland; uterus
bone marrow; 
colon; hart; ileum; 
liver; lymph node; 
pancreas; spleen; 
stomach
distributed and expressed in a great number of 
both normal and tumor cells and tissues. This 
finding is in line with the perfect homology of the 
gene with numerous human ESTs. Expression of 
the best studied EGF-TM7 molecules (CD97 and 
EMR1) is mainly seen in cells of the haematopoietic 
lineage and in solid-tumor-derived cell lines [116]. 
They are described as leukocyte antigens with a 
possible immunologic role.
Recently CD97 expression has also been 
described in thyroid tumors [128]. As for CD97, 
expression in (para)thyroid tumors is also the case 
for KIAA0279 (AA843289; EM BL), which like
TM7XN1 is mainly expressed in testis, brain, 
kidney, and prostate [129].
Chromosomal localization
Inspection of the Human Gene Map (NCBI) 
showed perfect homology of TM7XN1 with an 
unidentified transcript. This STS (Sequence Tagged 
Site) was called STSG1704 and located on 16q13 
between microsatelite markers D16S419 and 
D16S408 (65-72 cM). To confirm localization of 
TM7XN1 on chromosome 16, we performed an 
intronspanning PCR on D N A  of a human 
chromosome specific hybrid cell panel (hamster/
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Characteristics of TM7XN1 homologues. 1 SP = Signal Peptide; 2 RGD = Arg-Gly-Asp; TSP1 = Thrombospondin type 1; TM  
= Transmembrane; L-zipper = Leucine-zipper; LDL-RA = Low  Density Lipoprotein class A ; LR R  = Leucine Rich Repeats; 
cadherin = cadherin-like domain; lam inin A G  = lam inin A  G-domain; 3 only partial protein sequence known
Table II.
Protein Species EM B L
(nr.)
Length
(a.a.)
SP  1 
(a.a.)
N-term.
(a.a.)
EG F
dom ain
Cys-
box
M iscellaneous 
dom ains 2
Ref.
Secretin Rec. Calcitonin R. H.sapiens L00587 490 22 132 - - [130]
Secretin R. H.sapiens U20178 440 22 121 - - [131]
LN-TM7 TM7XN1 H.sapiens AJ011001 687 26 381 - +
HE6 H.sapiens X81892 1014 37 587 - + [132]
Latrophilin R.norvegicus U78105 1466 24 831 - + [133]
KIAA0786 3 H.sapiens AB018329 >1021 - >410 ? + ? [134]
KIAA0768 3 H.sapiens AB018311 >872 - >290 ? + ? [134]
BAI-1 H.sapiens AB005297 1584 25 924 - + RG D ; TSP1(5x) [135]
BAI-2 H.sapiens AB005298 1572 23 900 - + extraTMs; L- 
zipper;TSP1(5x)
[136]
BAI-3 H.sapiens AB005299 1522 24 855 - + TSP1(5x) [136]
B0286.2 C.elegans U39848 1582 - 907 - + extraTM [137]
B0457.1 C.elegans Z54306 1014 29 522 - + [137]
F31D5.5 C.elegans U28941 1817 50 1473 - - RGD [137]
BOSS D.melanogaster X55887 896 37 498 - - [138]
GRL101 L.stagnalis Z23104 1115 22 747 - - LDL-RA(12x);
LRR(6x)
[139]
EGF-TM 7 CD97 H.sapiens X84700 742 20 440 3-5 + RGD [140]
EMR1 H.sapiens X81479 886 17 583 1-6 + [141]
KIAA-0279 3 H.sapiens D87469 2408 21 1842 6 + cadherin(4x); L-
zipper
[129]
CELSR1 M.musculus AF031572 3034 26 2459 7 + cadherin(7x); 
lam inin AG(2x)
[142]
R29368.2 3 H.sapiens AC004262 >344 - >58 ? + ?
human or mouse/human). We only could detect the 
526 bp specific product in the D N A  sample of the 
chromosome 16 specific hybrid cell line (not 
shown). Some EGF-TM7 molecules map on 
chromosome 19p13, indicating the position of an 
EGF-TM7 gene-cluster on the short arm of
chromosome 19.
Alignment: LN-TM7
To get more insight into the relationship 
between TM7XN1, the secretin-like receptors and 
EGF-TM7 molecules we compared TM7XN1 with
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several other family members that were found 
previously and with other proteins that we 
additionally found during homology searches with 
parts of TM7XN1 (Table II) [16,130-142]. Some 
proteins of non-human origin were used in case no 
human homologue was known. A ll sequences 
aligned have seven C-terminal transmembrane 
domains. The proteins vary markedly in length, 
with the secretin and calcitonin receptors (G- 
protein-coupled receptor family 2) being the 
smallest. These peptide hormone receptors have a 
relatively short N-terminus (<200 a.a.), containing 
their hormone binding domain.
The recently described EGF-TM7 subfamily 
members have a much longer extracellular part 
containing several EGF-like domains [116]. Of the 
EGF-TM7 molecules several splice variants with 
variable numbers of EGF-like domains have been 
reported [143]. Our TM7XN1 protein is very 
homologous to the secretin receptor and to CD97 
and EMR1, but lacks any known domain in its long 
N-terminus.
In Table II we have made a separation between 
EGF-TM7 members and molecules with a long N- 
terminus lacking EGF-like domains, LN-TM7. Their 
N-terminus is longer than 300 bp and most proteins 
contain a so-called cysteine box (cys-box): C-X14-24- 
C-X1 1-C-X-C [132]. Cleavable signal peptides were 
found in all proteins of which the start of trans­
lation is known [144], except for B0286.2. 
Additional EGF-TM7 molecules are the human 
KIAA0279 and R29368.2 as well as mouse CELSR1. 
Because R29368.2 has a 50% identity with EMR1 
and because the gene is located on 19p13, as are 
CD97 and EMR1, we suspect this gene to be an 
EGF-TM7 family member. KIAA0279 is not located 
on chromosome 19p13, but on chromosome 1 [129],
while CELSR1 was mapped to human 22qter [142].
Instead of EGF-like domains some of the LN- 
TM7 molecules possess other known domains 
(Table II) in their long N-terminus. These putative 
dual-function proteins are believed to be formed by 
genetic rearrangements, like exon-shuffling, by 
which TM7 proteins gained additional domains 
from other genes [145-147]. Almost all LN- and 
EGF-TM7 molecules have a highly glycosylated 
mucin-like region within their N-terminal extracel­
lular part between the membrane-spanning domain 
and the N-terminal conformational domain(s). This 
region is often lacking cysteine residues. It was 
already postulated that the long N-termini capture 
a ligand and then present this ligand to the binding 
pocket situated inside the TM7 structure. The 
peptide hormone receptors do not need such a long 
N-terminus because of the small peptide ligand 
[139].
Figure 4 shows an alignment of the seven trans­
membrane domains and the cys-box preceding the 
first membrane domain of some representatives of 
the subfamilies investigated. A ll proteins have the 
characteristic conserved cysteines in loop 2 and 4 
(data not shown) which are thought to be necessary 
for stabilization of the transmembranal confor­
mation of G-protein-coupled receptors [148]. From 
the alignment of the cysteine box a LN-TM7 
specific protein consensus sequence for the cys-box 
can be distilled: C-X2-W-X6-16-W-X4-C-X1 1-C-X-C. 
Next to the consensus described earlier [132] also 
some very highly conserved tryptophane residues 
are present. Some less well-conserved but very 
frequent amino acids, like the FA VLM  sequence in 
the last part of the cys-box, are also indicated in 
Figure 4.
Based on the comparisons we argue for the
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a.a. C Y S - B O X  a.a.
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Figure 4.
M ultip le protein alignment of the cys-box and the transmembrane regions of the secretin receptor (white), LN-TM7 fam ily 
members (gray), and EGF-TM7 fam ily members (black). Strongly conserved amino acid residues are shaded black and 
bold; frequently homologues residues are bold. Gaps (-) are introduced to allow  maximal alignment. * only partial protein 
is known.
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delineation of a novel LN-TM7 subfamily of the 
secretin receptor family. For most members there is 
no experimental evidence for G-protein coupling. 
Only latrophilin has been shown to be linked to G- 
proteins (Gan) and inositol polyphosphate produc­
tion [133,149].
Since TM7XN1 does not have any known spe­
cific functional domain with regard to a possible 
ligand structure all reflections about its function 
are speculative. However, if TM7XN1, like CD97 
[150], should function as an adhesion molecule, 
downregulation as seen in the most aggressive 
melanoma cell lines might explain its involvement 
in the metastatic capacity of these tumor cells.
SU M M A R Y
TM7XN1 is a novel protein placed in a novel 
LN-TM7 family of seven transmembrane proteins, 
probably G-protein coupled, with long N-terminal 
domains. These domains are presented to the 
environment by a long rod-like glycosylated 
spacer. The whole extracellular domain seems to be 
carried and stabilized by a cysteine box, serving as 
a statue-foot on top of the seven transmembrane 
anchor. Although we found a marked downregu- 
lation of TM7XN1 expression in the highly metas­
tatic melanoma cell lines, a possible role of 
TM7XN1 in melanocytic tumor progression needs 
further studies which are in progress now.
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To identify new genes that m ay contribute to 
the m etastatic pathw ay of neoplastic cells we com pared mRNA expression of the pa­
rental hum an m elanom a cell line 1F6 and its m etastatic variant 1F6m using mRNA 
differential display. We isolated a cDNA clone that was exclusively expressed in 
1F6m. N orthern blot analysis on a broader panel of hum an m elanom a cell lines w ith 
different m etastatic capacity following subcutaneous inoculation into nude mice dem ­
onstrated that the gene was expressed only in the m ost aggressive, highly m etastatic 
cell lines, giving a band of 0.5 kb. The isolated full length cDNA clone show ed an ORF 
coding for a 97 amino acid putative protein containing a bipartite nuclear localization 
signal. To study the subcellular localization of the gene product COS-1 cells were 
transfected w ith  cDNA of the gene fused to eGFP. We found the fusion protein exclu­
sively present in  the nucleus. C om puter search show ed strong hom ology w ith hum an 
genomic clones all localized on chromosome X (Xq26.3-Xq27.1) and w ith  several ESTs, 
all from testis. Localization of the gene on chromosome X was confirmed by genomic 
PCR on a panel of hum an chromosome specific rodent/hum an hybrid cell lines.
N orthern blotting and RT-PCR on 17 different norm al hum an tissue samples 
show ed that the gene was only expressed in  norm al testis. RT-PCR on a great num ber 
of different hum an tum or cell lines show ed expression in  25 to 30% of the m elanom a 
and bladder carcinoma cell lines. Only 2 out of 29 other tum or cell lines were positive. 
Nested PCR analysis of a series of fresh hum an melanocytic tum ors dem onstrated 
expression in  7 out of 10 m elanom as tested. No expression was seen in  benign 
melanocytic tum ors. In addition to m elanom a also some m alignant tum ors from  other 
histological type were found to be positive.
Based on these data we conclude that the described gene, CTp11 (cancer/testis- 
associated protein of 11 kD), is a novel m em ber of the family of cancer/testis antigens.
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INTRODUCTION MATERIALS AND METHODS
Cutaneous melanoma, though accounting for 
less then 5%  of all human malignancies, is one of 
the most aggressive forms of cancer. Survival of 
patients with this type of skin cancer drastically 
decreases when the tumor has a thickness of only 
1.5 mm or more. Due to rapid metastasis so far the 
only cure is early detection and removal of the pri­
mary tumor [151]. Next to these features, 
accessibility of melanoma lesions and the relative 
ease of preparing cell lines make melanoma a 
frequently used cancer research model.
From many studies it is known that metastatic 
spread requires multiple changes in the biologic 
behavior and as a consequence in the phenotype of 
the tumor cells. Many genes are differentially 
expressed during subsequent processes involved in 
metastasis. To identify genes that may contribute to 
the metastatic pathway of neoplastic cells we 
compared m RNA expression of two closely related 
human melanoma cell lines, 1F6 and its metastatic 
variant 1F6m using m RNA differential display [51].
Here we describe the isolation and first 
characterization of a cDNA clone isolated with this 
model system. Expression studies on a panel of hu­
man melanoma cell lines with different metastatic 
behavior after s.c. inoculation into nude mice 
correlated with the metastatic behavior.
Based on the expression profile in normal 
tissues and a series of different malignant tumor 
tissues tested and the chromosomal localization of 
the gene we conclude that it belongs to the growing 
family of cancer/testis antigens (CTAs).
Cell lines and primary cultures
A  panel of eight different human melanoma 
cell lines containing 530, 1F6, MV1, M14, Mel57, 
BLM , MV3, and 1F6m was described earlier [115]. 
In this panel of cell lines 530 and 1F6 are poorly 
metastatic, while MV3, BLM  and 1F6m are highly 
metastatic cell lines. MV1, M14, and Mel57 are cell 
lines with an intermediate metastatic capacity. 
1F6m is a metastatic subline of 1F6. Most other cell 
lines used were described earlier [152]. Cell lines 
RAM OS and RA JI are from the ATCC. A ll cell lines 
were grown in Dulbecco's modified Eagle's 
medium as described earlier [153]. Cell line U2OS 
was a generous gift from Dr. F. Hartgers (Dept. of 
Tumor Immunology, UM C St Radboud, Nijmegen, 
The Netherlands). Normal human foreskin melano­
cytes and human nevus cells were cultured as 
described previously [124]. Several kidney, prostate 
and bladder cancer cell lines were a gift from Dr. 
M. Bussemakers (Dept. of Urology, UM C St 
Radboud, Nijmegen, The Netherlands).
Human tissues
Lesions from all stages of melanocytic tumor 
progression (common nevi, atypical nevi, primary 
melanoma and melanoma metastases) and other 
tumor specimens were excised from patients at the 
UM C St Radboud, Nijmegen, The Netherlands. As 
normal human tissues we used disease-free 
samples from surgically removed tissues or from 
autopsies with a post-mortem delay shorter than 4 
hours. Tissue samples were snap-frozen in liquid 
nitrogen and stored at -80°C until use.
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R N A  Isolation
From cultured cells total R N A  was isolated 
using the RNeasy kit (Qiagen, Hilden, Germany) 
following the manufacturer's protocol. From tissue 
samples total R N A  was isolated (following manu­
facturer's protocol) by disrupting about 25 frozen 
sections of 20 |am thickness in 1 ml RNAzolB™  
(Campro, Veenendaal, The Netherlands) using a 
pestle. The RNAzolB™  method was followed by an 
additional RNeasy cleaning step.
m RN A  differential display
Prior to m RNA differential display PCR, 
DNaseI treatment was performed on the R N A  sam­
ples using the Message-Clean™ kit (GenHunter 
Corporation, Nashville, TN). For differential 
display the RNAm ap™ protocol (GenHunter) was 
used with some minor modifications. Differing 
from the original protocol, we used [32P]-dATP 
instead of [35S]-dATP. For the PCR, combinations of 
the four T12M N  primers together with six arbitrary 
primers, A P 1, 2, 6, 7, 1 1 , 12 [53], were used.
Northern blotting
Ten micrograms of total R N A  were treated 
with glyoxal/DMSO [126], separated on a 1.2% 
agarose gel and blotted onto a Hybond N+ 
membrane (Amersham, Aylesbury, UK). cDNA 
probes were radiolabeled by [32P]-dATP incorpora­
tion using a random-primed D N A  labeling kit 
(Roche Diagnostics GmbH, Penzberg, Germany). 
Membranes were hybridized overnight with the 
radiolabeled probes at 65°C in a hybridization mix 
(0.25 M  sodium phosphate buffer pH 7.2, 7% SDS, 
1% BSA, 1 mM EDTA, 0.1 mg/ml single stranded 
salmon sperm DNA). Afterwards membranes were 
washed at 65°C with buffers containing decreasing
amounts of salt (1% SDS, 1 mM EDTA and 0.25­
0.05 M  sodium phosphate pH 7.2), and autoradio­
graphed using Kodak Xomat-S films.
cDNA library screening, sequencing and 
homology searching
cDNA probes were labeled as described before 
[126] and hybridized to a ÀZAP cDNA library of 
the human melanoma cell line MV3, kindly 
provided by Dr. G. Swart (Dept. of Biochemistry, 
University of Nijmegen, The Netherlands). After 
isolation of a full-length cDNA, both strands were 
sequenced using the Dye Terminator Reaction Mix 
(Perkin Elmer, Norwalk, CT). Homology searches 
were performed with BLAST  [80] and other 
software on all kinds of public servers of D N A  and 
protein databases as described earlier [152].
R T-PCR
Synthesis of cDNA (10' at 25°C, followed by 59' 
at 42°C) was performed on 0.5 - 1.0 |ag of total RN A  
using the A M V  RT kit (Roche Diagnostics GmbH). 
The reaction mixture was supplemented with 0.04 
U  of random hexadeoxynucleotide primers, 2 |al 25 
mM MgCl2, 1 |al 10 mM dNTPs, 1 |al of RT buffer 
(100 mM Tris/HCl pH 8.3, 500 |aM KCl), 25 U  
RNasin, 10 U  A M V  RT and water to a final volume 
of 10 |al. For amplification one tenth of the cDNA 
was supplemented with 2.5 |al PCR-buffer (200 mM 
(NH4)2SO4, 750 mM Tris/HCl pH 9, 0.1% Tween), 5 
|al 1M dNTPs, 10 pmoles of each primer, 2.5 |al 15 
mM MgCl2, 0.15 U  of Thermoperfectplus™ D N A  
polymerase (Integro, Zaandam, The Netherlands) 
and water to a final volume of 25 |al. PCR 
conditions were 45" at 94°C, 1' at 59°C and 1'30" at 
72°C for 30 cycles. These cycles were preceded by 3 
min. denaturation at 94°C and followed by a 5 min.
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elongation step at 72°C. The primer combination 
used was:
sense: 5'- CTGCCGCAGACATTGAAGAA-3' 
antisense: 5'- TCCATGAATTCCTCCTCCTC-3'
The PCR product length was 297 bp. When nested 
PCR was performed the conditions were 30" at 
94°C, 45" at 59°C and 1' at 72°C for 30 cycles, again 
preceded by denaturation and followed by 
elongation steps as described for the first PCR. For 
this nested PCR we used 2 |al of 100 times diluted 
product from the first PCR, again in a total volume 
of 25 |al. Nested primers used were: 
sense: 5'-TGTGAATCCAACGAGGTGAA-3' 
antisense: 5'-TTGATTCTGTTCTCTCGGGC-3' 
Nested PCR product length was 188 bp. 
ß2-Microglobulin primers used were: 
sense: 5'-CTCGCGCTACTCTCTCTTTCT-3' 
antisense: 5'-TGTCGGATTGATGAAACCCAG-3' 
The ß2-Microglobulin PCR product length was 136 
bp. D N A  molecular weight markers were from 
Roche Diagnostics GmbH.
Chromosomal localization
Chromosomal localization of the gene was 
determined by genomic PCR on a panel of hamster/ 
human and mouse/human hybrid cell lines [154]. 
For this PCR we used the intron enclosing primers 
of the first PCR shown above, yielding a 1 kb PCR 
product.
Plasmid construction and transfection
For localization studies we cloned a fragment 
(bp 1-330), containing the full length ORF minus 
the termination codon, in the SacI-KpnI sites of 
pEGFP-N3 (Clontech, Palo Alto, CA). This fuses 
eGFP C-terminally to our fragment with a linker 
coding for amino acids RSIAT. The in-frame
junction was confirmed by sequencing.
Transfections were performed using 
Fu G EN E™ 6  transfection reagent (Roche 
Diagnostics GmbH). In short, cells were seeded in 6 
well plates and grown till subconfluency. 
Transfections were performed with 1 |ag plasmid 
construct and 3 |al FuGENE™6 in 2 ml medium. 
Transient expression of the fusion protein was 
checked within 48 hours. Stable transfectants were 
created under Geneticin (Roche Diagnostics 
GmbH) selection (500 |ag/|al).
To visualize expression of the fusion protein, 
cells (grown on coverslips in 6 well plates) were 
fixed with 4% paraformaldehyde for 15 minutes at 
room temperature and subsequently placed for 2 
minutes in acetone at -20°C. Air-dried coverslips 
were put on a glass slide and mounted with 10 |al 
Tris-buffered glycerol (per 100 ml: 90 ml glycerol; 2 
ml Tris/HCl pH 8; 8 ml H 2O) containing 1:4 
Vectashield (Vector, Burlingame, CA) and 1:10,000 
D A PI (Sigma, Zwijndrecht, The Netherlands). 
Fluorescent images were obtained using a fluores­
cence microscope equipped with a CCD camera.
Western blotting
Cultured cells were lysed in SDS-lysis buffer 
(1% SDS; 5 mM EDTA; 10 ^g/ml leupeptin (Sigma); 
200 ^g/ml A EBSF (Sigma) and 10 ^g/ml chymo- 
statin (Sigma) in PBS). After centrifugation equal 
protein amounts of supernatant were diluted 1:1 
with non-reducing sample buffer and boiled for 5 
minutes. These samples were size-separated using 
SDS PA G E on a 10% gel along with a protein 
marker and afterwards blotted electrophoretically 
on a nitrocellulose membrane in blotting buffer (25 
mM Tris/HCl pH 8.6; 192 mM glycin; 20% 
methanol and 0.02% SDS). The marker-lane was
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separated and stained with amidoblack (0.1% 
amidoblack in methanokacetic acid:water of 
45:10:45) for size-reference. Previous to incubations 
blots were washed for 15 minutes in PBST and 
overnight incubated at room temperature with 
blocking solution (PBST containing 5% low fat milk 
powder and 0.01% antifoam A  (Sigma)). The blot 
was incubated for 1 hour with anti-eGFP poly­
clonal rabbit antiserum as first antibody and with 
peroxidase-labeled swine-anti-rabbit antiserum 
(Dako, Glostrup, Denmark) as second antibody. A ll 
incubations were performed in blocking solution 
and after each step the blot was washed 3 times 10 
minutes in PBST. Detection was done with ECL 
chemoluminescence (Roche Diagnostics GmbH) 
according to manufacturer's protocol. Blots were 
then exposed to Kodak Xomat-S films and 
developed.
R ESU LT S  
Isolation and cloning
Comparing m RNA expression between human 
melanoma cell lines 1F6 and 1F6m with differential 
display, using primer T12M A  in combination with 
A P 1 [53], yielded a 300 bp differential cDNA band 
(not shown). The band was abundantly present in 
the 1F6m lane and absent in the 1F6 lane. To study 
the expression in a broader panel of human mela­
noma cell lines with known metastatic behavior 
after subcutaneous inoculation into nude mice we 
performed Northern blotting using the 300 bp 
cDNA as a probe. This revealed a m RNA of about 
0.5 kb that was specifically expressed in the highly 
metastatic cell lines MV3, BLM  and 1F6m (Figure 
1). No expression could be detected in the 
intermediate and low metastatic cell lines.
1 2 3 4 5 6 7
To isolate a full length cDNA clone we 
screened a ÀZAP cDNA library of the MV3 
melanoma cell line using the 300 bp cDNA 
fragment as a probe. A  408 bp cDNA was picked 
up (EM BL: AJ238277). Sequencing revealed a 
perfect 3' match with the probe used and showed 
an ORF coding for a protein of 97 amino acids 
(Figure 2). This putative protein contains a possible 
bipartite nuclear localization signal (NLS) (a.a. 40­
57), though it is not completely consensus [155]. 
Another remarkable feature is its high content of 
glutamic acid residues (14%) resulting in an acidic 
C-terminal cluster (a.a. 83-89). Overall one third of
*  #  — 0.5 kb
Figure 1.
Northern blot analysis on a panel of human melanoma cell 
lines w ith different metastatic capacity after subcutaneous 
inoculation into nude mice. The blot is hybridized w ith the 
300 bp differential display cDNA. A rrow  indicates a band of 
0.5 kb exclusively present in the highly metastatic cell lines. 
Lane 1: 530; lane 2: 1F6; lane 3: M14; lane 4: Mel57; lane 5: 
MV3; lane 6: BLM ; lane 7: 1F6m.
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♦
c a a a a g c c t g c c g c a g a c a t t g a a g a a c c a a t a t a t a c a ATG GAC AAA CAA TCC 54
M D K Q S 5
AGT GCC GGC GGG GTG AAG AGG AGC GTC CCC TGT GAA TCC AAC GAG 99
S A G G V K R S V P C E S N E 20
GTG AAT GAG ACG ATG CCG GAG ACC CCA ACT GGG GAC TCA GAC CCG 144
V N E T M P E T P T G D S D P 35
CAA CCT GCT CCT AAA AAA ATG AAA ACA TCT GAG TCC TCG ACC ATA 189
Q P A P K K M K T S E S S T I 50
CTA GTG GTT CGC TAC AGG AGG AAC GTG AAA AGA ACA TCT CCA GAG 234
L V V R Y R R N V K R T S P E 65
GAA CTG CTG AAT GAC CAC
<---
GCC CGA GAG AAC AGA ATC AAC CCC CTC 279
E L L N D H A R E N R I N P L 80
CAA ATG GAG GAG GAG GAA TTC ATG GAA ATA ATG GTT GAA ATA CCT 324
Q M ■ E E E F M E I M V E I P 95
GCA AAG TAG c a a g a a g c t a c a t c t c t c a a c c t t g g g c a a t g a a a a t a a a g t t t g a g 380
A K * 97
a a g c t g a a a a a a a a a a a a a a a a a a a a a a 408
Figure 2.
CTp11 cD N A and deduced protein sequence. Prim ers used for PC R  are indicated by arrows (first PCR: closed arrowheads; 
nested PCR: open arrowheads). Polyadenylation signal is underlined, putative nuclear localization signal is shaded gray 
and poly-E acidic domain is shaded black. The stopcodon is marked by an asterisk.
the residues are charged (18 negative; 14 positive) 
and the expected molecular weight is 11 kD. The 
protein has a calculated pi of 5.0.
Homology search and chromosomal localization
Checking all kinds of databases we found 
homology of more than 90% with three human 
genomic clones (HS433M19; HS376H23; 
HSG164F24), all localized on chromosome X. The 
homology with HS433M19 even narrowed the 
gene-localization down to Xq26.3-Xq27.1. PCR  on a 
panel of human chromosome specific rodent/ 
human hybrid cell lines confirmed localization of 
the gene on chromosome X (not shown). Based on
the length of the genomic PCR  product and on the 
sequences of the three human genomic clones we 
deduced that the gene consists of two exons 
separated by an intron of approximately 655 bp 
which is located near basepair 112.
Homology on cD N A  level was restricted to 
several human ESTs which were all from testis 
(zt95b09; qg57b01; qe04h11; EST95628/EST95629) 
and which all code for the same putative protein. 
No substantial homology was found with clones of 
other species.
Expression profile
in addition to Northern blotting of our panel of
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Cell line Metastatic potential Cultured cells Xenografts 1 Table I.
530 low - —
m RN A expression determined by 
RT-PCR in cultured human mela-
1F6 low — NT noma cell lines and in subcutaneous
MV1 intermediate - — xenograft lesions. 1 NT: not tested
M14 intermediate — NT
Mel57 intermediate — —
1F6m high + +
MV3 high + +
BLM high + +
human melanoma cell lines with known metastatic 
behavior we also performed RT-PCR on R N A  of 
these cell lines. The PCR  results confirmed the 
expression pattern of the melanoma cell lines seen 
on Northern blots (Table i). A  specific product 
could only be detected in the highly metastatic cell 
lines 1F6m, MV3 and BLM . RT-PCR analysis on 
corresponding xenograft material also showed an 
expression profile that completely matched with 
the expression profile of the cultured cell lines (not 
shown).
Analysis of a larger series of human melanoma 
cell lines not studied in our nude mouse model 
showed expression in 3 (BRO, E10 and 518A2) out 
of 15 cell lines (Table ii).
Regarding expression in cell lines derived from 
other types of malignant tumors (Table ii) we 
found expression in 5 out of 17 bladder carcinoma 
cell lines whereas 6 kidney carcinoma cell lines and 
7 prostate carcinoma cell lines did not express the
gene. Finally, of 16 cell lines from other histological 
type then the ones already mentioned only two 
were positive (fibrosarcoma HT1080 and osteosar­
coma U2OS).
Expression of the gene in normal human 
tissues determined by RT-PCR is shown in Figure 
3. From 17 different tissue samples tested only 
testis was found to be positive.
Since we are especially interested in melanoma 
and 25% of the melanoma cell lines tested 
expressed the gene we screened a series of 
melanocytic lesions covering all stages of tumor 
progression for presence of the gene transcript 
(Figure 4). Nested RT-PCR analysis showed that 
PCR product was only detectable in advanced 
stages of melanocytic tumor progression. Three out 
of 4 primary melanomas (PM) and 4 out of 6 
melanoma metastases (MM ) were positive. No 
expression was found in normal skin (NS), 
common naevus naevocellularis (NN ) and atypical
Table II.
m RN A expression determined by RT-PCR in 
human tumor cell lines. 1 melanoma cell lines 
listed in  Table i  are included
Type of tumor cell line Expression
kidney 0/6
prostate 0/7
bladder 5/17
melanoma 6/23 1
other 2/16
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Figure 3.
(A ) RT-PCR on R N A  isolated from 17 different fresh 
normal human tissues. O nly testis is positive (297 bp 
cD N A band). In  a few samples a weak genomic D N A  
band is visible (1 kb). (B ) Control RT-PCR of ß2- 
M icroglobulin.
Figure 4.
(A ) Nested RT-PCR (188 bp) on R N A  isolated from 
samples of normal human skin and on R N A  isolated 
from tissue samples containing lesions w ith different 
stages of melanocytic tumor progression (N S = nor­
mal skin; N N  = common naevus naevocellularis; A N  
= atypical naevus; PM  = prim ary melanoma; M M  = 
melanoma metastasis). (B ) Control RT-PCR of ß2- 
M icroglobulin.
nevus (AN). Primary cultures of normal human tional samples of fresh normal human tissues and
foreskin melanocytes and cultures of naevus cells in tumor lesions from the same types of tissue. The
were also negative (not shown). results are summarized in Table III. Using nested
Finally, we determined expression in addi- PCR in the normal tissues expression was only seen
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Tissue type Normal tissue Tumor tissue
pancreas 0/3
esophagus 0/3
lung 0/3
breast 0/1
colon 0/3
bladder 0/1
melanoma 0/4 1
testis 3/3
in the three testis samples, which were already 
positive after the first PCR (30 cycles). The other 
normal tissues did not reveal any PCR product. In 
the tumor samples only sporadically expression 
was seen: lung (1 out of 5), breast (1 out of 4), colon 
(2 out of 9) and bladder (1 out of 11). Pancreas (n=5) 
and esophagus (n=6) tumors were negative.
Regarding the testis lesions studied 10 out of 
the 17 tumor samples were positive, only after 
nested PCR, while three normal testis samples were 
positive already after the first round of PCR.
Molecular weight determination and cellular 
localization
To determine the molecular weight of the 
protein Western blotting was performed on lysates 
from the BLM  transfectant using an anti-eGFP 
polyclonal antibody to detect the fusion protein. 
From Figure 5 it is evident that the transfected cells 
express the fusion protein. No specific band is seen 
in the lane containing lysate of non-transfected 
BLM  cells. From the difference in size of eGFP (27 
kD) and the fusion protein (38 kD) we deduced the 
size of the protein to be about 11 kD. Based on the 
m RNA expression profile and the molecular 
weight we named the protein CTp11: cancer/testis- 
associated protein of 11 kD.
0/5 
0/6 
1/5 
1/4 
2/9 
1/11 
7/10 
10/17 2
To get insight into the subcellular localization 
of CTp11 we fused the complete ORF in front of 
eGFP and transfected COS-1 cells. As a control we 
transfected COS-1 cells with a construct coding for 
eGFP alone. Fluorescence microscopy of COS-1 
cells transfected with eGFP alone revealed the 
eGFP protein to be present both in the cytoplasm 
and in the nucleus as expected (Figure 6A-C), 
whereas COS-1 cells expressing the fusion protein 
showed specific nuclear localization of the product
1 2 3
-------- < -  50 kD
4 P  4 -  38 kD
M - 27 kD
Table I II .
m RN A expression determined by nested 
RT-PCR in normal human tissues and in 
different types of cancer. 1 normal skin;
2 positivity may be caused by contami­
nating normal tissue
Figure 5.
Western blot analysis of cell lysates from BLM  (lane 1), BLM  
transfected w ith a construct containing only eGFP (lane 2) 
and BLM  w ith a construct containing the fu ll length cDNA/ 
eGFP fusion construct (lane 3). Bands were visualized by 
incubation w ith a polyclonal antibody against eGFP. Note 
that the 27 and 38 kD bands are specific and that the band at 
50 kD is aspecific.
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(Figure 6D-F); nucleoli appear negative for the 
fusion protein. Transfection of the human 
melanoma cell line B LM  showed comparable 
results (not shown) with identical nuclear 
localization.
D IS C U S S IO N
Here we report the identification of CTp11 
(cancer/testis-associated protein of 11 kD), detected 
with m RN A  differential display in search of 
potential diagnostic and prognostic markers for 
melanoma progression. The CTp11 cDNA was iso­
lated from human melanoma cell line 1F6m, a me­
tastatic subline of 1F6 which in turn was negative 
for this expression. Overall characteristics place the 
gene in the family of cancer/testis antigens (CTAs)
of which the first members, named M AGEs 
(melanoma antigens), were described by the group 
of Boon [156].
These CTAs, expressed in testis and cancers, 
are potential immunotherapy candidates [157]. 
Because testis is a immunological privileged site, 
lacking H L A  expression necessary for antigen 
presentation and direct contact with cells of the 
immune system, only the cancerous cells w ill be 
targetted by the cytotoxic T-cells [158,159] after 
immunotherapeutic treatment [159]. Some prelimi­
nary results have been reported for immuno­
therapy with MAGE-derived peptides [160].
The putative protein encoded by the ORF in the 
full-length cD NA  has a bipartite-like NLS. Though 
this was not completely consensus we did find a 
specific nuclear localization after fusing the ORF in
Figure 6. Fu ll colour on page 178
Fluorescence microscopy of COS-1 cells transfected w ith a construct containing only eGFP (A, B, C) or the full-length 
CTp11 cDNA/eGFP fusion-construct (D, E, F). DAPI-images show cell nuclei. (A , D ), while GFP-images show eGFP (B ) and 
cDNA-eGFP (E ) distribution. Finally, the merged images of A  and B (C ) and D  and E  (F) are represented.
A C
D
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front of eGFP, indicating that the bipartite-like 
nuclear localization sequence is indeed effective 
(Figure 6). The bipartite NLS consensus comprises 
two basic amino acids (lysine (K) or arginine (R)) 
separated by a region of ten amino acids from a 
basic cluster in which three out of the next five 
residues must be basic [155]. The spacer of ten 
amino acids was shown to be optimal, though 
effective bipartite nuclear localization signals were 
also found with elongated spacers [161]. This 
indicates the likeliness of the bipartite sequence in 
CTp11 (a.a. 40-57), with a 12 residue spacer, being 
responsible for localization in the nucleus. Bipartite 
N LS sequences have also been found in several 
members of the SSX-family, which also belong to 
the group of cancer/testis antigens [162]. The acidic 
C-terminal region with the high content of glutamic 
acid residues resembles a GAL4 domain, shown to 
be effective in transcriptional activation after inter­
action or fusion with a D N A  binding protein or 
domain [36]. The fact that CTp11, like the SSX 
proteins [162] and melanocyte-specific gene 1 
(MSG1) [163], lacks a DNA-binding domain 
strongly suggests that it interacts with the 
transcription-initiation complex in order to concert 
its putative transcriptional regulation. The high 
percentage of charged amino acids might 
contribute in such a protein-complex interaction.
The expression profile of CTp11 in normal 
tissues, tumor cell lines and tumor samples place 
the gene in the group of cancer/testis antigens, 
which already include M A G E  [164], BA G E  [165], 
G A G E [166], SSX [167], NY-ESO-1 [158], LAGE-1 
[168], PAGE-1 [169,170], and SCP-1 [171].
Criteria genes should fulfill to be considered as 
a member of the family of cancer/testis antigens are 
formulated in the literature [158,172,158]: (i)
predominant expression in testis and generally not 
in other normal tissues, (ii) induction/activation of 
m RNA expression in a wide range of human 
tumors, (iii) expression in malignancies in a 
lineage-nonspecific fashion, (iv) often existence of 
multigene families, (v ) mapping of the gene, with 
some exceptions, on the X-chromosome. CTp11 
clearly qualifies as a CTA-family member since it 
shares criteria i, ii, iii and v. Regarding presence of 
CTp11 highly homologues family members further 
investigation is required.
The CTp11 gene is localized on the X 
chromosome (Xq26.3-Xq27.1) and consist of two 
exons separated by an intron of about 655 bp as 
confirmed by PCR. This position is right next to the 
MAGE-C subfamily (Xq26) [164] and nearby CTAG 
(the gene for NY-ESO-1) and the MAGE-A cluster 
(both Xq28) [173].
CTp11 expression was found in 25-30% of the 
melanoma and bladder tumor cell lines tested, 
while cell lines established from other tumor types 
were only sporadically positive. For melanoma cell 
lines, which are the best studied regarding CTA 
expression, the percentage of positivity is 
comparable to the percentages of positivity for NY- 
ESO-1 (18%) [158,168], SSX-2 (25%) [174] and 
MAGE-B1 and -B2 (22% and 33%) [175,176]. 
MAGE-A1 (66%) [159,177] has a markedly higher 
expression coverage in melanoma cell lines and is 
expressed in 41% of other human tumor cell lines.
Testis-specific expression regarding normal 
tissues seen by RT-PCR confirms the exclusiveness 
of CTp11 homology with only ESTs from testis. In 
fresh human tumor samples we found melanoma 
to have the highest percentage of CTp11 positivity 
(70%; n=10). Comparable positivity was seen in 
primary (3 out of 4) as well as metastatic melanoma
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(4 out of 6). This percentage may be one of the 
highest compared to the other CTAs in melanoma, 
being 8, 17, 22, 35, 44, 44 and 52% for SCP-1, GAGE, 
BAGE, MAGE-1, SSX-2, NY-ESO-1 and MAGE-3 
respectively [178]. The relatively high percentage of 
CTp11 in bladder cell lines (30%) was not detected 
in bladder tumor samples in which only 1 out of 11 
was found to be positive.
The absence of CTp11 in benign and pre­
neoplastic stages of melanocytic tumor progression 
suggests an induction of expression in melanoma 
lesions rather than an upregulation of expression. 
Demethylation of the X-chromosome in testis and 
cancer might be an important factor in this induc­
tion of expression, as described previously for 
some CTAs [164,171,175]. However specific modu­
lation of this demethylation or additional factors 
are necessary to explain the differential expression 
patterns and the differences in percentages of 
positivity of the various CTAs in different tumor 
types [167].
Interestingly testis tumors showed a down- 
regulation of CTp11 expression compared to 
normal testis tissue, since only 10 out of 17 tumor 
lesions were positive after nested PCR. No 
positivity of testis tumor samples was seen after the 
first PCR. Positivity of these testis lesions, both 
seminomas and non-seminomas, could be caused 
by small amounts of normal testis tissue present. 
Another explanation may be that the tumor in the 
testis arose from a CTp11 negative cell type. 
Further studies, preferentially using antibodies, are 
necessary to address this question and to reveal 
which of the cells in normal testis and testis tumors 
express CTp11. Regarding the other CTAs it is 
known that MAGE-1 is mainly expressed in germ 
cells of the testis [179] and this finding is in line
with the fact that seminoma have a higher posi- 
tivity rate for MAGE-expression than non­
seminoma tumors [180]. Concerning the function of 
CTp11 we can only speculate about a role in 
transcriptional regulation, based on its nuclear 
presence in combination with its C-terminal 
negatively charged acidic domain, as seen in 
several transcription factors [36,181]. Biological 
functions for most CTAs are unknown so far. Only 
for SCP-1, a meiotic protein, aberrant expression 
has been implicated in genomic instability of cancer 
cells [171]. SSX-2 characteristics point out towards a 
possible role in negative control of proliferation 
[182]. MAGE-1 and MAGE-3 have been described 
as cytoplasmic proteins [183].
In summary, we isolated and characterized a 
new gene which, based on several criteria 
described in literature, can be placed in the family 
of cancer/testis antigens. Although expression was 
seen in several tumor types, melanoma had the 
highest percentage of expression. Like some other 
cancer/testis antigens the CTp11-protein is located 
in the cell nucleus.
For the near future it would be interesting to 
see if CTp11 contributes to additional positivity of 
tumor samples (especially melanoma) negative for 
other known CTAs, thereby making it attractive for 
use in immunotherapeutic treatment. So far 
coverage of about 75 %  of melanoma samples 
positive for at least one CTA can be achieved [178]. 
Immunotherapy using multiple tumor antigens 
might increase efficacy of treatment and minimize 
tumor cell escape [184]. Usefullness of CTp11 in 
differential diagnosis of melanocytic lesions and 
perhaps correlation with patient survival w ill need 
more extensive studies with larger numbers of 
tumor lesions.
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Multigenicity is one of the features 
of cancer/testis-associated genes. In the present study we analyzed the 
number and expression of genes of the SPANX01?11 family of cancer/testis- 
associated genes. Genomic database analysis, next to the four previously 
described SPANX genes, revealed the presence of a novel gene: SPANXE. 
Moreover, we detected an allelic variant of SPANXB resulting in one 
amino acid substitution in the encoded protein: SPANXB'. Most SPANX 
genes are present on contig NT_011574 located at Xq26.3-Xq27.1. Based 
on EST databases and RT-PCR analysis three additional novel SPANX 
sequences were identified, though not represented so far in the human 
genome sequence. Sequence alignments justify a subdivision of this gene 
family based on the absence (SPANXA-likes) or presence (SPANXB) of an 
18 base pair sequence stretch in the open reading frame. The alignments 
also reveal an unusually high level (99%) of intron homology. 
Furthermore, the nucleotide variations in the open reading frame almost 
all lead to amino acid substitutions. Southern blot and database analyses 
indicate that SPANX sequences are exclusively present in primates. With 
RT-PCR analysis on human sperm cell precursors and tumor cell lines 
most family members could be detected. SPANXB was only found in 
sperm cell precursors and could not be detected in the tumor cell lines 
tested. Overall SPANXA was the most frequently expressed SPANX 
variant in melanoma and glioblastoma cell lines.
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INTRODUCTION MATERIALS AND METHODS
Looking for differential gene expression during 
melanocytic tumor progression we identified 
CTp11 [185]. This gene coding for a small putative 
nuclear protein of 97 amino acids was expressed in 
normal testis and in metastatic lesions of 
melanoma, suggesting a cancer testis-associated 
expression profile. Based on genomic PCR using 
hybrid cell lines and on localization of BACs 
containing the gene, CTp11 was mapped on 
chromosome Xq26.3-27.1. Six months later CTp11 
homologues SPAN-Xa and SPAN-Xb (Sperm 
Protein Associated with the Nucleus, X-linked) 
were described as two proteins localized in nuclear 
craters and cytoplasmic droplets of ejaculated 
spermatozoa [186]. Using polyclonal SPAN-X 
antibodies 19 spots were detected on a 2-D Western 
blot indicative of a large number of SPAN-X 
homologous proteins. Shortly later CTp11 was 
renamed SPANXC [187].
Most cancer/testis-associated genes (CTAs) 
have been identified via their specific expression in 
malignancies and testis. They often represent 
multigene families. Database mining for the 
presence of SPANX homologues revealed four 
related Unigene entries: SPANXA: Hs.334464; 
SPANXB: Hs.293266; SPANXC: Hs.343879; and 
SPANXD: Hs.334482. First analyses showed several 
variations in the EST sequences of the Unigene 
entries for SPANXB and SPANXC transcripts.
To investigate the complexity of the SPANX 
gene family we performed database analyses and 
Southern blotting. RT-PCR was used to determine 
the expression of known and novel members of this 
gene family in human male germ cells and tumor 
cell lines.
Testis tissue
Human testes were obtained after surgical 
intervention to treat prostate cancer. The Local 
Ethical Committee (Medical School of Poznan) has 
approved the utilization of surgically removed 
organs for described experiments and written 
consent was obtained. Only organs from patients 
not treated with cytostatic drugs were selected for 
this study. In all cases, the active spermatogenesis 
was preserved and documented by evaluation of 
the status of seminiferous epithelium.
Isolation and fractionation of male germ cells
Germ cells were isolated, purified and 
fractionated according to previously described 
methods [188,189]. Both discontinuous and con­
tinuous (twice) Percoll gradients were used. 
Standard histochemical methods were used for the 
morphological identification of these cells [188]. 
Only fractions not contaminated with somatic cells 
(myofibroblasts, macrophages, Leydig cells) were 
selected for the molecular studies. Elongated 
spermatid fraction reached almost a 100% purity 
while the round spermatids were contaminating 
with various proportions of spermatocytes (up to 
15%).
Cell lines
The origin and culture conditions of the 
melanoma cell lines Mel57 [190] and MelJuSo [191] 
were described previously. Human glioblastoma 
cell line T98 was from the American Type Culture 
Collection (ATCC, Rockville, MD). EBV trans­
formed lymphoblastoid monkey cell lines were 
obtained from the European Collection of Cell
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Cultures (ECACC; e.g. gorilla EB(JC)660, chimpan­
zee EB176(PTR), orangutan EB185(JC)).
DNA isolation
Genomic DNA of eukaryotic cells was 
prepared as previously described [192]. Plasmid 
DNA was isolated using a standard alkaline lysis 
method [126]. Plasmid DNA solutions were treated 
20 min. with RNAse A (20 ^g/ml) (Carl Roth 
GmbH, Karlsruhe, Germany). To further purify the 
sample, plasmids were precipitated on ice in the 
presence of 0.4 M NaCl and 6.5% PEGsim
Southern blot analysis
Nine |ag of genomic DNA (cut with HindIII or 
P stI) were size-separated on a 0.7% agarose-gel and 
transferred to a Hybond N+ membrane using a 
standard alkaline capillary method [126]. Mem­
branes were hybridized overnight with a DIG- 
labeled SPANXCctp11 [185] probe at 68°C in 
hybridization solution (0.25 M sodium phosphate 
buffer pH 7.2, 1 mM EDTA, 20% SDS, 0.5% 
blocking reagent (Roche Diagnostics, Mannheim, 
Germany). After washing, three times 20 min. at 
65°C in wash-buffer (20 mM sodium phosphate 
buffer pH 7.2, 1 mM EDTA, 1% SDS), hybridized 
probes were visualized using the DIG nucleic acid 
detection kit (Roche Diagnostics, Mannheim, 
Germany) and Kodak Xomat S films.
RNA isolation
Total RNA was isolated using the peqGOLD 
TriFast™ kit (peqLAB, Erlangen, Germany) follow­
ing manufacturer's protocol. RNA samples were 
checked for integrity by gel electrophoresis.
PCR and RT-PCR
Synthesis of cDNA (60 min. at 42°C) was 
performed on 1.0 |ig of denatured (15 min. at 65°C) 
total RNA. The 20 |il reaction mixture contained 
100 pmol of oligo-(dT)15 primers, 1x Expand™ 
reverse transcriptase buffer, 100 |aM of each dNTP, 
1 mM DTT, 20 U RNasin and 50 U Expand™ re­
verse transcriptase (Roche Diagnostics, Mannheim, 
Germany). PCR amplifications were performed on 
1 |al of cDNA or 100 ng of genomic DNA in 1x 
PCR-buffer (Amersham Pharmacia Biotech, 
Buckinghamshire, UK) with 200 |aM of each dNTP,
7.5 pmol of each primer, 2 mM MgCl2 and 0.5 U 
Taq DNA polymerase (Amersham Pharmacia 
Biotech). PCR conditions were 30 sec. at 94°C, 45 
sec. at 60°C and 60 sec. at 72°C for 30 cycles. Total 
PCR samples were analyzed on agarose gels. As 
control for cDNA quality we performed a PCR 
with primers specific for HLA-E:
HLA-Es: 5'-cagcatgaggggctacccc-3'
HLA-Eas: 5' -gtgtgaggaagggggtcatc-3' 
which is expressed in human gametogenic cells 
[189]. Specific primers for the SPANX subsets are: 
5'-actgtagacatcgaagaacc-3' (Xb-F) and 
5'-cgaagtttgagggatgtagc-3' (Xb-R) for SPANXB; 
5'-ctgccgcagacattgaagaa-3' (Xa-F) and 
5'-ccaaggttgagagatgtagc-3' (Xa-R) for the 
SPANXA-like subfamily. As common reverse 
primer for all SPANX variants we used: 
5'-ttgattctgttctctcgggc-3' (Xall-R).
Database analyses and alignment
Homology searches for SPANX sequences were 
performed with the BLAST program [80] via the 
NCBI server (www.ncbi.nlm.nih.gov). Sequence 
procedures and alignments (ClustalW) were done 
with the BCM search launcher (searchlauncher.
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bcm.tmc.edu). The 5'-flanking regions of the 
SPANX genes were analyzed with the TRANSFAC 
database using MOTIF (www.motif.genome.ad.jp).
RESULTS 
Southern blot analysis of hum an genomic DNA
To get a first impression on the multigenicity of 
the SPANX genes in the human genome, we 
performed Southern blot analysis using genomic 
DNA of human thymocytes and of human 
melanoma cell line MelJuSo (Figure 1) The P stI 
lanes contain four bands ranging from 6 to 13 kb of 
about equal intensity. The H indIII pattern reveals 
three bands, of which the middle band (9.5 kb) is 
much more intense. Since the SPANXC gene of 
about 1 kb, located in BAC clone AL109799, does 
not contain H indIII or P stI restriction sites, the 
number and sizes of the bands are indicative for 
the existence of several genes homologous to the 
SPANXC sequence.
HTGS database query
At the start of this study the SPANX family 
was divided over four Unigene entries: Hs.334464
(SPANXA), Hs.293266 (SPANXB), Hs.343879 
(SPANXC) and Hs.334482 (SPANXD). BLAST 
searches using the denominator sequences of all 
four SPANX Unigene entries (AF098306, AF098307, 
AJ238277 and AF312765 respectively) identified 
several different SPANX genes, of which some 
have adjacent identical genes present on the same 
BAC or PAC clones (Figure 2). All genes exist of 
two small exons separated by an intron of about 
650 bp. The SPANXC gene was present in BAC 
clone AL109799. The SPANXA and SPANXB are lo­
cated as duplicated genes in AL121881 (SPANXA1 
and SPANXA2) and AL031078 (SPANXB1 and 
SPANXB2). BAC clone AL121881 also harbors the 
SPANXD gene as is the case for clone Z95703 (not 
shown).
Next to the four genes previously described we 
also identified two additional homologues. 
SPANXE, with highest homology to SPANXD, was 
situated in clone AC025096. Two identical se­
quences with only one nucleotide substitution in 
the coding region compared to SPANXB, were 
found in clone AL451048. This sequence, SPANXB', 
never co-occurred with SPANXB in cloned and 
sequenced PCR products either performed on
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Figure 1.
Southern  blo t analysis of h u m an  genomic 
DNA. Genom ic D N A  of h u m an  m elanom a cell 
line MelJuSo and  of h u m an  thym ocytes, 
treated  w ith  H ind III  or PstI, w ere probed w ith  
SPANXC cDNA.
62 Chapter 4
Figure 2.
Schematic representation  of hum an  BAC clones (AL121881, AL109799, AL451048, AL031078, AC025096) and  contig 
NT_11574.4 containing SPANX genes. Exons are depicted  by  num bered  boxes. N um bers indicate base-pair positions. Size 
references are given separately  for the bo ld  lines and  the (zoom ed-out) norm al lines.
NT 011574.4
AL121881 AL109799 AL451048
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SPANXB1 SPANXB2
cDNA or genomic DNA samples obtained from 
two male individuals (data not shown) and there­
fore is most likely another allele of the gene. This 
hypothesis is strengthened by the corresponding 
orientation and distances of their exons in clones 
AL031078 and AL451048 (Figure 2).
Of the duplicated genes (each couple present 
within 6 to 12 kb) only the SPANXA genes have a 
reverse orientation towards each other. Three of the 
BAC clones harboring SPANX genes are part of 
contig NT_011574 which is located on chromosome 
Xq27.1. The novel SPANXE gene was approved by 
the HUGO gene nomenclature committee and de­
posited in Genbank (AJ457792). We also deposited 
gene sequences for SPANXA (AJ457794), SPANXB 
(AJ457789), SPANXC (AJ457790) and SPANXD 
(AJ457791).
AC025096 
1 ^ ^ ^ ^ ^ * \ ™ ^ T 6 6 , 4 6 1
M3—0—"
92,088
SPANXE
EST database query
Beside analyses on genomic level we also 
performed BLAST searches using the EST 
databases and aligned all ESTs placed in the four 
SPANX Unigene clusters. We only included se­
quences that were represented by at least two 
individual ESTs. The data obtained revealed that 
the newly identified SPANXB' allele was indeed 
represented as ESTs (e.g. BG188065, BG207172). In 
the same Unigene cluster (Hs.293266) we 
furthermore found a new SPANX variant, which 
we named SPANXH (BG210314 and BG216253).
Most variants were detected among the ESTs 
that were placed in the SPANXC cluster. This 
cluster, next to SPANXC specific ESTs, contained 
several SPANXA, -D and -B' specific ESTs, as well 
as ESTs for two novel variants: SPANXG 
(BC005382 and BF212177) and SPANXI (BG182842
100,000 bp
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Figure 3.
A lignm ent of the pu tative  SPAN-X proteins. Exons boundaries 
are depicted  w ith  arrow s. The b ipartite  nuclear localization signal 
is boxed, w hile the acidic C-term inal part is underlined.
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and BG206671). SPANXE was not represented as 
EST. Since so far there is no evidence for the 
presence of the gene sequences we did not deposit 
SPANXH and -I.
SPANX ORFs
The putative proteins encoded by the ORFs 
present in the SPANX variants are aligned in 
Figure 3. Full length SPAN-Xh and SPAN-Xi 
putative proteins could not be deduced because of 
the limited size of the corresponding ESTs. We also 
included the allelic SPANXB' sequence. Based on 
the data the SPAN-X proteins can be divided into 
sequences with a deletion (ANEANK) at amino 
acid position 24 (SPAN-Xa-likes: SPAN-Xa, -Xc, - 
Xd, -Xe and -Xg (97 amino acids)) and one without 
(SPAN-Xb (103 amino acids)). SPAN-Xh and -Xi 
can not yet be placed into one of the two
subfamilies, though the C-terminal residues sug­
gest that these are SPAN-Xb-likes. A bipartite nu­
clear localization signal (KKxKTSESSTxLVxRYRR) 
is conserved in all SPAN-X proteins as is true for 
the high percentage of glutamic acid residues in the 
GAL4-like domain at the C-termini.
The SPAN-Xb proteins are about 75 to 80% 
identical to the proteins of the SPAN-Xa-like sub­
family. Members of the SPAN-Xa-like subfamily 
are about 90 to 98% identical to each other.
SPANX genes and transcripts
In Figure 4 we aligned all SPANX genomic 
sequences, including about 140 bp of the promoter 
regions and the intron site. The indicated 
transcription start sites are putative and based on 
previously reported mRNA sequences for 
SPANXA, -B and -C  [185-187]. The 18 bp deletion
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Figure 4.
A lignm ent of SPANX genes and  transcripts. Prom oter elem ents are show n  by  do tted  boxes, in  w hich consensus nucleotides 
are in bold. Putative transcrip tion  start sites are indicated  w ith  arrow heads. Prim ers are represented  by  sharp  arrow s w hile 
exon-intron boundaries are show n w ith  vertical lines and  arrow s w ith  filled arrow heads. D ouble underlined  the polyA-signal 
sequence, w hile X ho I rescriction sites are boxed. The ORF is capitalized w ith  the s tart and  s top  codons in bold.
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in the SPANXA-like sequences is located just prior 
to the end of exon 1. Throughout the ORFs there 
are 24 nucleotide substitutions and strikingly these 
all lead to amino acid substitutions (see Figure 3). 
All SPANX transcripts contain a poly-adenylation 
signal and all aligned SPANX genes have intron- 
exon boundaries with consensus gt-ag splice sites
[193]. Aligning the about 700 bp introns of the 
SPANX genes revealed a higher level of homology 
compared to the exon-sequences (data not shown).
The introns, containing a LTR46 long terminal 
repeat sequence of about 450 bp, are nearly identi­
cal for all genes (99%), while there is a substantially 
lower level of identity in the exon regions (91 to 
99%). The variation of promoter sequences lies 
between those of the intron and of the exons (96 to 
99%).
Expression profiles of SPANX genes
To get insight into the expression profile of the 
SPANX variants, we performed RT-PCR on total 
RNA of haploid male germ cells, two cutaneous 
melanoma cell lines (Mel57 and MelJuSo), glioblas­
toma cell line T98 and thymocytes. A first survey 
on SPANX mRNA expression was done on round 
and elongated spermatids with primer combina­
tions specific for the insert-containing variant 
(primers Xb-F and Xall-R) as well as for the insert- 
lacking variants (primers Xa-F and Xall-R). Both 
types of fractionated male germ cells were positive 
for both subfamilies of SPANX transcripts (Figure 
5). The HLA-E control PCR was positive for both 
samples of male germ cells. As additional positive 
control a lane is shown with a PCR on genomic 
DNA. For the SPANX PCRs this reveals an 
expected band of about 900 bp.
To obtain PCR products including the full ORF 
we used reverse primers further downstream. 
PCRs with these combinations (primers Xb-F and - 
R for SPANXB; primers Xa-F and -R for the 
SPANXA-like subfamily members SPANXA, -C, - 
D, -E, and -G) was performed on cDNA of sperm 
cell precursors, two melanoma cell lines, a 
glioblastoma cell line and thymocytes. Both types 
of PCR were negative for melanoma cell line 
MelJuSo and for thymocytes. PCR products
Figure 5.
(A) RT-PCR on RNA from  elongated and  round  sperm atids/ 
sperm atocytes for SPANXA-like transcripts (prim ers Xa-F and  Xa-R) 
and  SPANXB transcrip ts (prim ers Xb-F and  Xb-R). (B) RT-PCR for 
HLA-E (prim ers HLA-Es and  HLA-Eas). Control PCRs are done on 
genom ic DNA (+) and  w ater (-).
SPANXA-like SPANXB HLA-E
cDNA (242 bp) ■
A
G r?<? + <? +
DNA (900 bp) 
cDNA (260 bp)
B
DNA (1600 bp) 
cDNA (400 bp)
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obtained from the other samples were cloned and 
further analyzed for presence of SPANX variants 
by Xhol restriction analysis and some also by 
sequencing (Table I). SPANXB transcripts were 
only detected in sperm cell precursors. Several 
members of the SPANXA-like subfamily were also 
expressed in sperm cell precursors, but none of the 
cloned products contained the SPANXC sequence. 
Melanoma cell line Mel57 expressed all SPANXA- 
like variants, whereas glioblastoma cell line T98 
was only positive for SPANXA transcripts.
Promoter analysis
A survey for consensus transcription factor 
binding sites in about 400 bp of the promoter 
region of the SPANX genes was done with MOTIF 
(cut-off score of >95%). The 5'-flanking region 
contains potential DNA binding domains for cap
[194] at -377, Nkx-2.5 [195] at -367, MZF1 [196] at 
-350, SRY [197] at -233 and -97 and HSF2 [198] at 
-20; all positions correspond to the SPANXA gene
Putative CCAAT- (at -126) and TATA-Boxes 
(at -54) were only detected at lower cut-off levels of 
respectively 90% and 85%, though not for all 
S P A N X  genes. The CCAAT-Box of the SPANXB 
promoter was less consensus compared to the other 
aligned SPANX genes. A reasonable consensus 
TATA-Box was only present in the SPANXA-like 
subfamily members. Next to the SRY elements, we 
also found another sequence specific for testis- 
associated transcription factors. This 6-bp palin­
dromic sequence (at -136), just preceding the 
CCAAT-Box, was detected in the promoter of the 
histone H1t gene [199]. In the SPANX promoters no 
CpG islands could be detected. Analysis of 
upstream sequences revealed an ALU-sequence at 
about -700 bp (not shown).
Southern blot analysis of primate genomic DNA
Database queries for SPANX homologous 
sequences were negative for all non-human
(Figure 4; only shown starting at about -140).
SPANXB
PCR (Xb-F/R)
SPANXA-like subfamily
PCR (Xa-F/R) S a mples (n) Composition
Sperm cell precursors 30 =25% SPANXA 
=30% SPANXD, -E 
=45% SPANXG
Melanoma Mel57 43 =50% SPANXA 
=30% SPANXC 
=15% SPANXD, -E 
= 5% SPANXG
Glioblastoma T98 100% SPANXA
Table I.
m RNA expression profile of SPANX genes
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Figure 6.
Southern b lo t analysis on genomic 
DNA of several prim ates. (A) results 
w ith  SPANXC cDNA probe. (B) Con­
trol hybrid ization  w ith  a HLA-E DNA 
probe.
organisms including S. cerevisiae, C. elegans, D. 
melanogaster and M . m usculus. To see if SPANX 
genes are human-specific or arise late in evolution, 
we performed Southern blot analysis with PstI 
restricted genomic DNA of several primates 
(Figure 6). The SPANXC probe only recognizes two 
bands of 4.2 and 6 kb for chimpanzee (Pan 
troglodytes) and gorilla (Gorilla gorilla). No bands 
were visible in the lanes specific for orangutan 
(Pongo pygm aeus) or squirrel monkey (Saimiri 
sciureus), though HLA-E control hybridization was 
positive.
DISCUSSION
From our data it is clear that the SPANX family 
can be divided into SPANXB and SPANXA-like 
genes, differing mainly by the presence or absence 
of an 18 bp insert. SPANXB is only detected in 
sperm cell precursors and not in any of the tumor 
cell lines tested. All SPANXA-like variants except 
SPANXC could be detected in male germ cells. The
SPANXCCTp11, picked up from melanoma as 
described previously [185], might therefore not be a 
real CTA, but a tumor specific expressed gene. 
Since there were no clues for the presence of 
several SPANX variants at that time not all 
products were sequenced.
Though negative for SPANXB, members of the 
SPANXA-like subfamily are expressed in several 
tumors cell lines. Most of the transcripts analyzed 
were SPANXA (50% in melanoma cell line Mel57, 
100% in glioblastoma cell line T98). SPANXC was 
responsible for 30% of the SPANX expression in 
melanoma cell line Mel57. With respect to mela­
noma tumor tissues, a recent study, using 35 cycles 
of PCR, suggests a preferential expression of 
SPANXC in primary melanoma (9 out of 20) 
compared to melanoma metastases (7 out of 32) 
[200]. These finding are in contrast with our results 
in which we found expression of SPANXC only 
after nested PCR (60 cycles) in about 70% of both 
primary and metastatic melanoma lesions (n=10) 
[185]. In neither study was obvious which of the
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SPANX genes were responsible for the positivity 
since not all products were sequenced.
SPANXA and SPANXB genes, transcribed 
post-meiotically, are one of the few examples of 
haploid expression from X-linked genes [186]. This 
testis-specific expression of X-linked genes is nor­
mally underrepresented compared to autosomal 
genes [201]. Presence of SPAN-X proteins in 50% of 
the spermatids was expected, but surprisingly 
these were equally distributed over X- and Y- 
bearing germ cells. One explanation is that these 
transcripts are exchanged via intercellular bridges. 
The corresponding proteins were detected in 
nuclear vacuoles and in the redundant nuclear en­
velop of haploid round and elongated spermatids 
[187]. Normally, transcription is silenced after 
differentiation from round to elongated spermatids 
[202]. Presence of SPANX mRNA in fully 
developed spermatids, as shown for only a few 
other genes like HLA-E [189] and ß1-integrin [203], 
might be caused by stabilization of the transcripts 
after binding to protector proteins [204].
Differences in expression profiles between the 
SPANX genes could be due to the variations 
present in their promoters. Since there are no CpG 
islands and no differences in SRY elements or H1t 
sequences in the 5'-flanking region, other regula­
tory factors are involved. In contrast to the CTA 
MAGE-1, containing a CpG island (methylation- 
dependent control) and lacking consensus TATA- 
and CCAAT-Boxes [205], it is obvious that SPANX 
genes are under control of other regulatory mecha­
nisms.
With respect to functions of the transcription 
factors binding to the SPANX promoter elements, 
MZF1 was originally described as a transcriptional 
regulator of hematopoiesis [196], while Nkx-2.5
contains a sequences recognized by a cardiac- 
specific homeodomain gene [195]. HSF2, is a tran­
scription factor binding to heat shock elements to 
induce transcription of proteins like HSP70 [198]. 
Two other factors (SRY and H1t) have been impli­
cated in testis. The Y-chromosomal testis- 
determining factor SRY is essential for sperm 
development and is expressed in mouse embryos 
several days post-coitum [197]. The palindromic 
CCTAGG sequence, named H1t, was shown to be 
an element in the promoter of testis-specific histone 
H1t, located just upstream the CCAAT-Box. Ex­
pression of this histone was induced upon binding 
of a certain factor present in pachytene primary 
spermatocytes [199]. A similar promoter as the one 
found in SPANX genes has been described for a 
testis-specific isoform of the ACBP gene, called 
ELP, which like SPANX is expressed in late haploid 
stages of germ cell development. The combination 
of TATA-less promoter with presence of several 
testis-specific elements was also described for 
serine protease testisin, expressed by premeiotic 
male germ cells [206].
A recent review on CTA families discusses the 
putative role for genes with a CTA expression pro­
file in gametogenesis and cancers [207]. The author 
states that given their cell biological homologies to 
male germ cells, developing cancer cells, often 
exhibiting dedifferentiation undermining their 
normal cell faith, could at some point switch on 
(parts of) the gametogenic pathways and express 
"testis-specific" proteins .
The location of the SPANX genes on a contig 
from Xq26-Xq27 is in concordance with the re­
ported mapping of SPANXA, -B and -C using FISH 
and radiation hybrid panels [185,186]. The side-to- 
side presence of identical genes for SPANXA and
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SPANXB is probably caused by tandem gene 
duplications in recent history. The intronic LTR 
and the ALU region could be involved in the 
creation of this tight multigene cluster of SPANX 
genes within a region of about 850 kb. LTR and 
ALU sequences have previously been implicated in 
gene duplication and multigene formation [208]. 
LTR elements have also been found in highly 
homologous intronic sequences of the HLA-DRB 
multigene family. Presence of such an element in 
the corresponding DRB gene from chimpanzee 
implies an evolutionary role for this LTR [209].
Exclusive presence of SPANX sequences in 
higher primates, and the unique high intronic 
homology between the human SPANX genes both 
point to a late arrival of these genes in evolution.
The SPANX gene family is mapped in a locus 
region containing a susceptibility gene for testicu­
lar germ cell tumors [210]. Together with their 
expression profile in testis and tumors these data 
appoint the SPANX genes as candidates for this 
malignancy as is true for both MAGE-C1CT7 and 
MAGE-C2CT10 located on the same contig.
The nucleotide variations between the SPANX 
genes, mostly occurring outside the conserved NLS 
and acidic C-terminus, almost all lead to amino 
acid substitutions. This suggests a positive selec­
tion pressure, developing protein variability in 
order to optimize the functions of these gene 
products. So far it is not yet clear if all described 
SPANX genes co-exist or that subpopulations of 
humans contain a certain subset of SPANX genes.
Based on their expression profiles so far only 
members of the SPAN-Xa-like subfamily seem to 
be immunotherapy candidates since we only 
detected SPANXB sequences in testis samples. 
However, recently SPANXB transcripts were found 
in 20 to 30% of patients with hematologic tumors 
[211]. Discovery of high titer antibodies against 
SPAN-Xb in sera of these patients clearly show that 
the expressed proteins are immunogenic. Based on 
the high level of SPAN-X protein identity T cells 
might recognize peptides shared by multiple 
SPAN-X proteins, thereby possibly increasing effi­
ciency of putative immunotherapeutic interven­
tions.
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Suppression subtractive hybridization, 
comparing mRNA expression profiles of common nevocellular nevi and melanoma 
metastases, was used to identify potential markers of melanoma progression. From 
the metastases we isolated XAGE-1b, a 470 bp transcript of the XAGE-1 gene. In 
general, expression of XAGE-1b was much more prominent than expression of the 
longer XAGE-1 transcript, isolated from for Ewing's sarcoma. The XAGE-1b open 
reading frame codes for a putative protein of 81 amino acids, harboring a functional 
bipartite nuclear localization signal and a C-terminal acidic transcription-activation­
like domain. On nucleotide level XAGE-1b has a 50% homology with members of the 
GAGE family. However, homology between the corresponding proteins is weak. 
Expression of XAGE-1b in normal tissues was mainly restricted to testis, while 
placenta and brain were sporadically positive. In human tumor cell lines, as well as in 
human tumor lesions expression was most frequently found in melanocytic tumors 
and Ewing's sarcoma. In the different stages of melanocytic tumor progression 
expression was exclusively seen in melanoma metastases (38%; n=61), while all tested 
common and atypical nevi (n=10), as well as primary melanomas (n=8) were negative. 
Upregulation of expression after treatment with demethylating agent 5-aza-2'- 
deoxycytidine was detected in 1 out of 4 human melanoma cell lines tested. The 
XAGE-1 gene consists of 4 exons and is located on chromosome Xp11.21-Xp11.22. 
After transfection into COS cells, the corresponding protein can direct the coupled 
fluorescent protein to the nucleus, showing a distinct speckled staining aspect. Our 
data imply the nuclear cancer/testis-associated XAGE-1b to be a marker for late 
melanocytic tumor progression.
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INTRODUCTION MATERIALS AND METHODS
Melanoma, a tumor originating from melano­
cytes, is one of the cancers with the highest rising 
incidence-rate to date. For this type of tumor, 
marked by a relative young age of onset, early 
metastasis and low therapeutic success-rates, 
prognosis of advanced stages is poor [4]. To 
achieve efficient metastatic potential, tumorigenic 
cells need to acquire several functional abilities, 
among which proliferative and invasive capacity 
are essential [24]. Hereby phenotypical changes 
occur due to shifts in gene expression patterns. In 
order to be able to identify clinically relevant 
differentially expressed genes during melanoma 
progression, we compared mRNA populations of 
microdissected melanocytic cells from common 
nevi with those from melanoma metastases.
For differential expression analysis we used 
Suppression Subtractive Hybridization (SSH) [68]. 
With this technique multiple differentially ex­
pressed sequences, including novel ones, can be 
isolated simultaneously. Moreover, it is less time­
consuming and has a lower false-positivity rate [93] 
compared to the previously used differential 
display [152]. Recently in some other studies SSH 
has been successfully used, also in tumor biology 
[70,212].
Here we describe the isolation and characteri­
zation of XAGE-1b, a clone isolated from mela­
noma metastases, which is a short but major 
transcript of the previously described XAGE-1 gene 
[213]. Its expression profile clearly defines XAGE- 
1b as a cancer/testis-associated gene.
H um an tissues
Normal tissues and lesions from all stages of 
melanocytic tumor progression (normal skin, 
common nevus, atypical nevus, primary melanoma 
and melanoma metastasis) and from various types 
of other tumors were excised from patients at the 
UMC St Radboud, Nijmegen, The Netherlands. As 
normal human tissues we used disease-free 
samples from surgically removed tissues or from 
autopsies with a post-mortem delay shorter than 4 
hours. Representative slices from the tissue 
samples were snap-frozen in liquid nitrogen and 
stored at -80°C until use.
Cell lines and primary cell cultures
We used primary cultures of melanocytes, 
nevus cells, keratinocytes, dendritic cells, PBMCs, 
fibroblasts, endothelial cells, pericytes and smooth 
muscle cells. Human tumor cell lines used were: 14 
melanoma cell lines (530, 1F6, MV1, M14, MEL57, 
BLM, MKR, ZKR, WM164, 451Lu, E10, 518A2, 
OMM1, OCM1), 7 bladder cell lines (jon, RT4, j82, 
5367, 647v, 575a, 253j), 6 colon cell lines (CaCo2, 
LOVO, Colo320, LS147T, T84, SW1398), 7 prostate 
cell lines (LNCaP, DU145, PC3, TSU, Alva31, PPC, 
JCA), 6 kidney cell lines, 3 Ewing's sarcoma cell 
lines (Ew1, Ew2, Ew3), and 18 cell lines established 
from other histological tumor types (603, A431, 
Daudi, H1080, HEL, HepG2, HT29, Jurkat, K562, 
Kasumi, KM3, LAMA, Molt4, Raji, Ramos, U2OS, 
U937, Umscc2). Origin and culture conditions for 
most of the human tumor cell lines and primary 
cell cultures used, were described previously 
[152,185]. Ewing's sarcoma cell lines were gener­
ously supplied by Dr. B. Jansen (Dept. of Human
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Genetics, UMC St Radboud, Nijmegen, The Nether­
lands). AML tumor cell lines LAMA and Kasumi, 
as well as PBMCs were a kind gift of Dr. H. Dolstra 
(Dept. of Haematology, UMC St Radboud, Ni­
jmegen, The Netherlands). Colon carcinoma cell 
lines Colo320, LS174T and T84 are from ATCC. 
Culturing of colon carcinoma cell line SW1398 was 
described previously [214]. COS-1 cells were 
generously supplied by Dr. E. Cuppen (Dept. of 
Cell Biology, University of Nijmegen, Nijmegen, 
The Netherlands).
For demethylation experiments, human mela­
noma tumor cell lines (530, 1F6, MV1 and BLM) 
were cultured in the presence of 1 mM of 5-aza-2'- 
deoxycytidine (DAC; Sigma, Zwijndrecht, The 
Netherlands) for 72 hours, supplemented to 
standard medium.
RNA isolation
Total RNA was isolated from cultured cells 
using the RNeasy kit (Qiagen, Hilden, Germany). 
From tissue samples total RNA was isolated by 
disrupting about 25 frozen sections of 20 |am thick­
ness in 1 ml RNAzolB™ (Campro, Veenendaal, The 
Netherlands) using a pestle. The RNAzolB™ 
method was followed by an additional RNeasy 
cleaning step. For all methods we followed the 
manufacturer's protocols.
Suppression Subtractive Hybridization
We performed Suppression Subtractive Hy­
bridization (SSH), comparing 2 pooled common 
nevi (NN) and 3 pooled melanoma metastases 
(MM). Nests of melanocytic nevus cells and mela­
noma cells were isolated by laser-assisted 
microdissection (PALM microbeam system, PALM 
GmbH, Wolfratshausen, Germany) from multiple
frozen sections, stained with toluidin blue for mor­
phological recognition. As MM samples locore- 
gional metastases located in the skin were used to 
minimize background differences. After total RNA 
isolation, cDNA synthesis was performed on 100 
ng of each RNA sample using the SMART PCR 
cDNA Synthesis kit (Clontech, Palo Alto, CA).
Following successful cDNA amplification, 
purification and digestion, adapter ligations and 
subtractive hybridizations were performed with 
the PCR-Select cDNA Subtraction kit (Clontech). 
From this, NN-specific cDNAs (NN as tester, and 
MM as driver), as well as MM-specific cDNAs (MM 
as tester, and NN as driver) were generated. After 
two steps of hybridization, two rounds of PCR (30 
and 12 cycles) were performed to suppress 
abundantly present differential cDNAs and to 
increase the total amount of normalized 
differentially expressed product.
Efficiency of subtraction was checked by PCR 
analysis of the housekeeping gene GAPDH 
(following manufacturer's protocol; data not 
shown). PCR end products were cloned into a 
pCR2.1 TOPO-TA cloning vector (Invitrogen, Leek, 
The Netherlands). From all colonies mini-preps 
were made. A first redundancy check was per­
formed by determining the length of the different 
inserts using PCR. Subsequently control 
hybridization experiments with duplicate nylon 
membranes were prepared on which equal 
amounts of insert-specific PCR products (prepared 
by using nested adapter primers) of all clones were 
spotted. These blots were hybridized with the 
subtracted nested PCR products (used for cloning) 
which were radioactively labeled (additional 20 
cycles PCR; [32P]-dCTP). Equal amounts of 
radioactive-labeled probe were used for
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Target
(size)
[MgCl2]
(mM)
T-ann. Primers Ref.
ß2M 
(136 bp)
1.5 59°C s 5'-CTCGCGCTACTCTCTCTTTCT-3' 
as 5'-TGTCGGATTGATGAAACCCAG-3'
[185]
PBGD 
(339 bp)
1.5 59°C s 5'-CTGGTAACGGCAATGCGGCT-3' 
as 5'-GCAGATGGCTCCGATGGTGA-3'
[215]
XAGE-1 2.0 60°C F1 s 5'-ATAAGGAGGGGCACCACAG-3'
F2 s 5'-CTTTGGTGCCCACCTCAGT-3'
F3 s 5'-TGGATTCTTTCTCCGCTACTG-3'
F4 s 5'-AGTCCCAGGAGCCCAGTAATGGA-3'
R1 as 5'-CTTTATTGAGATAGTTTAAGTCAAATATCT-3' 
R2 as 5'-AAACCAGCTTGCGTTGTTTC-3'
R3 as 5'-GGTTGCTCTTCACCTGCTTC-3'
SPAN-XcCTp11 
(297 bp)
1.5 59°C s 5'-CTGCCGCAGACATTGAAGAA-3' 
as 5'-TCCATGAATTCCTCCTCCTC-3'
[185]
MAGE-1 
(421 bp)
1.5 67°C s 5'-CGGCCGAAGGAACCTGACCCAG-3' 
as 5'-GCTGGAACCCTCACTGGGTTGCC-3'
[216]
GAGE-1/2 
(243 bp)
1.5 56°C s 5'-GACCAAGACGCTACGTAG-3' 
as 5'-CCATCAGGACCATCTTCA-3'
[217]
NY-ESO-1 
(313 bp)
1.5 66°C s 5'-CACACAGGATCCATGGATGCTGCAGATGCG-3' 
as 5'-CACACAAAGCTTGGCTTAGCGCCTCTGCCC-3'
[158]
SSX-2 
(434 bp)
1.5 60°C s 5'-GTGCTCAAATACCAGAGAAGATC-3' 
as 5'-,nirGGGTCCAGATCTCTCGTG-3'
[167]
CT7MAGE-C1
(289 bp)
1.5 60°C s 5'-GCTCCAGAAAGCAGGAGTTG-3' 
as 5'-AGTCCTCCCCCTCAGGATAA-3'
Table I.
PCR prim ers
hybridization. To select the most differential clones, 
both the NN-specific and MM-specific probes were 
hybridized with a blot containing their correspond­
ing clones as well as with a blot of the 'other-way- 
around' specific clones.
cDNA sequencing and homology searching
All sequencing reactions were performed using
the Dye Terminator Reaction Mix (Perkin Elmer, 
Norwalk, CT) on an ABI-373 sequencer. Homology 
searches were performed with BLAST [80] and 
other software on all kinds of public servers of 
DNA and protein databases of which most were 
described earlier [152].
LabOnWeb (www.labonweb.com) was used to 
possibly elongate sequences of interest and to get
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RT- PCR
Synthesis of cDNA (10' at 25°C; 59' at 42°C; 5' 
at 95°C) was performed on 1.0 |ig of total RNA. The 
20 |il reaction mixture contained 250 pmol of 
random hexadeoxynucleotide primers, 3 mM 
MgCl2, 200 |aM of each dNTP, 50 mM Tris/HCl pH
8.3, 75 mM KCl, 10 mM DTT and 200 U MMLV 
reverse transcriptase (Promega, Madison, WI, 
USA). For amplification one |al of cDNA was 
supplemented with 2.5 |al PCR-buffer (200 mM 
(NH4)2SO4, 750 mM Tris/HCl pH 9, 0.1% Tween), 5 
|al 1 M dNTPs, 10 pmoles of each primer, x |al 25 
mM MgCl2, 0.15 U of Thermoperfectplus™ DNA 
polymerase (Integro, Zaandam, The Netherlands) 
and water to a final volume of 25 |al. PCR 
conditions were 30'' at 94°C, 45'' at T-annealing (T­
ann.) and 90'' at 72°C for 30 or 35 cycles. These 
cycles were preceded by a 3 min. denaturation step 
at 94°C and followed by a 5 min. elongation step at 
72°C. For nested PCRs, comprising an additional 30 
PCR cycles, 2 |al of 100 times diluted product of the 
first PCR were used under the same buffer condi­
tions as described above. In case of a nested set-up 
the first PCR always consisted of 30 cycles.
Primer-sequences, [MgCk] and annealing 
temperatures for each of the cDNA-specific PCRs 
are given in Table I. ß2-Microglobulin (ß2M) and/or 
porphobilinogen deaminase (PBGD) served as 
control PCRs. DNA molecular weight markers 
were from Roche Diagnostics GmbH. Per sample 
10 |al of product was analyzed on agarose gel using 
ethidium-bromide staining.
Northern blot analysis
Ten micrograms of total RNA were treated and
an overview of homologues sequences. size-separated using the formaldehyde method 
[126] on a 2.0% agarose gel containing ethidium 
bromide. UV illuminated images of the marker lane 
(RNA marker I, Roche Diagnostics GmbH, 
Penzberg, Germany) and of the ribosomal RNA 
bands were taken prior to blotting (Hybond-N+ 
membrane, Amersham, Aylesbury, UK), for size 
reference and loading control respectively. The 
cDNA probe (PCR products of primers F3 and R2) 
was radiolabeled by [32P]-dCTP incorporation 
using a random-primed DNA labeling kit (Roche 
Diagnostics GmbH, Penzberg, Germany). The 
membrane was hybridized overnight with the 
radiolabeled probe at 65°C in a hybridization mix 
(0.25 M sodium phosphate buffer pH 7.2, 7% SDS, 
1% BSA, 1 mM EDTA, 0.1 mg/ml single stranded 
salmon sperm DNA). Afterwards membranes were 
washed at 65°C with buffers containing decreasing 
amounts of salt (1% SDS, 1 mM EDTA and 0.25­
0.05 M sodium phosphate pH 7.2), and autoradio­
graphed using Kodak BioMax films.
Chromosomal localization
Genomic localization of XAGE-1 was deter­
mined by PCR on the Stanford G3RH panel with 83 
radiation hybrid clones (Research Genetics Inc., 
Huntsville, AL) [218]. Primers for this PCR are 
localized on the first exon of XAGE-1:
5'-TCCCTGAGGTCTGGATTCTTT-3' 
and the first intron:
5'-CGTCTGGGGAGTCCAGAAT-3' , 
yielding a DNA-specific product of 337 bp. PCR 
conditions (30 cycles) were the same as described 
above for the cDNA PCRs, except for a MgCl2 
concentration of 1.5 mM and an annealing 
temperature of 60°C.
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Plasmid construction and transfection
Fusion constructs of the previously reported 
longer XAGE-1 transcript (here named XAGE-1a) 
with eGFP and XAGE-1b with eGFP and DsRed 
were constructed for localization studies. For 
constructs with C-terminal eGFP or DsRed, PCRs 
on corresponding templates (cloned ORFs in 
pCR2.1 TOPO TA cloning vector) were performed 
using a M13F primer (upstream of startcodon and 
EcoRI-site) in combination with a primer mutating 
the stopcodon and introducing a BglII restriction 
site. For XAGE1b-eGFP and XAGE1a-eGFP : 
5'-CCAGATCTAACTTGTGGTTGCTCTTCA-3'
For XAGE1b-DsRed:
5'-CCAGATCTCGAACTTGTGGTTGCTCTTCA-3'
The EcoRI and BglII sites were used to fuse the 
ORFs in-frame N-terminally to eGFP (eGFP-N3; 
EcoRI-BamHI restricted) or DsRed (pDsRed-N1; 
EcoRI-BamHI restricted). This introduced small 
peptide linkers between the two original ORFs (for 
XAGE1b-eGFP and XAGE1a-eGFP: RSIAT; for 
XAGE1b-DsRed: RDPPVAT). PCRs for constructs 
with N-terminal eGFP were performed using a 
M13R primer (downstream of stopcodon and 
EcoRI) in combination with a primer introducing a 
BglII restriction site directly in front of the 
startcodon. For eGFP-XAGE1b: 
5'-GGAGATCTAGTCCCAGGAGCCCAGTAAT-3' 
For eGFP-XAGE1a:
5'-GGAGATCTGAGGGAACCTCACTGCGCAT-3'
BglII and EcoRI sites were used to fuse the 
ORFs in-frame C-terminally to eGFP (eGFP-C1; 
BglII-EcoRI restricted), again introducing small 
peptide linkers between the ORFs of eGFP and 
XAGE (YKSGLRSSPRSPV for eGFP-XAGE1b; 
YKSGLRSEGTSLR for eGFP-XAGE1a). All vectors 
coding for the fluorescent proteins were from
Clontech, Palo Alto, CA. The in-frame junctions 
were confirmed by sequencing.
Transfections were mediated by FuGENE™6 
transfection reagent (Roche Diagnostics GmbH). In 
short, cells were seeded in 6 well plates and grown 
till subconfluency. Transfections were performed 
with 1 |ag plasmid construct and 3 |al FuGENE™6 
in 2 ml medium. Transient expression of the fusion 
protein was checked within 48 hours. To visualize 
expression of the fusion protein, cells (grown on 
coverslips in 6 well plates) were fixed with 4% 
paraformaldehyde for 15 minutes at room tempera­
ture and subsequently placed in aceton for 1 
minute at -20°C. Coverslips were put on glass 
slides, mounted with 10 |al Tris-buffered glycerol 
(per 100 ml: 90 ml glycerol; 2 ml Tris/HCl pH 8; 8 
ml H 2O) containing 1:4 Vectashield (Vector, Burlin­
game, CA) and 1:10,000 DAPI (Sigma, Zwijndrecht, 
The Netherlands). Fluorescent images were ob­
tained using a fluorescence microscope equipped 
with a CCD camera.
RESULTS
Cloning, sequencing and homology search
From the MM-NN Suppression Subtractive 
Hybridization experiment we selected several 
differentially expressed clones after control reverse 
Northern hybridizations (data not shown). One of 
the melanoma metastases specific clones was a 470 
bp cDNA. Sequencing and subsequent homology 
database searching reveal it to be the C-terminal 
part of XAGE-1, a recently identified cancer/testis- 
associated gene isolated from a Ewing’s sarcoma 
cell line [213,219]. This gene showed some C- 
terminal homology (33% identity; 60% similarity in
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the last 30 C-terminal amino acids) to members of 
the GAGE family of cancer/testis antigens (CTAs). 
Interestingly all 31 ESTs found, belonging to the 
XAGE-1 Unigene cluster (Hs.112208), are placed at 
the C-terminal part of the XAGE-1 mRNA, just like 
the clone isolated in our experiment. However, 
none of the ESTs showed any homology in the first 
130 bp of the XAGE-1 transcript. To determine if 
this is a general phenomenon due to the enrich­
ment of 3' sequences based on practical aspects we 
also studied the distribution of ESTs representing 
three other CTAs (MAGE-1 (Genbank: NM- 
004988), GAGE-2 (U19143) and NY-ESO-1 
(AJ003149)). For this we performed a BLAST search 
for the full mRNA sequences using the human EST 
database from NCBI. In case of NY-ESO-1 and 
GAGE-2 the ESTs were evenly distributed through­
out the full transcript. ESTs representing MAGE-1 
were even more abundant at the 5' part of the 
mRNA (data not shown). Finally, using the 470 bp 
clone in a LabOnWeb electronic RACE we were 
unsuccessful in elongating the 5'-end of our 
sequence, further proving the lack of ESTs with N- 
terminal XAGE-1 homology.
Northern blot analysis
To determine the full length of the XAGE-1 
transcript we prepared a Northern blot consisting 
of two melanoma (1F6 and Mel57) and 3 Ewing’s 
sarcoma cell lines (Ew1, Ew2 and Ew3). To be sure 
of good quality RNA we chose cell lines instead of 
tissue samples. RNAs were run on a denaturing 
gel of 2% agarose to optimize size separation of 
smaller mRNAs. The blot was hybridized with a 
probe corresponding to a 357 bp PCR product of 
our isolated clone (present in the C-terminal part of 
the full XAGE-1 transcript). Figure 1a shows a
major transcript of about 0.5 kb in melanoma cell 
line 1F6 and in Ewing’s sarcoma cell line Ew3. A 
hardly visible band of about 0.7 kb was detected in 
all three Ewing’s sarcoma cell lines. Figure 1b 
shows rRNA bands as loading reference. These 
data strongly indicate the 0.7 kb mRNA to be the 
full length XAGE-1 transcript and the 0.5 kb band 
to correspond to the transcript represented by the
Figure 1.
(a) N orthern  b lot analysis of hum an  tum or cell lines 1F6, 
Mel57, Ew1, Ew2 and Ew3. The blo t is hybrid ized  w ith  a 
random -prim ed cDNA probe from  the XAGE-1 PCR p ro d ­
uct of prim ers F3 and R2 (357 bp). XAGE-1 transcrip ts are 
m arked w ith  ^  (XAGE-1b; around  0.5 kb) or ^  (XAGE-1a; 
around  0.7 kb). The e th idium -brom ide stained RNA m arker 
is aligned on the left. (b) E thidium -brom ide stained gel 
show ing 28S and 18S rRNA bands.
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Figure 2.
XAGE-1a and  XAGE-1b cDNAs and  deduced pro te in  sequence. Prim ers used  for PCR are indicated by  num bered  arrows. 
Putative start of XAGE-1b mRNA is show n by -►; XAGE-1b protein-part is underlined. Polyadenylation signal is double 
underlined; pu ta tive  b ipartite  nuclear localization signal is shaded  gray; possible transm em brane dom ain  is m arked w ith  a 
do tted  line; startcodon of XAGE-1a is fat; startcodon of XAGE-1b is fat and  underlined; stopcodon is represen ted  by  an 
asterisk. 1, m arks the exon-intron boundary  sites.
ggacctgggaaggagcataggacagggcaaggcgggataaggaggggcaccacagccctt 6 0
aaggcacgagggaacctcactgcgcatgctcctttggtgcccacctcagtgcgcatgttc 12 0
M L L W C P P Q C A C S 12
i- ►
actgggcgtcttcccatcggccccttcgccagtgtggggaacgcggcggagctgtgagcc 180
. . . .L. . . . .G . . . .V . . . .F. . . . .P. . . . .S. . . A P S P V W G T R R S C E P 32
irai .
ggcgactcgggtccctgaggtctggattctttctccgctactgagacacggcggacacac 24 0 
A T R V P E V W I L S P L L R H G G H T 52
r n \
acaaacacagaaccacacagccagtcccaggagcccagtaatggagagccccaaaaagaa 3 00
Q T Q N H T A S P R S P V M E S P K K K 72
gaaccagcagctgaaagtcgggatcctacacctgggcagcagacagaagaagatcaggat 360
N Q Q L K V G I L H L G S R Q K K I R I 92
1acagctgagatcccagtgcgcgacatggaaggtgatctgcaagagctgcatcagtcaaac 420
Q L R S Q C A T W K V I C K S C I S Q T 112
accggggataaatctggatttgggttccggcgtcaaggtgaagataatacctaaagagga 480
P G I N L D L G S G V K V K I I P K E E 132
< ----------1 --------------------^  <
acactgtaaaatgccagaagcaggtgaagagcaaccacaagtttaaatgaagacaagctg 54 0
H C K M P E A G E E Q P Q V * 14 6
_____________________n n  ^ __________________________________u n
aaacaacgcaagctggttttatattagatatttgacttaaactatctcaataaagttttg 600
cagctttcaccaaaaaaaaaaaaaaa 626
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ESTs of Unigene cluster Hs.112208 and our isolated 
clone. The 0.5 kb band is unlikely to be a degrada­
tion product of the 0.7 kb band since this would not 
lead to a distinct band but to a smear. Moreover, in 
the three Ewing's sarcoma cell lines the 0.5 kb 
transcript is only present in Ew3, while all three 
cell lines show the 0.7 kb band at same intensity. 
Based on the Northern blot results we named the 
larger 0.7 kb transcript XAGE-1a and the 0.5 kb 
transcript XAGE-1b.
XAGE-1 transcript features
The previously reported XAGE-1a transcript 
(Genbank entry AF251237) [213], and the XAGE-1b 
clone we picked up from melanoma metastases are 
depicted in Figure 2. The XAGE-1a transcript is 611 
bp long (without poly-A tail) and codes for a 
putative protein of 146 amino acids (start at nt- 
position 86; stop at nt-position 524) with a possible 
transmembrane domain (a.a. 1-18) and a bipartite 
nuclear localization signal (NLS; a.a. 70-89). The 
XAGE-1b transcript (Genbank entry AJ290447) is 
about 456 bp without poly-A tail and therefore 
starts behind the startcodon of XAGE-1a. The 
putative ORF of XAGE-1b is 81 amino acids in 
length and in-frame with the longer XAGE-1a. The 
putative XAGE-1b protein lacks the possible 
transmembrane domain, but still contains the 
bipartite NLS.
The XAGE-1b putative protein is rich in 
charged residues (27%), especially lysines (K; 
14.8%). With 15 basic (lysine (K; 12) and arginine 
(R; 3)) and 7 acidic residues (aspartic acid (D; 1) 
and glutamic acid (E; 6)) the corresponding protein 
has an overall positive charge. Most of the glutamic 
acid residues are located at the C-terminus making 
this part of the putative protein highly acidic. The
calculated pi and Mw are 9.65 and 9 kD respec­
tively. In contrast to XAGE-1b, the first part, 
specific for the XAGE-1a putative protein (a.a. 1-65) 
has a much lower content of charged residues 
(11%). A striking feature in this part of the larger 
protein is the great number of prolines present (P; 
15.4%).
RT-PCR: XAGE-1a versus XAGE-1b
To discriminate between XAGE-1a and XAGE- 
1b we composed several PCR primer combinations 
throughout the cDNA sequence (Figure 2; Table I). 
With these primers three different nested PCRs 
were set-up. The first nested PCR makes use of a 
first (primers F1 and R1) and second amplification 
round (F2 and R2) which are both XAGE-1a 
specific. In the second nested PCR the first XAGE- 
1a specific amplification round (F2 and R2) was 
followed by a round (F4 and R3) amplifying both 
XAGE-1a and XAGE-1b. Finally, a nested PCR was 
set-up in which both rounds of PCR (1st: F3 and R2; 
2nd: F4 and R3) recognize both XAGE-1 transcripts. 
With this RT-PCR strategy we analyzed RNA of the 
same cell lines as used for Northern blot analysis 
(melanoma: 1F6 and Mel57; Ewing's sarcoma: Ew1, 
Ew2 and Ew3), as well as three fresh human tissue 
samples (normal testis, Ewing's sarcoma, mela­
noma metastasis). Using the XAGE-1a specific PCR 
(1st: F1 and R1; 2nd: F2 and R2) a specific band was 
visible in all Ewing's samples, only after the second 
round of PCR (Figure 3). The weak bands detected 
after the first PCR correspond to bands visible in 
the DNA control. Testis and all melanoma samples 
tested were negative.
With the primer combination of a first XAGE- 
1a specific amplification followed by a PCR ampli­
fying both XAGE-1 transcripts (1st: F2 and R2; 2nd:
XAGE-1b 81
F4 and R3) positivity was seen in all Ewing's 
samples, melanoma cell line 1F6 and in testis (254 
bp). The first amplification round in this nested 
PCR showed weak positivity only in the Ewing's 
sarcoma cell lines.
Finally, the non-discriminating XAGE-1 nested 
PCR (1st: F3 and R2; 2nd: F4 and R3) showed strong 
PCR products (254 bp) for all RNA samples tested. 
The results of the first round of PCR correspond 
very well with the results of the Northern blot: 
marked bands in 1F6 and Ew3; weak bands in Ew1
positive after the first round of amplification, 
though the bands in the testis and Ewing's sarcoma 
samples were very weak.
Gene structure and chromosomal localization
During efforts to amplify and sequence the 
intron sequences present in our clone, a large DNA 
fragment was found in Genbank (AC025553), 
containing the full genomic sequence of gene 
XAGE-1, from which we deduced the genetic exon-
intron build-up (Figure 4; Genbank accession nr. 
and Ew2; Mel57 was negative. Regarding the AJ400997). The gene, spanning about 5 kb, consists 
additional samples tested (melanoma metastasis, of 4 exons and 3 introns (1416, 527 and 2590 bp 
normal testis and Ewing's sarcoma) all were respectively). All introns have consensus gt/ag
Figure 3.
N ested  PCR analysis of h u m an  m elanom a (1F6 an d  Mel57) and  Ewing's sarcom a (Ew1, Ew2 and  Ew3) 
cell lines w ith  prim ers recognizing bo th  XAGE-1 transcripts, as w ell as XAGE-1a specific p rim er com bi­
nations. First and  nested  PCRs consisted bo th  of 30 cycles. H ousekeeping genes PBGD and  [32- 
M icroglobulin served  as control PCR. U sed prim ers are listed in Table I.
cell lines tissues
559 bp 
468 bp
468 bp 
254 bp
357 bp 
254 bp
339 bp 
136 bp
1st: F1 and R1 
2nd: F2 and R2
1st: F2 and R2 
2nd: F4 and R3
1st: F3 and R2 
2nd: F4 and R3
PBGD
ß2M
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Figure 4.
Schematic representation  of a 5 kb region containing the h u m an  XAGE-1 gene and  its tw o pu tative  transcrip tion  products. 
The intronic spacing, un transla ted  regions (UTR), start- (AUG) and  stopcodon (UAA), open  reading  fram e (ORF, black 
box), possible transm em brane region  (TM?, do tted  box) and  nuclear localization signal (NLS, hatched box) are depicted.
boundary sequences (Table II) [193]. Both XAGE-1 
transcripts start in the first exon. The coding 
sequence of XAGE-1a starts in the first exon, while 
the startcodon of the XAGE-1b putative protein 
resides in the exon 2. Using Southern blot analysis 
Liu et al. showed that the XAGE-1 gene is located 
on the X-chromosome. To further narrow down the 
locus of the gene a DNA-specific PCR on the 83 
radiation hybrid clones of the G3RH-panel was 
performed. This mapped XAGE-1 to region 
Xp11.21-Xp11.22, between the markers DXS1204 
and DXS1199.
XAGE-1 expression profile
Homology to mainly testis ESTs prompted us 
to look for XAGE-1 expression in a series of normal 
tissues. Using RT-PCR with a primer combination 
amplifying both XAGE-1a and XAGE-1b (F3 and 
R2) we found XAGE-1 expression mainly in testis 
(Figure 5a). A comparable 30 cycle PCR specific for 
XAGE-1a (F2 and R2) was negative for all samples 
shown in Figure 5 (not shown). Screening a larger 
number of normal tissues showed XAGE-1 
expression in testis (3 out of 3), placenta (1 out of 4) 
and brain (1 out of 6) (Table III). No expression was 
detected in 20 other normal tissues, including
EXON-Intron 1 Intron (bp) Intron-EXON
ACACGGCGGgt aggtcca 1 (1416) tttatct agACACACACA
H G G QTH
AGATCCCAGgtgctggga 2 (527) attttgaagTGCGCGACA
R S Q C A T
CAGAAGCAGgtatgttat 3 (2590) ctgttatagGTGAAGAGC
P E A G E E
Table II.
Exon-intron organization  of the 
h u m an  XAGE-1 gene.
1 Exon sequences are in  upper-case 
characters; in tron  sequences in 
lo w e r-c a se . C o n se n s u s  g t/a g  
b o undary  sequences are show n in 
bold.
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Table III.
XAGE-1 m RNA expression in  h um an  tissues using  RT- 
PCR (prim ers F3 and  R2; 30 cycles).
1 n.d. = no t determ ined
Tissue type XAGE-1
Normal
expression
Tumor
Bladder 0/1 n.d.1
Bone marrow 0/1 n.d.
Brain 1/6 0/1
Breast 0/2 0/4
Colon 0/3 0/4
Esophagus 0/3 0/5
Ewing's sarcoma n.d. 6/10
Gal bladder 0/1 n.d.
Heart 0/1 n.d.
Ileum 0/3 0/4
Kidney 0/1 n.d.
Liver 0/1 n.d.
Lung 0/3 1/5
Lymph node 0/1 n.d.
Ovarium 0/3 n.d.
Pancreas 0/4 0/5
Placenta 1/4 n.d.
Prostate 0/4 1/3
Spleen 0/1 n.d.
Stomach 0/1 n.d.
Testis 3/3 2/5
Thymus 0/1 n.d.
Thyroid 0/1 n.d.
Uterus 0/1 n.d.
Table IV.
XAGE-1 m RN A  expression in lesions of the m elanocytic 
tum or progression  lineage using  RT-PCR (prim ers F3 and  
R2; 30 cycles). 1 Fisher's exact test com paring 0/8 versus 
23/61: p=0.045
Stage of melanoma lineage XAGE-1 expression
Normal skin 0/3
Common nevocellular nevus 0/5
Atypical nevus 0/5
Primary melanoma 0/8 1
Melanoma metastasis 23/61 1
Table V.
XAGE-1 m RN A  expression in  cultured  h um an  tum or cell 
lines using  RT-PCR (prim ers F3 and  R2; 30 cycles).
Type of cell line XAGE-1 expression
Bladder 1/7
Colon 1/6
Ewing's sarcoma 3/3
Kidney 0/6
Melanoma 6/14
Prostate 2/7
Other 2/18
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Figure 5.
(a) XAGE-1 RT-PCR (prim ers F3 and  R2; 357 bp) on  RNA from  a panel of fresh norm al h u m an  tissues.
(b) [32-Microglobulin control PCR. U sed prim ers are listed in Table I.
ovarium, prostate and thyroid.
From several tissue types we also tested some 
tumors. Regarding non-melanoma samples, we 
found XAGE-1 expression in 6 out of 10 Ewing's 
sarcoma samples (Table III). Again this positivity 
could mainly be described to XAGE-1b expression, 
since only 3 Ewing's sarcoma samples were weakly 
positive after a 30 cycle PCR using the XAGE-1a 
specific primer-combination of F2 and R2 (not 
shown). Occasionally other tumor types were 
XAGE-1 positive: 1 out of 5 lung tumors, 1 out of 3 
prostate tumors and 2 out of 5 testicular malignan­
cies (Table III).
Expression of XAGE-1 in the various stages of 
human melanocytic tumor progression was con­
fined to melanoma metastases (38%, n=61) (Table 
IV). No expression was seen in normal skin (n=3), 
common nevocellular nevus (n=5) and atypical 
nevus (n=5) and primary cutaneous melanoma 
(n=8). No XAGE-1a specific bands (30 cycles; F2 
and R2) were seen in 10 melanoma metastases
positive for a PCR amplifying both XAGE-1 
transcripts (not shown).
An inventory of XAGE-1 expression in primary 
cell cultures and tumor cell lines showed similar 
expression patterns compared to fresh tumor 
material. None of nine different primary cell 
cultures tested, including melanocytes and nevus 
cells, were positive (data not shown). XAGE-1 was 
detected in all three Ewing's sarcoma cell lines 
tested (Ew1, Ew2 and Ew3) and in 43% (6/14) of the 
melanoma cell lines (1F6, MKR, ZKR, 518A2, 
OMM1 and OCM1). Expression in several other 
non-melanoma tumor cell lines was limited to 1 
(jon) out of 7 bladder cell lines, 1 (Colo320) out of 6 
colon cell lines, 2 (LNCaP, DU145) out of 7 prostate 
cell lines and 2 (Kasumi (AML), U2OS 
(osteosarcoma)) out of 18 tumor cell lines of other 
origin (Table V).
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Upregulation of XAGE-1 expression by 
dem ethyla tion
Transcriptional regulation on the DNA level by 
differential methylation of promoters has been 
described for some CTAs. To see if XAGE-1 expres­
sion can also be upregulated by demethylation, we 
treated 4 human melanoma cell lines (530, 1F6, 
MV1 and BLM) with DAC. Induction of expression 
of some CTAs, known to be responsive to DAC 
treatment, was done as positive control. As can be 
seen in Figure 6, strongest effects of the treatment 
were seen for NY-ESO-1 and GAGE-1/2, with 
induction in cell lines MV1 and BLM. Furthermore 
NY-ESO-1 was markedly upregulated in 1F6 cells, 
as is the case for GAGE-1/2 in 530 cells. MAGE-1 
revealed a DAC-dependent upregulation of expres­
sion for 530 and MV1. No effects of demethylation
were detected for SSX-2, CT7MAGE-C1 and SPAN- 
XcCTp11, as well as for the housekeeping PBGD con­
trol. Regarding XAGE-1 we saw a weak induction 
of expression in one (BLM) of the four treated cell 
lines.
C ellular localization
Localization of the putative XAGE-1a and 
XAGE-1b proteins in the cell was studied by trans­
fecting COS-1 cells with cDNA-fusion constructs 
with fluorescent proteins eGFP and DsRed. Control 
transfections with constructs coding for the 
fluorescent eGFP and DsRed only, revealed these 
proteins to be present in the cytoplasm as well as in 
the nucleus (Figure 7e and 7g). Both XAGE-1b/ 
eGFP and XAGE-1b/DsRed coupled fusion proteins 
were localized solely in the nucleus, irrespective of
Figure 6.
RT-PCR on RNA from  4 h u m an  m elanom a cell lines cu ltu red  w ith  and  w ithou t the dem ethylating  agent 5-aza-2'- 
deoxycytidine. N am es of the specific genes investigated  are indicated at the right of the eth id ium -brom ide stained gel. The 
bottom  panel represents the PBGD control PCR. U sed prim ers are listed in Table I. A ll PCRs consisted of 35 cycles.
- demethylation + demethylation
421 bp 
243 bp 
313 bp 
434 bp
289 bp
297 bp 
357 bp 
339 bp
MAGE-1
GAGE-1/2
NY-ESO-1
SSX-2
CT7mage-c1
SPAN-Xcctp11
XAGE-1 (F3 and R2)
PBGD
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Figure 7. Full co lour on  page 179
Fluorescence m icroscopy of COS-1 cells transfected w ith  constructs containing ORFs for eGFP (a, e, i), XAGE-1b/eGFP (b, 
f, j, m), DsRed (c, g, k), XAGE-1b/DsRed (d, h, l), eGFP/XAGE-1b (n), XAGE-1a/eGFP (o), eGFP/XAGE-1a (p), and  XAGE- 
1a/eGFP in  com bination w ith  XAGE-1b/DsRed (q-s). DAPI im ages show  nuclei (a-d), eGFP-derived fluorescence is show n 
in  green (e, f, i, j, m-p, q, s), w hile red  coloring represents fluorescence of the DsRed (g, h, k, l, r, s). In  im ages m -p eGFP- 
derived  fluorescences are m erged w ith  the corresponding DAPI recordings. O ther m erged im ages are derived of a and  e 
(i), b and  f (j), c and  g (k), d  and  h  (l), and  q and  r (s).
b  »
II 0
%
q
%
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the fluorescent protein used (Figure 7f and 7h). The 
fusion pro tein is visible as distinct intra-nuclear 
dots, while nucleoli are negative. To exclude 
possible artifacts introduced by the position of the 
fluorescent protein we also tested eGFP/XAGE-1b. 
Both XAGE-1b/eGFP (Figure 7j and 7m) and eGFP/ 
XAGE-1b (Figure 7n) are visible as nuclear speck­
les. Fusion constructs with the larger XAGE-1a 
ORF showed identical nuclear localizations (XAGE- 
1a/eGFP: Figure 7o; eGFP/XAGE-1b: Figure 7p). 
The merged image (Figure 7s) of a COS-1 cell 
transfected with XAGE-1a/eGFP (Figure 7q) and 
XAGE-1b/DsRed (Figure 7r) simultaneously, shows 
a good co-localization of both fusion constructs.
DISCUSSION
Since the detection of MAGE-1, a decade ago 
[156], many more CTAs have been identified. Often 
these genes, which are immunotherapy candidates, 
are part of large families. So far most research has 
been done on the MAGE family, with four 
subfamilies and 33 genes the largest family known. 
Here we describe the isolation and characterization 
of XAGE-1b, a major transcript of the XAGE-1 
gene. Based on its expression pattern and chromo­
somal localization it is a member of the cancer/ 
testis antigen family, since it fulfills most of the de­
scribed family criteria: (i) predominant expression 
in testis and not in other normal tissues; (ii) expres­
sion in a range of malignancies; (iii) localization on 
the X-chromosome (with some exceptions); (iv) 
existence of multigene families; (v) expression in a 
lineage non-specific fashion [172].
Recently a longer transcript of the XAGE-1 
gene (which we have named XAGE-1a) was 
reported to be expressed mainly in testis and Ew­
ing's sarcoma [213]. XAGE-1b codes for a putative 
protein that is in-frame with the previously 
reported XAGE-1a, but lacks its N-terminal 
domain. Here we show the 0.5 kb XAGE-1b 
transcript to be the major product of the XAGE-1 
gene, responsible for frequent expression in testis, 
melanoma metastases and Ewing's sarcoma. Using 
RT-PCR and Northern blot analysis we could only 
detect a weak expression of XAGE-1a in Ewing's 
sarcoma samples. These results are in line with the 
expression found by Liu et al., since they used 
primers and probes recognizing both transcripts of 
the XAGE-1 gene. The single band shown in their 
Northern blot analysis is therefore most likely the 
same mRNA as we detect at 0.5 kb.
Our RT-PCR results are in line with the 
Northern blot data. Randomly tested samples 
(other than Ewing's sarcoma) positive in RT-PCR 
for XAGE-1b (primers F3 * R2; 357 bp), were 
always negative in XAGE-1a RT-PCR using various 
XAGE-1a specific primer-combinations (data not 
shown). Based on the small difference in length 
(468 bp versus 357 bp) these marked differences 
cannot be explained by more efficient amplification 
of shorter fragments. Moreover, we can easily 
amplify the 1.8 kb PCR product when using the 
XAGE-1a specific primer set (F2 * R2) on genomic 
DNA, indicating that this PCR can efficiently am­
plify this large fragment (data not shown). Regula­
tion of expression by transcription of different 
mRNA-lengths from one gene coding for in-frame 
protein variants was previously shown for several 
genes of the eukaryotic organism S. cerevisiae 
[220,221].
Expression of XAGE-1b transcripts in normal 
tissues is mainly restricted to testis. Out of 20 
different other tissues studied we found only
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expression in placenta (1 out of 4) and brain (1 out 
of 6). Sporadic expression in non-testis tissues, 
mostly in organs involved in reproduction, is also 
described for several other CTAs. NY-ESO-1 [158], 
GAGE-7 [169] and CT9 [222] expression is found in 
ovary, while placenta is positive for several MAGE­
type genes [172,222,223]. For SSX the exception is 
thyroid [215]. mRNA expression analysis in differ­
ent types of tumors indicated that XAGE-1b expres­
sion is highest in Ewing's sarcoma and melanoma.
Remarkably, in our series of melanocytic tu­
mors tested we found only expression in metasta- 
ses (23 out of 61) while all primary melanomas 
were negative (0 out of 8; Fisher's exact test: 
p=0.045). Induction of expression in metastases 
might be a result of a different micro-environment, 
possibly affecting the methylation status of cells in 
the metastatic lesion. Testing larger series of pri­
mary melanoma lesions is necessary to prove that 
XAGE-1b expression during melanocytic progres­
sion is really confined to metastases.
With 38% positivity the frequency of XAGE-1b 
expression in melanoma metastases is comparable 
to SSX-2 (44%), NY-ESO-1 (44%) and MAGE-1 
(35%). MAGE-3 (52%) has the highest coverage of 
mRNA expression in melanoma. Expression of 
BAGE (22%), GAGE (17%) and SCP-1 (8%) are 
significantly lower [178]. The recently described 
CT10 is present in 50% (n=10) of the melanoma 
metastases [167], while CT9 is absent in melanoma 
[222]. In other studies, for MAGE-3 (76%) [224] and 
GAGE (41%) [225] much higher frequencies of 
positivity in melanoma metastases have also been 
described.
In non-melanoma tumors expression of XAGE-
1 transcripts could only sporadically be detected, 
whereas several other CTAs are expressed in a
wide variety of tumor types. Regarding the 
expression of CTAs, we should realize that most 
studies have been performed on mRNA level. 
Recently, however, some studies investigated pro­
tein expression of CTAs using immune- 
histochemistry. For MAGE-3 this revealed a huge 
discrepancy compared with mRNA expression. 
While RT-PCR positivity for MAGE-3 in melanoma 
ranges between 50 and 75%, protein could only be 
detected in 25% of the lesions [224]. A good 
correlation between RT-PCR and immuno- 
histochemistry (IHC) was shown for SSX [215]. 
These results stress the importance of IHC to study 
genuine expression of CTAs.
Expression of CTAs in testis and cancers is 
believed to be effectuated by a decrease in 
methylation of CpG islands in their promoter- 
regions. A correlation between methylation status 
of tumors and expression of MAGE-type genes was 
found [226]. Furthermore, induction or upregula- 
tion of expression after treatment of cells with the 
demethylating agent DAC was shown for several 
members of the MAGE, GAGE and LAGE gene- 
families [205], as well as for SSX [215]. In agree­
ment with this we showed (Figure 5) elevated 
expression after DAC-treatment for MAGE-1, 
GAGE-1/2 and LAGE family member NY-ESO-1.
Using SSX-2 specific primers we did not see an 
induction for SSX. Induction of SSX previously 
found [215] was detected with primers able to 
amplify all 5 SSX genes and could therefore be 
caused by a non-SSX-2 family member. For 
CT7MAGE-C1 and SPAN-Xc^11 we saw no changes in 
expression, indicating that demethylation alone is 
not sufficient to drive expression of all CTAs. A 
weak induction of expression was detected for 
XAGE-1 in human melanoma cell line BLM. Since
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not all genes are switched-on by DAC treatment 
there seem s to be an interplay between methylation 
status and presence of transcription factors.
Another feature shared by most CTAs, is 
localization on chromosome X. Using the G3RH 
panel we could map the XAGE-1 gene on Xp11.21- 
Xp11.22, between DXS1204 and DXS1199. Interest­
ingly this is the region where also the CTA families 
of SSX (Xp11.2), GAGE (Xp11.2-Xp11.4) and 
MAGE-D (Xp11) reside [225,227].
The putative ORF of XAGE-1b contains several 
features, being a NLS and a acidic C-terminus, 
which resemble features of other CTAs. The 
bipartite NLS, though not completely consensus, is 
also encountered in SPAN-Xcctp11 [185] and SSX 
[167]. Bipartite NLS sequences have been described 
as two basic amino acids (lysine (K) or arginine (R)) 
separated by a linker of about 10 amino acids from 
a group of 5 residues of which at least three are 
basic [161].
Transfection of fluorescently labeled XAGE-1b 
cDNA constructs in COS-1 cells showed that its 
NLS is able to achieve nuclear translocation of the 
coupled fluorescent protein. The speckled distribu­
tion pattern, in which nucleoli are negative, was 
seen in both C-terminal and N-terminal placed 
eGFP-constructs. Constructs of the longer putative 
XAGE-1a coupled to eGFP showed identical 
speckled nuclear localization, making the presence 
of a functional transmembrane domain (TM) very 
unlikely. Database searches for a putative TM do­
main in XAGE-1a, using three different programs 
(SOSUI -; TSEG +/-; TMpred +), were not conclu­
sive.
The speckled staining aspect might be asso­
ciated with one of the many types of nuclear bodies 
[228,229]. For SSX a co-localization in nuclear
speckles with the Polycomb-group proteins, 
associated with transcriptional regulation, has 
already been shown [230]. Another striking feature 
is the acidic C-terminus and an overall high 
amount of charged residues present in the putative 
XAGE-1 proteins. Highest homology of XAGE-1 
with other CTAs (especially members of the GAGE 
family) is shared mainly in the C-terminus [164]. 
Though less consensus compared to for instance 
SPAN-XcCTp11 the C-terminal region of XAGE-1 
alikes a GAL4 acidic transactivation domain [36]. 
For SSX, the C-terminal domain (SSXRD) has been 
demonstrated to be able to regulate transcription 
[231]. CT9, a testis-specific member of the RING 
family, is also implicated in transcriptional 
regulation [222]. For XAGE-1 a role in transcription 
remains speculative. Since it has no DNA-binding 
domain XAGE-1, like SPAN-Xcctp11 and SSX, will 
be dependent on interaction with DNA binding 
proteins or in order to exert a potential regulatory 
function.
For melanoma, one of the most immunogenic 
tumors, vaccination studies using MAGE-3 derived 
HLA class restricted peptides have been performed 
[217]. Low success-rates so far might be caused by 
heterogeneity of antigen expression in tumors, 
shown to be the case for MAGE [224]. Heterogene­
ity of expression has also been described for an­
other group of immunotherapeutical target mole­
cules, being the melanoma differentiation antigens 
[117]. Immunotherapy by vaccination may induce a 
survival of tumor cells that have lost the target 
antigen or HLA expression. To minimize immune 
escape strategies using polyvalent vaccination are 
needed to attack as many tumor cells and tumor 
types as possible.
In summary, we identified XAGE-1b, a major
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transcript of cancer/testis-associated gene XAGE-1, 
mainly expressed in normal testis, Ewing's sarcoma 
and metastastic lesions of melanoma. Additional 
experiments are necessary to address the useful­
ness of XAGE-1b in diagnosis and prognosis of 
melanoma patients. With respect to an eventual 
immunotherapeutic application, our results 
strongly suggest that this will be mainly melanoma 
and Ewing's sarcoma restricted.
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Existence of XAGE genes was 
first reported after database homology searches for PAGE-like 
sequences, identifying three XAGE EST clusters. One of these 
clusters, XAGE-1, has in later studies been identified as 
cancer/testis-associated gene. Here we report the expression 
profiles of all three reported XAGE genes, as well as several 
splice variants of XAGE-1, in normal human tissues and in 
Ewing's sarcoma, and melanocytic tumors. We also provide 
the genetic structure of the corresponding genes. Moreover, 
by searching the databases for XAGE homologues, we 
identified three additional members of these GAGE-like 
genes. RT-PCR studies showed frequent expression in 
melanoma metastases and Ewing's sarcoma for two XAGE-1- 
derived transcripts. XAGE-2 was expressed at lower 
frequency in these tissues, while XAGE-3 was only seen in 
normal placenta. Due to a frameshift the largest XAGE-1 
putative protein is far less homologous to GAGE-like proteins 
than the other XAGEs. Interestingly, all GAGE-like genes 
contain a large secondary open reading frame which putative 
proteins are homologues to the XAGE-1 primary protein. The 
XAGE family of cancer/testis-associated genes is located on 
chromosome Xp11.21-Xp11.22. The data presented outline a 
superfamily of GAGE-like cancer/testis antigens, consisting of 
at least 19 genes.
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During the last decade ever more interest has 
risen for cancer/testis-associated genes (CTAs). 
Since the detection of the first MAGE (Melanoma 
AntiGEn) many MAGEs [232] and MAGE-like 
genes as well as other CTAs have been found. 
CTAs, often present as multigene families on the X- 
chromosome, are in general only expressed in 
normal testis and in cancerous tissues [172]. This 
expression pattern qualifies them as potential 
immunotherapy candidate genes. So far very little 
is known on the role of CTAs in gametogenesis and 
in tumor development [207].
Based on earlier work we are interested in the 
GAGE-like XAGE genes [233,234]. Since the detec­
tion of the GAGE-family (GAGE-1-6) of CTAs 
[166], the number of GAGE-homologous genes has 
been steadily growing. PAGE-1, a GAGE-like gene 
mainly expressed in prostatic tissues, was found by 
mRNA differential display using prostate cancer 
cell lines [169]. Other members of the PAGE-family 
(PAGE-2, -3, and -4) were found by computerized 
EST database mining [170]. Expression profiling 
and alignment of the various GAGEs was reported 
by the group of Boon [225]. Except for GAGE-1, 
which contains an additional exon, the GAGE 
members vary mainly by amino acid substitutions 
and therefore are highly homologous. The PAGEs 
are far less homologous with the GAGEs as well as 
with each other.
Screening EST databases for PAGE-4 homolo­
gous genes identified the XAGE-family consisting 
of three homologous EST clusters (XAGE-1, -2, and 
-3) that are mainly expressed in testis, placenta and 
sarcoma tissue [219]. Existence of XAGE-1 mRNA, 
which only has a substantial homology to the
INTRODUCTION GAGE/PAGE-genes at its C-terminus, was reported 
by the same group [213]. They demonstrated that 
XAGE-1 is expressed in testis, and in about 50% of 
the sarcoma samples tested. Recently we have 
detected a smaller transcript of XAGE-1 in a screen 
for genes differentially expressed during melano- 
cytic tumor progression [233]. This transcript, 
named XAGE-1b, was expressed in a higher 
percentage and at a higher level in melanoma and 
Ewing's sarcoma compared to the previously 
described XAGE-1 transcript (here named XAGE- 
1a) [213]. During experiments to discriminate 
XAGE-1b from XAGE-1a expression, and by 
analyzing the ESTs of the XAGE-1 EST cluster 
(Unigene Hs.112208), we found two other alterna­
tively spliced XAGE-1 variants, XAGE-1c and 
XAGE-1d. By HTGS database searches we 
identified the corresponding genes of XAGE-1, -2, 
and -3 on BAC clones. Based on these data we 
outlined their genetic structure and aligned the 
putative proteins with other members of the 
GAGE/PAGE family. Finally, we determined the 
expression profile of the XAGE-family of cancer/ 
testis-associated genes in normal human tissues, 
Ewing's sarcoma and in melanocytic tumors.
MATERIALS AND METHODS 
H um an tissues
Normal human tissues, Ewing's sarcoma 
samples and lesions from all stages of melanocytic 
tumor progression (common nevus, atypical nevus, 
primary melanoma and melanoma metastasis) 
were obtained from patients at the UMC St 
Radboud, Nijmegen, The Netherlands. As normal 
human tissues we used disease-free samples from 
surgically removed tissues or from autopsies with a
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post-mortem delay shorter than 4 hours. Represen­
tative slices from the tissue samples were snap- 
frozen in liquid nitrogen and stored at -80°C until 
use.
Cell lines
We used 4 Ewing's sarcoma cell lines (Ew1, 
Ew2, Ew3 and SK-ES-1). Ewing's sarcoma cell lines 
Ew1, Ew2 and Ew3, all grown in Dulbecco's 
modified Eagle's medium supplemented with 10% 
fetal calf serum and antibiotics, were generously 
supplied by Dr. B. Jansen (Dept. of Human 
Genetics, UMC St Radboud, Nijmegen, The 
Netherlands). Total RNA from SK-ES-1 (American 
Type Culture Collection) was kindly provided by 
R. Willems (Dept. of Pathology, UMC St Radboud, 
Nijmegen, The Netherlands).
RNA isolation
Total RNA was isolated from cultured cells us­
ing the RNeasy kit (Qiagen, Hilden, Germany). 
From tissue samples total RNA was isolated by dis­
rupting about 25 frozen sections of 20 |am thickness 
in 1 ml RNAzolB™ (Campro, Veenendaal, The 
Netherlands) using a pestle. The RNAzolB™ 
method was followed by an additional RNeasy 
cleaning step. For all methods we followed the 
manufacturer's protocols.
RT-PCR
Synthesis of cDNA (10' at 25°C; 59' at 42°C; 5' 
at 95°C) was performed on 1.0 |ig of total RNA. The 
20 |il reaction mixture contained 250 pmol of 
random hexadeoxynucleotide primers, 3 mM 
MgCl2, 200 |aM of each dNTP, 50 mM Tris/HCl pH
8.3, 75 mM KCl, 10 mM DTT and 200 U MMLV 
reverse transcriptase (Promega, Madison, WI,
USA). For amplification, 1 |al of cDNA was 
supplemented with 2.5 |al PCR-buffer (200 mM 
(NH4)2SO4, 750 mM Tris/HCl pH 9, 0.1% Tween), 5 
|al 1 M dNTPs, 10 pmoles of each primer, x |al 25 
mM MgCl2, 0.15 U of Thermoperfectplus™ DNA 
polymerase (Integro, Zaandam, The Netherlands) 
and water to a final volume of 25 |al. PCR condi­
tions were 30 sec. at 94°C, 45 sec. at 60°C and 60 
sec. at 72°C for 30 cycles. These cycles were 
preceded by a 3 min. denaturation step at 94°C and 
followed by a 5 min. elongation step at 72°C. For 
nested PCRs, comprising an additional 30 PCR 
cycles, 2 |al of 100 times diluted product of the first 
PCR were used under the same buffer conditions as 
described above. DNA molecular weight markers 
were from Roche Diagnostics GmbH. Per sample 5 
|al of product was analyzed on an agarose gel using 
ethidium-bromide staining.
To specifically amplify 6 different XAGE 
transcripts we made use of PCR with primers listed 
in Table I and shown in Figure 1. Primers, product 
lengths and positions in the corresponding mRNAs 
are: XAGE-1a first PCR (467 bp): F1a (92-110) x R1 
(540-559); nested (252 bp): NF1ab (263-283) x NR1 
(496-515), XAGE-1b first PCR (356 bp): F1b (47-67) 
x R1 (384-403); nested (252 bp): NF1ab (107-127) x 
NR1 (340-359), XAGE-1c first PCR (657 bp): F1c (21­
39) x R1 (659-678); nested (459 bp): NF1c (176-195) x 
NR1 (616-635), XAGE-1d first PCR (212 bp): F1d 
(207-225) x R1 (400-419); semi-nested (169 bp): 
NF1d (207-225) x NR1 (357-376), XAGE-2 first PCR 
(444 bp): F2 (105-124) x R2 (526-549); nested (251 
bp): NF2 (264-284) x NR2 (496-515), XAGE-3 first 
PCR (468 bp): F3 (30-49) x R3 (467-498); nested (361 
bp): NF3 (111-130) x NR3 (454-472). All first rounds 
of PCR as well as the nested PCRs consisted of 30 
cycles. For XAGE-1d we used a semi-nested set-up
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Target Code Primer
ß2M Fß 5'-CTCGCGCTACTCTCTCTTTCT-3'
Rß 5'-TGTCGGATTGATGAAACCCAG-3'
PBGD Fp 5'-CTGGTAACGGCAATGCGGCT-3'
Rp 5'-GCAGATGGCTCCGATGGTGA-3'
XAGE-1 F1a 5'-CTTTGGTGCCCACCTCAGT-3'
F1b 5'-TGGATTCTTTCTCCGCTACTG-3'
F1c 5'-TGAGACACGGCGGGTAGGT-3'
F1d 5'-AGCTGAGATCCCAGGTGCT-3'
R1 5'-AAACCAGCTTGCGTTGTTTC-3'
NF1ab 5'-AGTCCCAGGAGCCCAGTAAT-3'
NF1c 5'-CCCATGGACCTTCTTGTCTC-3'
NF1d 1 5'-AGCTGAGATCCCAGGTGCT -3'
NR1 5'-GGTTGCTCTTCACCTGCTTC-3'
XAGE-2 F2 5'-CAGCCGTCTGGACTCTTTCT-3'
R2 5'-TTGTGTTGTTTCAGCTTATCTTCC-3'
NF2 5'-TGCTTGAACCCACTGATGAA-3'
NR2 5'-TGATTTCCCTTCACCTGCTT-3'
XAGE-3 F3 5'-TTGCCCTGAGACTTAGTTCG-3'
R3 5'-TTTGGAGAAAGCTGCAAAAG-3'
NF3 5'-ACCACCTCCTGAGCTGATTG-3'
NR3 5'-TGCCTGTCACCTCCTTCTG-3'
Table I.
PCR prim ers
1 sem i-nested (F1d=NF1d)
(F1d = NF1d). Only samples positive for both ß2- 
Microglobulin (ß2M) and porphobilinogen deami­
nase (PBGD) control PCRs were included in this 
study.
cDNA sequencing and homology searching
All sequence analyses of PCR products were 
done using the Big Dye terminator kit and ABI- 
3700 DNA analyzer (Perkin Elmer, Norwalk, CT). 
Homology searches and sequence alignments were 
performed with BLAST [80] and other software on 
various public servers of databases [152].
RESULTS
EST database query
Database queries show that the XAGE family of 
CTAs consists of three homologous EST clusters 
[219]. XAGE-1 transcripts are gathered in Unigene 
cluster Hs.112208 of which almost all ESTs are 
located at the 3'-part of the XAGE-1(a) transcript 
(AF251237) [213], corresponding to the length of 
the more frequently expressed XAGE-1b transcript 
described earlier [233]. In PCR experiments dis­
criminating XAGE-1b from XAGE-1a we found a 
PCR product of unexpected length possibly
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representing a splice variant (data not shown).
Sequencing revealed that it contained an insert 
of 220 bp compared to the XAGE-1b mRNA. This 
transcript was represented in the XAGE-1 Unigene 
cluster by two ESTs (BE875341 and BE881023) and 
was annotated XAGE-1c (AJ318878). We also iden­
tified XAGE-1d (AJ318879), a variant with a 16 bp 
insert compared to XAGE-1b (represented by ESTs 
AW386180 and AW386185). The XAGE-2 and 
XAGE-3 ESTs [219] belong to the GAGE-8 similar 
Unigene cluster Hs.16323 and the GAGE-1 similar 
Unigene cluster Hs.43879 respectively. In these 
Unigene clusters we could not detect any splice 
variant.
HTGS database query
To study the genomic XAGE sequences, we 
performed a BLAST search for the consensus EST 
cluster sequences using the HTGS database. For all 
three XAGEs we found at least one BAC clone 
containing the genetic sequence. The XAGE-1 gene, 
containing four exons (AJ400997) [233], was present 
in clone AC025553.5 (bp 157,000-152,000). The 
XAGE-2 gene was present on the same BAC-clone 
in two distinct regions (exon 1 and 2 at bp 24,000­
25,600 (reverse orientation) and exon 3, 4 and 5 at 
bp 50,000-56,000). This separation and reverse 
orientation of two parts of the gene is most likely 
caused by the unordered subfinal status of the BAC 
clone. XAGE-3 was present in clones AL445227.7 
(bp 89,500-95,000) and AL445236.22 (bp 39,000­
44,500). Both XAGE-2 (AJ318891 and AJ318892) and 
XAGE-3 (AJ318893) genes contain five exons.
Using a radiation hybrid panel (Stanford 
G3RH) we could map XAGE-1 on chromosome 
Xp11.21-Xp11.22 [233]. Since AL445236.22 is 
mapped on chromosome Xp11.21-Xp11.3 and
XAGE-2 is present on the same BAC-clone as 
XAGE-1, all three XAGEs are present at the same 
chromosomal region. Next to these three XAGE 
genes, we found several BAC-clones containing 
highly homologous sequences that will briefly be 
discussed later in this paper.
XAGE genes, transcripts and ORFs
In Figure 1 an alignment of the four different 
transcripts of the XAGE-1 gene and the transcripts 
of XAGE-2 (AJ318880) and XAGE-3 (AJ318881) is 
shown. The origin of the XAGE-1a and XAGE-1b 
transcripts was discussed earlier [233]. The alterna­
tive transcripts XAGE-1c and XAGE-1d contain an 
additional 220 bp sequence of intron 1 (exon 1') and 
a 16 bp sequence of intron 2 (exon 2 ' ) respectively. 
These alternatively spliced parts are all derived 
from consensus splice sites [193].
Homology between XAGE-1 and the other two 
XAGE genes (XAGE-2 and -3) is mainly present in 
the part starting at 37 bp in exon 2 of XAGE-1. This 
corresponds to the start of exon 3 in XAGE-2 and - 
3. XAGE-2 differs from XAGE-3 mainly by an 
elongated exon 1. Since the start of the open 
reading frame (ORF) for XAGE-2 and -3 is in exon 2 
this does not change the length of the putative 
proteins.
Schematic representations of the three XAGE- 
genes, their transcripts and ORFs are given in 
Figure 2. The ORF of XAGE-1a, the largest XAGE-1 
transcript, starts upstream in exon 1 compared to 
the other three XAGE-1 variants. The XAGE-1b 
ORF starts further downstream in exon 2 and codes 
for a smaller putative protein which is in-frame 
with the putative XAGE-1a protein. The main ORF 
of XAGE-1c starts in exon 1', but shares exon 2-4 
with XAGE-1a and -1b. XAGE-1d shares the
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X A G E - 1 a  GG ACCTG GG A  AGGA G CA TA G  GACAGGGCAA GGCGGGATAA GGAGGGGCAC CA CA G CC CTT AAGGCACGAG G GAACCTCAC T G CG CA T G CT  CC TTT G G T G C  1 0 0
X A G E - 1 a
X A G E - 1 b
X A G E - 1 d
CC A C CTCA G T G C G C A T G T TC  A CTG G G C G TC TT C C C A TC G G  C C C C T T C G C C  A G TG TG G GG A  A CGCGGCGGA GCTG TGA G CC GGCG ACTCG G  G TCCCTGA G G  2 0 0
X A G E - 1 a
X A G E - 1 b
X A G E -1 C
X A G E - 1 d
T C T G G A T T C T  T T C T C C G C T A  CTGAGACACG GCGG
3T A G G T  CCACAGGCAG A T C CA A CTG G  GA GTTG A AG T GTGAGTGAGA GTGAAGAGGA ACCAGCAGGC 9 9
7 8
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X A G E - 1 b  ____
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X A G E - 1 d
X A G E -2
X A G E -3
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CGACAGAAGA T T C T G G A C T C  CCCAGACGGG ACCAGGAGAG GGACGGCATG AGCG
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Figure 1. con tinued  on  next page
A lignm ent of XAGE cDNAs. Exon boundaries are indicated  by  vertical lines and  sharp  arrow s. Prim ers used  in  the first 
round  of PCR are show n w ith  closed arrow s; nested  prim ers are represented  by  arrow s w ith  open  heads. Start- and
stopcodons are show n in  bold. The polyA -signal sequence is underlined.
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Figure 1. 
continued
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Figure 2.
Schematical representation of XAGE-1, -2, and  -3: genes, transcripts and  ORFs. Exons are coded w ith  num bered  boxes. 
Prim ary ORFs are show n by  black bars; secondary ORFs are given in dotted  bars. The asterisk indicates a stopcodon in 
case of an  ORF w ithout a starting methionine. Introns w ith  double diagonal lines are no t d raw n on scale. Size of intron 2 
for XAGE-2 could no t be deduced  from  BAC-clone AC025553. Transcription start-sites w ith in  exon 1 are in  italic.
intron 1 (1406 bp) intron2 (527 bp) intron 3 (2590 bp)
XAGE-1
-length
81 a. a. 69 a.a.
XAGE-1d
(471 bp)
91 a. a. 70 a.a.
XAGE-2 
(610 bp)
111 a.a.
1 2 3 4 5
intron 1 (108 bp) intron2 (516 bp) intron3 (1532 bp) intron 4 (2134 bp)
XAGE-3
106 bp89 bp-length: 51 bp 110 bp
XAGE-3 
(483 bp)
111 a
82 a.a
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Figure 3.
A lignm ent of XAGE-1 pu tative  proteins. (A) P rim ary  ORFs. The nuclear localization signal is 
shaded  gray. (B) A lternative open  read ing  fram e (indicated w ith  #). A n asterisk m arks a stopcodon.
A
XAGE-1a 1 MLLWCPPQCACSLGVFPSAPSPVWGTRRS CEPATRVPEVWIL SPLLRHGGHTQTQNHTASPRSPV 65
XAGE-1c 1 MRCHAHGP SCLVT AITREEGGPRSGGAQAKLGCCWGYPSP* STWN*DR*FWTPQTGPGEG* ■E R ................. 79
XAGE-1a 66 MESPKKKNQQLKVGILHLGSRQKKIRIQLRSQCATWKVICKSCI SQTPGINLDLGSGVKVK11PKEEHCKMPEAGEEQPQV 146
XAGE-1b 1 .......................................................................................................................................................................................................................................................................  81
XAGE-1c 80 .......................................................................................................................................................................................................................................................................  160
XAGE-1d 1 ..................................... VLG-------------------------------------------------------  38
B
XAGE-1a# 1 * GLDS FSATE TRRTHTNTE PHSQ SQ EPSNG EPQKEE PAAE SRD PTPGQQTEEDQDTAEIPVRDMEGD LQELHQSNTGD KSGFGFRRQGEDNT 91
XAGE-1b# 1 * ............................................................................................................ ..91
XAGE-1c# 1 *A................................................................................................80
XAGE-1d# 1 * ......................................................................GAGKGNARHGR 70
XAGE-1d 39 ---------------------------------------------------------------------R EM.................................... ..69
initiation codon of XAGE-1b, but its reading frame 
is shifted due to the 16 bp insertion (exon 2'). All 
four XAGE-1 main ORF proteins share a nuclear 
localization signal (Figure 3; boxed).
Interestingly, all XAGE-transcripts contain a 
relatively large secondary ORF (out of frame) 
though for XAGE-1 these lack a start codon (Figure
2 and 3; dotted bars). Because of its frame shift, the 
C-terminal part of the primary XAGE-1d ORF is 
identical to the C-terminal part of the alternative 
reading frame of the other three putative proteins.
Expression profiles of XAGEs
To determine whether all XAGE transcripts 
have a CTA expression profile, we tested the 
expression of XAGE-1, -2 and -3 mRNAs in normal 
tissues (n=29), melanocytic lesions (n=36) and 
Ewing's sarcoma (n=9) using the primer sets de­
scribed in Table I and in Materials and Methods. 
Sixty cycles of RT-PCR were conducted to show a 
specific cancer/testis-associated expression pattern, 
even of the low abundant XAGE variants.
Regarding normal tissues we performed RT- 
PCR on four different samples each of testis and
Table II.
Expression profile in XAGE-positive norm al h um an  tissues.
1 O ther tissues tested (n = 1, bu t for b ra in  (n =3)) negative for all 6 transcripts: appendix, artery, bladder, bone 
m arrow , brain, duodenum , esophagus, gall b ladder, heart, ileum, kidney, larynx, liver, lym ph node, m edulla 
(spinal), m uscle (psoas), pancreas, prostate, rectum , spleen, stomach, thym us, thyroid, uterus, and  vein. Black 
boxes are positive PCR results; w hite boxes are negative. 2 Total num ber of PCR cycles
Tissue 1 N XAGE-1a
302 602
XAGE-1b
30 60
XAGE-1c
30 60
XAGE-1d
30 60
XAGE-2
30 60
XAGE-3
30 60
Ovary 1 -  - -  - -  - -  - -  1/1 -  -
Placenta 4 -  - -  1/4 -  1/4 -  1/4 4/4 4/4 2/4 4/4
Testis 4 -  3/4 4/4 4/4 -  4/4 -  4/4 -  4/4 -  -
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placenta. From other tissues, except brain (n=3), we 
tested only one sample. XAGE transcripts were 
only found in testis, placenta and ovary (Table II). 
In most testis samples 5 out of the 6 different XAGE 
transcripts could be detected after 60 cycles of PCR. 
XAGE-3 was undetectable in all four testis samples. 
Only XAGE-1b PCR was positive in testis after the 
first round of PCR (30 cycles). XAGE-2 and -3 were 
expressed at higher levels in placenta compared to 
testis. After the first PCR rounds XAGE-3 was seen 
in 2 out of 4 placenta samples, while all 4 samples 
were positive for XAGE-2. Regarding expression of 
XAGE-1 transcripts in placenta we did not find 
expression of XAGE-1a whereas XAGE-1b, -1c, and 
-1d could be detected in 1 out of 4 samples after 
nested PCR. Next to testis and placenta, XAGE-2 
was also expressed in ovary.
From the origin of the ESTs belonging to the
XAGE Unigene clusters and from previous reports 
regular expression of XAGEs was expected in 
Ewing's sarcoma [213,233]. All four Ewing's 
sarcoma cell lines tested were positive for XAGE- 
1a, -1b and -1d after 30 cycles (Table III). XAGE-1c 
was detected in 3 out of 4 cell lines after the nested 
PCR. Only one cell line showed a XAGE-1c PCR 
product after the first round of PCR (30 cycles). 
XAGE-2 was only found in cell line Ew1 after 60 
cycles. All Ewing's sarcoma cell lines were negative 
for XAGE-3. In a number of fresh tumor samples 
of Ewing's sarcoma we could also detect all four 
XAGE-1 transcripts. One round of PCR yielded 
products for XAGE-1a, -1b, -1c and -1d in respec­
tively 3, 3, 2, and 5 of 9 samples tested.
Nested XAGE-1 PCRs were all positive except 
for one XAGE-1a PCR and three XAGE-1c PCRs. 
Though only detectable after nested PCR, XAGE-2
Tissue Sample XAGE-1a
30 2 60 2
XAGE-1b
30 60
XAGE-1c
30 60
XAGE-1d
30 60
XAGE-2
30 60
X A G E -3  1
30 60
Ewing's sarcoma EW1 + + +  + -  - + + -  + -  -
Cell lines EW2 + + +  + +  + + + -  - -  -
EW3 + + +  + -  + + + -  - -  -
SK-ES-1 +  + +  + -  + + + -  - -  -
Ewing's sarcoma ES1 -  - -  + -  - - + -  + -  -
Lesions ES2 -  + -  + -  - - + -  + -  -
ES3 -  + -  + -  - - + -  + -  -
ES4 -  + -  + -  + - + -  + -  -
ES5 -  + -  + -  + - + -  + -  -
ES6 -  + -  + -  + + + -  + -  +
ES7 + + +  + +  + + + -  - -  -
ES8 + + +  + -  + + + -  + -  -
ES9 -  + -  -
Table III.
XAGE expression profile in  Ew ing's sarcoma. W eak p roduct is show n gray
1 This sequenced p roduct w as the XAGE-3-like XAGE-4 (AJ318895)
2 Total n um ber of PCR cycles
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expression was seen in a much higher percentage 
of Ewing's sarcoma lesions (89%; 8 out of 9) 
compared to the cell lines (25%; 1 out of 4). A 
"XAGE-3" PCR product was seen after 60 cycles in 
one of the tumor samples, but sequencing revealed 
it to be a XAGE-3-like sequence, which we named 
XAGE-4 (AJ318895). All other sequenced PCR 
products (several randomly selected products per 
XAGE-specific PCR) revealed the right sequences.
Since we are interested in human melanoma, 
from which XAGE-1b was isolated [233], we tested 
several samples from all stages of the melanoma 
progression lineage for XAGE expression (Table 
IV). In these samples substantial expression (PCR 
product after 30 cycles) was only seen in melanoma 
metastases for XAGE-1b (43%, n=23) and -1d (35%). 
Though after nested PCR most XAGE transcripts 
were detectable in several melanoma metastases, 
some were also found in a high percentage of 
nevus samples after 60 cycles. XAGE-2 nested PCR 
was even positive for all eight nevi tested, while 
only detectable in 1 primary melanoma and 3 mela­
noma metastases. Regarding primary melanoma 
this was the only sample with a positive XAGE 
PCR. All melanocytic tumor samples lacked XAGE-
3 expression.
XAGE-like genes
To see if we could find the gene corresponding 
to the XAGE-4 transcript found in one of the 
Ewing's sarcoma samples, we searched the HTGS 
database for XAGE-like sequences. This search did 
not yield a XAGE-4 gene, but we found a number 
of very homologous exons and gene sequences on 
different BAC clones (data not shown). Most of 
these clones did not code for XAGE-like proteins 
due to early stopcodons. Only one gene, which we
named XAGE-5 (AJ318894), has a XAGE-like ORF. 
XAGE-5 was not represented in the human EST 
database. Since XAGE-5 was located on the same 
BAC clone (AL445227) as XAGE-3 it can also be 
mapped on Xp11.21-Xp11.3.
BLAST searches with mRNA sequences of all 
known GAGEs, XAGEs and PAGEs rendered one 
additional member. Using the PAGE-2a consensus 
sequence (AA909141) we found a PAGE transcript 
(PAGE-5; deposited as AJ344352), represented by 
ESTs belonging to Unigene cluster Hs.245431.
XAGE/GAGE/PAGE alignment
To deduce consensus sequences for the ORFs of 
XAGE-like genes we aligned the putative protein 
sequences of the five XAGE genes described in this 
paper with two members of the GAGE family 
(GAGE-1 and GAGE-2), the four known members 
of the PAGE family, and PAGE-5 deduced from 
Unigene cluster Hs.245431 (Figure 4). As represen­
tative for XAGE-1 we selected XAGE-1a. Since 
most GAGE-like genes have a second large ORF, to 
which the primary ORF of XAGE-1 is partly 
homologous, we next to the primary ORF (Figure 
4A) also aligned the secundary ORFs (Figure 4B).
Previous work indicated that the XAGE-1a and 
-1b proteins were only homologous to the GAGEs 
at the C-terminus [233]. This C-terminal homology 
is visualized in the alignment of Figure 4A (XAGE- 
1a; amino acid 119-146). The consensus deduced 
from the N-terminal and central part of the GAGE­
like proteins is present in the alternative frame of 
XAGE-1 (XAGE-1a#; amino acid 1-91), indicating 
that the main ORF of XAGE-1 must have acquired 
a frameshift mutation compared to the other 
GAGE-like genes. This frameshift is indeed visible 
as an insert of 1 nucleotide in exon 3 in XAGE-1
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Tissue Sam ple XAGE-1a XAGE-1b XAGE-1c XAGE-1d XAGE-2 XAGE-3
30 2 60 2 30 60 30 60 30 60 30 60 30 60
N orm al skin NH1
NH2
N evus nevocellularis 1 NN1 -  - — — — — — — — —
NN2
NN3 — — — + — — — — — —
A typical nevus 1 AN1 -  — — — — — — — — + — —
AN2 — — — + — — — — — + — —
AN3 — — — + — + — — — + — —
AN4 — — — + — — — + — + — —
AN5 — — — + — — — + — + — —
Prim ary m elanom a PM1
PM2
PM3
PM4
PM5 — — — — — — — — — + — —
M elanom a m etastasis MM1
MM2
MM3
MM4
MM5
MM6
MM7
MM8
MM9 — — — — — — — + — — — —
MM10 — — — + — — — — — — — —
MM11 — — — + — — — — — — — —
MM12 — — — + — — — — — — — —
MM13 — — — + — — — + — — — —
MM14 — — +  +
Table IV. MM15 — — +  +
XAGE expres sion profile MM16 — — +  + — +
in  the h u m an  MM17 — — +  +
m elanocytic t um or MM18 — — +  +
progression  lineage. MM19 — — +  + — — — — — + — —
1 pooled (2-4 lesions per MM20 — — +  + — — +  — — + — —
sam ple) MM21 — — +  + — — — — — + — —
2 total num ber of PCR
MM22 — + +  +
cycles
MM23 — + +  +
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compared to XAGE-2, and -3 (Figure 1; position 444 
in XAGE-1 a). As a consequence part of the putative 
primary XAGE-1 protein (XAGE-1a; amino acid 66­
118) resembles the proteins encoded by the 
secondary ORF of the other GAGE-like genes 
(Figure 4B).
The alignment of the ORFs of the GAGE-like 
genes clearly reveals the consensus sequences 
(Figure 4; bold) present in all XAGE, GAGE and 
PAGE families. The primary ORF proteins (aligned 
in Figure 4A) all have low pi values ranging from 
4.2 to 5.1. The consensus residues (52%; 57 out of an 
average of 109) mainly consist of prolines and 
charged amino acids. The consensus of the 
alternative reading frames (Figure 4B) has a far 
higher pi value of about 11.5. The putative XAGE- 
1a has an N-terminal extension of 65 amino acids 
which is not present in the other GAGE-like genes 
and also has no homology to other known proteins 
in the database.
Compared to the other XAGEs XAGE-4 has an 
internal deletion of 14 amino acids corresponding 
to the last part of exon 3 of XAGE-2, and -3. This 
segment might be lost in the XAGE-4 gene or 
spliced out in its transcript. The PAGE family 
members clearly vary more in length and sequence 
from the consensus than the GAGEs and XAGEs. 
They also have a much shorter secondary ORF and 
most of them do not contain an AUG start codon.
DISCUSSION
In this paper we characterize the XAGE family 
of CTAs. Next to the identification of several new 
transcripts and genes, an exploration of their 
expression pattern in normal tissues, Ewing's 
sarcoma and melanocytic tumors is given.
Alignment of the XAGEs with other homolo­
gous CTAs clearly outline a GAGE-superfamily, 
consisting of at least 9 GAGEs, 5 PAGEs, and 5 
XAGEs.
Database mining is an ever more powerful and 
reliable tool in exploration of expression profiles of 
genes [83,235]. Though libraries of several tissues 
and tumor types are underrepresented, an insight 
in the distribution of the transcript can be obtained 
by the origin of ESTs present in its Unigene cluster. 
A clear example is the XAGE-3 transcript, which 
expected placental-specificity (based on the ESTs in 
Unigene cluster Hs.43879) was confirmed by our 
PCR results.
Furthermore, we were able to prove the exis­
tence of splice-variants XAGE-1c and -1d, encoun­
tered in the database, by RT-PCR and sequencing. 
For other CTAs splice-variants have also been 
described. The GAGE-1 transcript has an additional 
exon, which resembles the intron of the other 
GAGEs [225]. Intron-including transcripts have 
also been found for the NY-ESO-1 family member 
LAGE-1, leading to a putative protein with an 
altered C-terminus [168]. For PAGE-2 two variants 
even have their own specific cluster (PAGE-2a: 
Hs.293317; PAGE-2b: Hs.245431). PAGE-2b has a 17 
amino acids deletion compared to PAGE-2a [219]. 
Since little is known about the function of CTAs, 
the role of these variant-encoded proteins is also 
unclear.
Like most CTAs XAGE-1, -2, -3 and -5 genes 
are localized on chromosome X (Xp11.21-Xp11.3). 
Co-existence of several XAGE genes on the same 
BAC clones makes it very likely that the unidenti­
fied XAGE-4 gene also resides on that chromosome 
region. In the same region the GAGE [225], SSX 
[236] and MAGE-D, -H, -I and -J [232] families
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A lignm ent of GAGE-like proteins. (A) Putative proteins encoded by the p rim ary  ORF of the genes.
(B) A lternative ORFs of GAGE-likes. H ighly conserved residues are shaded  black. Consensus 
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have been mapped, marking this region as CTA- 
rich. Rega rding the PAGEs, only for PAGE-1 a 
subchromosomal localization (Xp21.3-Xp11.3) was 
reported in the Unigene mapping information 
locating it nearby the other GAGE-like genes. The 
genetic organization of XAGE-2 and -3 is much 
more similar to the GAGEs than that of XAGE-1. 
Like XAGE-2, and -3 the GAGEs consist of 5 exons 
and the primary ORF starts at the beginning of the 
second exon [225].
From the PCR results it is evident that XAGE-1 
and -2 transcripts share a cancer/testis- 
characteristic expression pattern. Expression in fe­
male reproductive tissues is a common phenome­
non among CTAs [158,169,172,222,223]. In tumor 
tissues XAGE-1 transcripts are more abundantly 
expressed than XAGE-2 transcripts. In melanocytic 
tumors highest percentages of expression are found 
for XAGE-1b, expressed in 43% (10 out of 23) of 
melanoma metastases after 30 cycles of PCR. This 
level of expression compares well with the 
percentages of 38% (23 out of 61 after 30 cycles) 
[233] and 43% (20 out of 47 after 35 cycles) [234] 
reported before. XAGE-3 might not be a real CTA 
since we could only detect it in normal placenta 
and not in normal testis or any tumor lesion.
More frequent expression of XAGEs in mela­
noma metastases compared to primary melanoma 
might be induced by loss of regulation of gene­
expression. This deregulation may be a result of 
phenomena like altered methylation status or 
cumulative genetic damage in later stages of tumor 
progression. With regard to an eventual use of 
XAGEs in immunotherapy, immunohistochemistry 
has to clarify their potential. This will be of special 
interest for Ewing's sarcoma, since XAGEs are the 
first CTAs described to be expressed in this tumor
type. Interestingly several CTL-recognized epitopes 
have been described to be derived from non­
primary ORFs of melanoma differentiation antigen 
TRP-1 [237] and from CTA NY-ESO-1, called 
CAMEL [238]. Later studies have shown that 
efficient generation of CTL epitopes, capable of in­
ducing anti-tumor response, can occur simulta­
neously from both ORFs of NY-ESO-1 [239].
A possible explanation for the production of 
both proteins from two overlapping ORFs on one 
mRNA could be the proposed leaky-scanning 
mechanism regularly passing the first AUG [237]. 
CTL anti-tumor epitopes can even be derived from 
alternative ORFs of widely expressed genes like N- 
acetylglucosaminyl transferase V [240] and intesti­
nal carboxyl esterase [241]. The latter epitope was 
processed from a non-AUG defined reading frame.
The protein alignment in Figure 4 clearly 
outlines the consensus present in the putative 
proteins of the GAGE-like genes. The short AUG 
start codon missing secondary ORFs of the PAGEs 
makes it unlikely that the corresponding proteins 
will be expressed. However, alternative translation 
starts from CUG codons (coding for leucine) have 
been described before in humans [242,243]. Most of 
the non-AUG secondary ORFs shown in Figures 3 
and 4 indeed have a CUG codon at the beginning 
of their ORF. The bipartite nuclear localization 
signal, described in the XAGE-1 transcripts, is also 
present in the putative secondary ORF defined 
proteins of most other GAGE-like genes. The 
striking difference in pI values of the GAGE-like 
proteins derived from both ORFs indicates that, if 
produced, these proteins will most probably have 
different biological functions.
In summary, we studied the XAGE family of 
CTAs. The high expression of several members of
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the XAGE family in melanoma and Ewing's 
sarcoma could be of interest in immunotherapeutic 
strategies. Homology searching identified several 
new members of the XAGE and PAGE families of 
GAGE-like CTAs and their genetic structure.
Alignment of the XAGE, PAGE, and GAGE pu­
tative proteins clearly outline a GAGE-like super­
family of CTAs. Future studies are needed to 
address their biological function in testis and can­
cers and their putative use in cancer immunother­
apy.
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Vaccination-based therapy of 
melanoma so far has mainly focussed on monovalent 
approaches using either melanoma differentiation antigens or 
cancer/testis antigens. To study the complementarity of 
expression from these two families of antigens recognized by 
T-cells, we screened 47 metastatic lesions of cutaneous 
melanoma for the expression of 3 melanoma differentiation 
antigens and 8 cancer/testis antigens using RT-PCR. The 
melanoma differentiation antigens were expressed in a 
somewhat higher percentage of lesions (94% positive for at 
least one marker) than cancer/testis antigens (91% positive for 
at least one marker). Nearly all melanoma metastases could 
be covered when looking for positivity of at least one of all 
markers tested (98%). One melanoma metastasis was negative 
for all markers. Two out of 47 lesions did not express any of 
the 3 differentiation markers, but expressed one or more 
markers of the cancer/testis antigens, indicating some 
additional potential of these antigens compared to the 
melanoma differentiation antigens. Therefore, we conclude 
that polyvalent immunotherapy using multiple epitopes from 
both families of antigens might increase eligibility of 
melanoma patients and efficacy of treatment.
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During the last decade melanoma, an immuno­
genic skin tumor with fast rising incidence for 
which conventional therapeutic options are limited, 
has been the type of tumor most often used for 
studying and optimizing cancer immunotherapy. 
Since the detection of MAGE-1 [156], many more 
melanoma-expressed antigens, recognized by T 
cells, have been identified as possible immuno­
therapy candidates [157]. These antigens can be 
divided into several groups, among which are the 
melanoma differentiation antigens (MDAs) (e.g. 
tyrosinase, gp100, MART-1MELAN'A, TRP-1, TRP-2) 
[177] and the cancer/testis antigens (CTAs) (e.g. 
MAGE [244], BAGE [165], GAGE [225], NY-ESO-1 
[158], SSX [167], XAGE [213], CT7MAGE-C1 [164,172], 
CT9 [222], CT10 [245], CTp11 [185]).
Some of these antigens have already been used 
in clinical vaccination trials, but so far showing 
limited effectivity [160,246,247]. This low success­
rate may be due to antigen heterogeneity within 
tumors or immune-induced antigen loss-variants. 
Identification of new immunotherapy candidate 
genes and suitable epitopes within these antigens 
[248,249], should increase the number of patients 
eligible for vaccination-based therapy.
Screening of the expression profile of candidate 
antigens within the tumor as well as determination 
of the HLA-status of a patient are prerequisites for 
the selection and inclusion of these patients into 
vaccination trials. Up till now for melanoma most 
studies focussed on either MDAs [117,250,251] or 
CTAs [158,166,174,178,252] separately. Only very 
few studies have combined these two and have 
looked for co-expression of MDAs and CTAs; 
however, the number of tested markers or the
INTRODUCTION
To investigate the coverage of melanoma 
metastases eligible for immunotherapy against one 
or more antigens, we determined the combined 
mRNA expression of three MDAs and eight 
members of different families of CTAs in metastatic 
lesions from 47 melanoma patients. The selected 
genes represent the most commonly known 
melanoma-associated antigens or antigen families. 
Next to immunotherapeutic relevance, these ex­
pression profiles may also have consequences for 
the efficiency of detecting occult metastatic 
melanoma cells in peripheral blood, bone marrow 
and/or sentinel lymph nodes.
MATERIALS AND METHODS 
Cell lines
Fifty-six metastatic lesions from human 
melanoma, excised from patients at the UMC St 
Radboud (Nijmegen, The Netherlands) and at the 
Leiden University Medical Center (Leiden, The 
Netherlands), were selected irrespective of the site 
in the body. Representative slices from the tissue 
samples were snap-frozen in liquid nitrogen and 
stored at -80°C until use. Four-micron sections 
were prepared for H&E-staining to score percent­
ages of tumor present in the samples.
RNA isolation
Total RNA was isolated by disrupting at least 5 
frozen sections of 20 |am thickness in 1 ml RNA- 
zolB™ (Campro, Veenendaal, The Netherlands) us­
ing a pestle. The RNAzolB™ method was followed 
by an additional RNeasy (Qiagen, Hilden, 
Germany) cleaning step. For all methods we 
followed the manufacturer's protocols.
number of lesions were limited [253,254].
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Synthesis of cDNA (10 min at 25°C; 59 min at 
42°C; 5 min at 95°C) was performed on 0.5-1.0 |ig of 
denatured (5 min at 90°C) total RNA. The 20 |il 
reaction mixture contained 250 pmol of random 
hexadeoxynucleotide primers, 3 mM MgCl2, 200 
|aM of each dNTP, 50 mM Tris/HCl pH 8.3, 75 mM 
KCl, 10 mM dithiothreitol and 200 U Moloney 
Murine Leukemia Virus reverse transcriptase 
(Promega, Madison, WI).
cDNA synthesis PCR assays
PCR analysis was performed for three MDAs 
(gp100, MART-1MELAN-A and tyrosinase) and eight 
representatives of several families of CTAs (BAGE, 
CT7MAGE-C1, GAGE-1/2, MAGE-1, MAGE-3, XAGE-
1, NY-ESO-1 and SSX-2). For amplification one |al 
of cDNA was supplemented with 2.5 |al PCR-buffer 
(200 mM (NH4)2SO4, 750 mM Tris/HCl pH 9, 0.1% 
Tween), 5 |al 1 M dNTPs, 10 pmoles of each primer, 
x |al 25 mM MgCk, 0.15 U of Thermoperfectplus™
Table I.
PCR prim ers and  conditions.
1 Ta = annealing tem perature  used  in PCR.
Target Ta 1 Primers Reference
(size)
1 & 
ß2
b )
59°C s 5'-CTCGCGCTACTCTCTCTTTCT-3' 
as 5'-TGTCGGATTGATGAAACCCAG-3'
[185]
PBGD 
(339 bp)
60°C s 5'-CTGGTAACGGCAATGCGGCT-3' 
as 5'-GCAGATGGCTCCGATGGTGA-3'
[215]
gp100 
(751 bp)
60°C s 5'-GCTTGGTGTCTCAAGGCAACT-3' 
as 5'-CTCCAGGTAAGTATGAGTGAC-3'
[117]
MART-1 
(384 bp)
60°C s 5'-ATGCCAAGAGAAGATGCTCAC-3' 
as 5'-AGCATGTCTCAGGTGTCTCG-3'
[117]
Tyrosinase 
(254 bp)
60°C s 5'-TTGGCAGATTGTCTGTAGCC-3' 
as 5'-GCTATCCCAGTAAGTGGACT-3'
[117]
BAGE 
(286 bp)
58°C s 5'-TGGCTCGTCTCACTCTGG-3' 
as 5'-CCTCCTATTGCTCCTGTTG-3'
[217]
CT7MAGE-C1
(289 bp)
60°C s 5'-GCTCCAGAAAGCAGGAGTTG-3' 
as 5'-AGTCCTCCCCCTCAGGATAA-3'
-
GAGE-1/2 
(243 bp)
56°C s 5'-GACCAAGACGCTACGTAG-3' 
as 5'-CCATCAGGACCATCTTCA-3'
[217]
MAGE-1 
(421 bp)
67°C s 5'-CGGCCGAAGGAACCTGACCCAG-3' 
as 5'-GCTGGAACCCTCACTGGGTTGCC-3'
[217]
MAGE-3 
(725 bp)
66°C s 5'-TGGAGGACCAGAGCCCCC-3' 
as 5'-GGACGATTATCAGGAGGCCTGC-3'
[ 217]
XAGE-1 
(355 bp)
55°C s 5'-TGGATTCTTTCTCCGCTACTG-3' 
as 5'-AAACCAGCTTGCGTTGTTTC-3'
[213]
NY-ESO-1 
(313 bp)
66°C s 5'-CACACAGGATCCATGGATGCTGCAGATGCG-3' 
as 5'-CACACAAAGCTTGGCTTAGCGCCTCTGCCC-3'
[158]
SSX-2 
(434 bp)
60°C s 5'-GTGCTCAAATACCAGAGAAGATC-3' 
as 5'-,nirGGGTCCAGATCTCTCGTG-3'
[167]
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DNA polymerase (Integro, Zaandam, The Nether­
lands) and water to a final volume of 25 |al. PCR 
conditions were 30 sec at 94°C, 45 sec at T­
annealing (Ta.) and 90 sec at 72°C for 35 cycles. 
These cycles were preceded by a 3 min denatura­
tion step at 94°C and followed by a 5 min 
elongation step at 72°C.
Primer-sequences and annealing temperatures 
for each of the cDNA-specific PCRs are given in 
Table I. For the control PCRs, ß2-Microglobulin 
(ß2M) and porphobilinogen deaminase (PBGD), we 
performed 30 instead of 35 cycles. The standard 
final concentration for MgCl2 was 1.5 mM; for 
gp100, MART-1MELAN-A, tyrosinase and XAGE-1 a
2.0 mM MgCl2 concentration was used. DNA 
molecular weight markers were from Roche Diag­
nostics GmbH. Per sample 10 |al of product was 
analyzed on 1.5% agarose gel using ethidium- 
bromide staining.
RESULTS 
Sample inclusion and scoring
After scoring the H&E-stained sections, lesions 
with tumor percentages less then 10% were omitted 
from further analysis. From the remaining samples 
(n=51) total RNA was isolated. Subsequently, RT- 
PCR for two housekeeping genes (ß2M and PBGD) 
was performed as a control to test the quality of the 
RNA samples. Forty-seven out of 51 samples 
showed a PCR-product for both ß2M and PBGD. Of 
these 47 MMs, cDNA was tested for the expression 
of three melanoma differentiation antigens (MDAs) 
and eight cancer/testis antigens (CTAs) known to 
be regularly expressed in melanoma (Table II sum­
marizes the results). To have a better comparison 
with results from other studies, where 30 as well as
35 PCR cycles are used, we scored strong PCR 
signals (black) separately from the weak bands 
(gray).
Frequencies of co-expression of the tested 
MDAs and CTAs are shown in Table III.
Finally we depicted the percentages of MMs 
positive for one or more MDAs, CTAs and MDAs + 
CTAs in Figure 1.
Melanoma differentiation antigens
Expression of MDAs was found in a high 
percentage of MMs (Table II). Only 3 out of 47 
MMs (6%) were negative for all three MDAs tested. 
A ll other 44 samples (94%) were at least positive for 
MART-1MELAN-A, tyrosinase and gp100 were each 
detected in 85% of the MMs (40/47). Expression of 
all three MDAs was seen in 79% of the lesions 
(37/47). Fifteen percent showed expression of one 
or two MDAs. If only strong positivity is taken into 
account the percentages of MDAs positive lesions 
are somewhat lower: MART-1MELAN-A (87%), gp100 
(79%), tyrosinase (74%).
Co-expression frequencies for the three MDAs 
are shown in the light-gray area of Table III. 
MART-1MELAN-A is always present when one of the 
other two MDAs (gp100 or tyrosinase) is detected. 
The co-expression frequencies of gp100 and 
tyrosinase are 93% (37 MMs positive for gp100 are 
also positive for tyrosinase, as well as the other- 
way-around), while each of them separately are 
found in 91% (40/44) of the MART-1MELAN-A positive 
lesions.
Coverages of MMs positive for one or more 
MDAs are shown in Figure 1: 94% of the lesions 
express at least one of the markers (m>1); 91% at 
least two (m>2), and 79% all three markers (m=3). If 
only strong RT-PCR signals are considered these
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Table II. Expression pattern of markers in metastatic lesions of hum an cutaneous melanoma using RT-PCR (35
cycles) RT-PCR. Strong signals are shown black; weak signals gray. 1 % T  = Percentage of tumor cells w ith in lesion.
N R  % T  i M ART1 gp100 tyro. M D A M A G E3 M A G E1 CT7 XAGE1 NYeso1 G A G E BA G E SSX2 CTA
MM-1 90 + + + 3/3 + + + + + + + + 8/8
MM-2 70 + + + 3/3 + + + + + + + + 8/8
MM-3 80 + + + 3/3 + + + + + + + + 8/8
MM-4 70 + + + 3/3 + + + + + + + + 8/8
MM-5 90 + + + 3/3 + + + + + + + + 8/8
MM-6 80 + + + 3/3 + + + + + + + — 7/8
MM-7 80 + + + 3/3 + + + + + + + — 7/8
MM-8 30 + + + 3/3 + + + + + + + 7/8
MM-9 80 + + + 3/3 + + + + + + + 7/8
MM-10 80 + + + 3/3 + + + + + + + — 7/8
MM-11 80 + + + 3/3 + + + + + + — 6/8
MM-12 80 + + + 3/3 + + + + — + — 6/8
MM-13 90 + + + 3/3 + + + + — — + — 6/8
MM-14 50 + + + 3/3 + + + — — + — + 5/8
MM-15 40 + + + 3/3 + + + — — — — + 5/8
MM-16 80 + + + 3/3 + + + + — — — — 4/8
MM-17 80 + + + 3/3 + + + + — — — — 4/8
MM-18 70 + + + 3/3 + + — — + — + 4/8
MM-19 40 + + + 3/3 + + + + — — — — 4/8
MM-20 30 + + + 3/3 + + — + + — — 4/8
MM-21 80 + + + 3/3 + + + — — — — — 3/8
MM-22 80 + + + 3/3 + — + — + — — — 3/8
MM-23 60 + + + 3/3 + — — + — — + 3/8
MM-24 90 + + + 3/3 + — + — — — + — 3/8
MM-25 80 + + + 3/3 + — + — — + — — 3/8
MM-26 80 + + + 3/3 + + — — — — — — 2/8
MM-27 80 + + + 3/3 + + — — — — — — 2/8
MM-28 80 + + + 3/3 + + — — — — — — 2/8
MM-29 90 + + + 3/3 + + — — — — — — 2/8
MM-30 90 + + + 3/3 — — — — — — — 0/8
MM-31 70 + + + 3/3 — — — — — — — 0/8
MM-32 90 + + + 3/3 + + + + + — + + 7/8
MM-33 90 + + + 3/3 + + + + + + + 7/8
MM-34 80 + + + 3/3 + + — — + — + + 5/8
MM-35 70 + + + 3/3 — — — — — + — 1/8
MM-36 20 + + + 3/3 — — — — — — — 0/8
MM-37 20 + + + 3/3 — — — — — + + — 2/8
MM-38 80 + + — 2/3 + + — + — + + + 6/8
MM-39
MM-40
90
70
+
+
+
+
2/3
2/3
+ + — +
+
+ — 4/8
1/8
MM-41 60 + + — 2/3 + + + + + + + — 7/8
MM-42 30 + — + 2/3 + — — — — — + + 3/8
MM-43 90 + — + 2/3 + + — — + — — 3/8
MM-44 90 + — — 1/3 + + — + + + + — 6/8
MM-45 70 — — — 0/3 + + + + + + + + 8/8
MM-46 90 — — — 0/3 + — + + — — — — 3/8
MM-47 30 
Strong 
%  
W eak 
%  
Total 
%
41/47
87
3/47
6
44/47
94
37/47
79
3/47
6
40/47
85
35/47
74
5/47
11
40/47
85
0/3
35/47
74
3/47
6
38/47
81
23/47
49
10/47
21
33/47
70
22/47
47
5/47
11
27/47
57
20/47
43
4/47
9
24/47
51
17/47
36
6/47
13
23/47
49
18/47
38
5/47
11
23/47
49
18/47
38
3/47
6
21/47
25
11/47
23
6/47
13
17/47
36
0/8
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1 M ART1 gp100 Tyro. M A G E3 M AG E1 CT7 XAGE1 NYeso1 G A G E BA G E SSX2 cum ulative
MART-1 40/44
(91%)
40/44
(91%)
36/44
(82%)
32/44
(73%)
25/44
(57%)
22/44
(50%)
22/44
(50%)
22/44
(50%)
20/44
(45%)
16/44
(36%)
80/88
(91%)
275/440
(63%)
gp100 40/40
(100%)
37/40
(93%)
33/40
(83%)
30/40
(75%)
25/40
(63%)
21/40
(53%)
19/40
(48%)
21/40
(53%)
18/40
(45%)
15/40
(38%)
77/80
(96%)
259/400
(65%)
Tyro. 40/40
(100%)
37/40
(93%)
32/40
(80%)
28/40
(70%)
24/40
(60%)
18/40
(45%)
20/40
(50%)
18/40
(45%)
17/40
(43%)
15/40
(38%)
77/80
(96%)
249/400
(62%)
MAGE-3 36/38
(95%)
33/38
(87%)
32/38
(84%)
31/38
(82%)
25/38
(66%)
22/38
(58%)
20/38
(53%)
19/38
(50%)
18/38
(47%)
17/38
(45%)
152/266
(57%)
253/380
(67%)
MAGE-1 32/33
(97%)
30/33
(91%)
28/33
(85%)
31/33
(94%)
22/33
(67%)
23/33
(70%)
20/33
(61%)
19/33
(58%)
18/33
(55%)
14/33
(42%)
147/231
(64%)
237/330
(72%)
CT7 25/27
(93%)
25/27
(93%)
24/27
(89%)
25/27
(93%)
22/27
(81%)
20/27
(74%)
16/27
(59%)
16/27
(59%)
15/27
(56%)
12/27
(44%)
126/189
(67%)
200/270
(74%)
XAGE-1 22/24
(92%)
21/24
(88%)
18/24
(75%)
22/24
(92%)
23/24
(96%)
20/24
(83%)
17/24
(71%)
17/24
(71%)
17/24
(71%)
11/24
(46%)
127/168
(76%)
188/240
(78%)
NY-ESO-1 22/23
(96%)
19/23
(83%)
20/23
(87%)
20/23
(87%)
20/23
(87%)
16/23
(70%)
17/23
(74%)
16/23
(70%)
16/23
(70%)
12/23
(52%)
117/161
(73%)
178/230
(77%)
G A G E 22/23
(96%)
21/23
(91%)
18/23
(78%)
19/23
(83%)
19/23
(83%)
16/23
(70%)
17/23
(74%)
16/23
(70%)
15/23
(65%)
12/23
(52%)
114/161
(71%)
175/230
(76%)
BA G E 20/21
(95%)
18/21
(86%)
17/21
(81%)
18/21
(86%)
18/21
(86%)
15/21
(71%)
17/21
(81%)
16/21
(76%)
15/21
(71%)
11/21
(52%)
110/147
(75%)
165/210
(79%)
SSX-2 16/17
(94%)
15/17
(88%)
15/17
(88%)
17/17
(100%)
14/17
(82%)
12/17
(71%)
11/17
(65%)
12/17
(71%)
12/17
(71%)
11/17
(65%)
89/119
(75%)
135/170
(79%)
cum ula­
tive
80/80
(100%)
77/84
(92%)
77/84
(92%)
152/168
(90%)
147/173
(85%)
126/179
(70%)
127/182
(70%)
117/183
(64%)
114/183
(62%)
110/185
(59%)
89/189
(47%)
275/286
(96%)
259/290 249/290 
(89%) (86%)
253/292
(87%)
237/297
(80%)
200/303
(66%)
188/306
(61%)
178/307
(58%)
175/307
(57%)
165/309
(53%)
135/313
(43%)
Table I II .
Co-expression frequencies of markers expressed in melanoma metastases.
percentages are lower: 91% m>1, 83% m>2, and 
66% for m=3.
Cancer/testis antigens
Regarding mRNA expression of CTAs in 
melanoma metastases the order of positivity was: 
81% MAGE-3 (38/47), 70% MAGE-1, 57% CT7MAGE- 
C1, 51% XAGE-1, 49% NY-ESO-1, 49% GAGE-1/2, 
45% BAGE and 36% for SSX-2 (Table II). Directly 
visible from Table II is the much more heterogene­
ous expression pattern compared to the MDAs. 
Four MMs were negative for all 8 CTAs tested 
(9%), while 13% (n=6) expressed all CTA genes.
Highest MM-coverage, positive for at least one of 
two CTAs, were seen for the combinations MAGE- 
3 + GAGE-1/2 (n=42; 89%) and MAGE-3 + NY-ESO- 
1 (n=41; 87%). When scoring positive only for 
strong PCR signals, frequencies of expression for 
MAGE-3, MAGE-1, CT7MAGE-C1, XAGE-1, NY-ESO- 
1, GAGE-1/2, BAGE and SSX-2 are respectively: 
74%, 49%, 47%, 43%, 36%, 38%, 38%, and 23%.
CTA co-expression frequencies (dark-gray area 
of Table III) reveal MAGE-3 expression in 90% (152 
out of 168 analyses) of the MMs positive for at least 
one of the other CTAs. For the 17 SSX-2 positive 
lesions MAGE-3 is present in all of them. MAGE-1,
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known to be often simultaneously expressed with 
MAGE-3, is expressed in 31 out of 38 MMs (82%) 
positive for MAGE-3. In metastases expressing 
XAGE-1 co-expression with MAGE-1 (23 out of 24; 
96%) and MAGE-3 (22 out of 24; 92%) are almost 
perfect.
Expression of at least one of the eight CTAs 
(m>1) was found in 91% of the MMs. For m>2 and 
m>3 these percentages are 87% and 77% respec­
tively. Considering only strong positive PCR 
signals, percentages are: m>1, m>2 and m>3 being 
85%, 70%, and 57% respectively (Figure 1).
Comparison of M D A and CTA expression
To see whether expression of CTAs increases 
the number of MMs expressing potentially 
immunotherapeutic interesting antigens, we com­
bined the MDA and CTA data. As expected some 
MMs expressed only MDAs and no CTAs (n=3; 
6%). On the other hand, we found expression of 
CTAs in two metastatic lesions that were negative
for all three MDAs. One of these lesions even 
expressed all 8 CTAs tested. One lesion completely 
lacked detectable expression of any of the 11 
markers tested, whereas expression of all 11 
markers was found in 5 lesions (11%).
Expression of MART-1MELAN'A, gp100 and 
tyrosinase on average was found in respectively 
95% (195/206), 88% (182/206) and 83% (172/206) of 
MMs positive for one or more CTAs. Co-expression 
with MDAs was lowest in MMs positive for XAGE- 
1 (92%, 88% and 75% for MART-1MELAN-A, gp100 
and tyrosinase respectively). The other-way- 
around comparison yields a co-expression for 
CTAs of about 63% in samples positive for at least 
one of the MDAs.
By combining the results for MDAs and CTAs 
a maximum of 98% of the MMs expressed at least 
one of the 11 tested markers (46 out of 47). This 
coverage remains for at least two or three positive 
markers. Combining MART-1MELAN'A and MAGE-3 
this level of positivity is already reached.
Figure 1.
Percentages of melanoma metastases positive for one or more M DAs, CTAs or MDAs+CTAs; 
m = number of markers positive w ith in the group; t = total of markers tested in the group.
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Marker Own results (%  pos. M M ) 
A ll Strong only
Published results 
%  pos. M M  cycles Reference
gp100 85 79 83 35 [253]
89 35 [255]
MART-1MELAN-A 94 87 87 30 [254]
84 35 [255]
Tyrosinase 85 74 81 30 [254]
92 35 [253]
81 30 [256]
100 35 [255]
BAGE 45 38 22 35 [178]
26 30 [165]
25 30 [254]
CT7MAGE-C1 57 47 70 35 [172]
53 35 [164]
GAGE-1/2 49 38 17 30 [178]
28 30 [166]
41 30 [225]
43 30 [254]
MAGE-1 70 49 35 30 [178]
48 30 [257]
50 30 [254]
55 30 [258]
MAGE-3 81 74 52 35 [178]
76 30 [257]
56 30 [254]
85 30 [258]
NY-ESO-1 49 36 34 35 [158]
29 35 [168]
44 35 [178]
42 30 [259]
SSX-2 36 23 35 35 [174]
44 35 [178]
Table IV .
Observed and published 
frequencies of expression 
of the tested M D A  and 
CTA genes in melanoma 
metastases by RT-PCR
Considering strong positivity only (as depicted 
by the black bars in Figure 1) still 98% of the MMs 
expressed at least one (m>1) or two (m>2) of the 
genes tested. In 87% of the MMs three or more 
markers are expressed (m>3).
Overall no obvious correlations are seen 
between level of positivity of any of the markers 
tested, as shown by intensity of the PCR band, and 
the percentages of tumor cells present in the 
samples (Table II), as well as with the site of 
metastases in the body (data not shown).
D ISCUSSIO N
One of the main factors for T-cell mediated 
immunotherapeutic success, next to expression of 
H LA  molecules, is expression by the tumor of 
genes coding for immunogenic peptides. So far 
mainly monovalent immunotherapeutic ap­
proaches have been used with limited effectivity. 
To circumvent problems of heterogeneity or 
absence of expression of one or more candidate 
immunotherapy markers, polyvalent vaccination 
might be beneficial [222] In this way efficacy of 
anti-tumor treatment should improve by recog­
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nition of: (i) multiple tumor types, (ii) higher 
percentage of lesions for a certain tumor type, (iii) 
higher percentage of cells within a tumor, (iv) 
multiple antigens on tumor cells and, (v) epitopes 
with divers HLA-restriction.
To investigate the expression profile of multi­
ple melanoma-associated antigens in melanoma we 
performed RT-PCR for three MDAs and eight 
CTAs in metastatic lesions from 47 melanoma 
patients. The individual frequencies of expression 
observed by us match very well with the results of 
others (Table IV). Regarding the CTAs only BAGE 
is somewhat higher expressed as found in earlier 
studies. The reported high level of positivity (70%) 
for CT7 is only based on 10 samples [172]. Expres­
sions levels of most CTAs in MMs found by Sahin 
et al. [178] are considerably lower than found by us 
and reported by others (Table IV).
In our study 6% of the lesions did not express 
any MDA. Absence of expression of MDAs by RT- 
PCR was observed in 2 out of 16 patients by 
Dalerba et al. [254], though they only looked for ty­
rosinase and MART-1MELAN-A. Using immunohisto-
chemistry, a technique that is less sensitive, absence 
of MDAs has been found more often: 17% negativ­
ity for gp100, MART-1MELAN-A and tyrosinase [117]; 
12% negativity for gp100 and MART-1MELAN'A [20]. 
Reports on total coverage of MMs by MDAs are 
more common [251,253,255]. For a few patients, 
samples used in this study were also screened in an 
earlier study for MDA expression based on immu- 
nohistochemistry [117]. Overall these data revealed 
good correlation, though RT-PCR was somewhat 
more sensitive (Table V).
Based on their lower frequency of expression 
CTAs are more likely to be heterogeneously 
expressed. As expected the highest expressed CTA, 
being MAGE-3, has the highest percentage of co­
expression with other CTAs (overall 90%). While 
Sahin et al. [178] detected MAGE-3 in all MAGE-1 
positive MMs, we found two lesions only positive 
for the latter. A  high frequency of CT7MAGE-C1 and 
MAGE-3 co-expression was also reported by Lucas 
et al. [164]. They saw expression of at least one 
MAGE-A in 94% of the MAGE-C1 positive MMs. 
Similarly 98% of BAGE positive MMs also
Table V .
Comparison of immunohistochemistry and RT-PCR for M D As: gp100, MART-1MELAN-A and 
tyrosinase. 1 35 cycles RT-PCR: Strong signals are scored black; weak signals are shown in gray;
2 Performed by de Vries et al. [117]; scored by percentage of tumor cells positive
Sample RT-PCR 1 
MART-1 gp100 tyrosinase MART-1
IH C  2 
gp100 tyrosinase
MM-3 + + + 50-75% 1-10% 1-10%
MM-7 + + + 50-75% 50-75% 75-100%
MM-13 + + + 75-100% 75-100% 75-100%
MM-22 + + + 50-75% 50-75% 50-75%
MM-26 + + + 50-75% 25-50% 10-25%
MM-29 + + + 75-100% 75-100% 75-100%
MM-33 + + + 0% 0% 0%
MM-39 + + _ 1-10% 1-10% 0%
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expressed one or more of MAGE-1, -2, -3 or -4
[166]. XAGE-1 has a very high co-expression with 
MAGE-1 (96%).
High frequencies of co-expression might be ex­
plained by use of common regulatory mechanisms. 
The heterogeneous expression of CTAs in mela­
noma metastases might be caused by interplay of 
heterogeneous promotor-methylation and presence 
of relevant transcription factors. The maximum 
coverage of MMs by CTA expression (91%, Figure 
1) is higher compared to the 74% positivity for at 
least one of 9 CTAs tested by Sahin et al. [178], 
though they also tested five of the CTAs most 
frequently expressed by MMs, using 35 cycles of 
RT-PCR. We saw no obvious correlation between 
MDA and/or CTA expression and site of metasta­
sis.
In our study the maximum coverage of MMs 
positive for MDAs (94%) is somewhat higher than 
for the CTAs (91%). Combining expression profiles 
of CTAs and MDAs increases the percentage of 
MMs positive for at least one marker to 98%. This 
high frequency of positivity is the same when 
including only MMs positive for at least two or 
three antigens. Of the three MDA negative MMs in 
our study two expressed one or more CTAs, 
implicating an additional potential of CTAs in 
immunotherapy of melanoma compared to MDAs. 
Positivity only for CTAs and not for MDAs was not 
seen in a comparative study by Dalerba et al. [254].
Use of CTA-based immunotherapy has the 
advantage that it is not necessarily restricted to 
melanocytic tumors and that no-side effects, such 
as vitiligo for MDA-based immunizations, are ex­
pected since testis lacks expression of the HLA 
genes and melanocytes do not express CTAs.
In summary, we performed a RT-PCR based
multiple-gene co-expression analysis on a large 
number of MMs. While suitable for this type of 
study, one should keep in mind that implementa­
tion of quantative mRNA detection techniques 
would give more insight in the comparative levels 
of expression. However, we should realize that 
mRNA-based studies might not always represent 
protein expression. For instance using antibody 
57B, which recognizes MAGE-1, -2, -3, -4, -6 and -12 
[258], much lower and varying percentages of 
positivity have been reported compared to mRNA- 
based frequencies (about 75% for MAGE-3 alone; 
see Table IV) [258,260,261]. On the other hand good 
correlations between mRNA expression and 
protein levels were found for SSX and NY-ESO-1 
[215,259].
In addition, we should realize that the chance 
for effective immune therapy is determined by the 
expression of the peptide-harboring gene times the 
expression frequency of the HLA-type gene 
binding and presenting the specific peptide. It is 
therefore crucial to select a patients' eligibility for 
specific immunotherapy by screening the expres­
sion of HLA-, MDA- and/or CTA-genes in tumor 
biopsies. Subsequently, polyvalent immunotherapy 
using multiple epitopes (of different HLA- 
restrictions expressed by the patient) from multiple 
melanoma-associated antigens present might sort a 
stronger beneficial result.
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Cancer/testis-associated genes 
(CTAs) are a subgroup of tumor antigens with a restricted 
expression in testis and malignancies. During the last decade 
many of these immunotherapy candidate genes have been 
discovered using various approaches. Most of these genes are 
localized on the X-chromosome, often as multigene families. 
Methylation status seems to be the main, but not only 
regulator of their specific expression pattern. In testis CTAs 
are exclusively present in cells of the germ cell lineage, 
though there is a lot of variation in the moment of expression 
during different stages of sperm development. Likewise, there 
is also a lot of heterogeneity in the expression of CTAs in 
melanoma samples. Clues regarding functionality of CTA for 
many of these proteins point to a role in cell cycle regulation 
or transcriptional control. Better insights in the function of 
these genes may shed light on the link between 
spermatogenesis and tumor growth and could be of use in 
anti-tumor therapies. This chapter outlines the CTA family 
and focuses on their expression and putative function during 
male germ cell development and melanocytic tumor 
progression.
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PREFACE
Though the melanoma research community is 
small compared to those studying big killers like 
lung, colon and breast cancer it has contributed to 
major advances in understanding the biology of 
tumor development [262]. One of the areas of 
cancer research where insights from melanoma 
have made a substantial impact is that of T cell- 
mediated immunotherapy. Many human tumor 
antigens have been identified and characterized as 
a result of melanoma research. Main reasons for the 
frequent use of melanoma as tumor type in 
immunotherapy-related research are the high 
success-rate in establishing melanoma cell lines and 
the relatively good immunogenic properties of this 
tumor type [263].
HUM AN TUM OR AN TIG EN S
Since the isolation and partial characterization 
in 1991 of the first T cell recognized human tumor 
antigen, called MAGE-1 (Melanoma AntiGEn-1) 
[156], many more human tumor antigens and their 
derived T cell epitopes have been described. Based 
on their origin and expression profile human tumor 
antigens (given with examples for melanoma) are 
divided into four distinct groups [263]:
Differentiation antigens
Differentiation antigens are lineage-specific 
genes: expressed in tumor cells as well as in the 
normal cells from which the tumors arise. For 
melanoma differentiation antigens (MDAs) this 
means that they are expressed throughout all 
stages of the melanocytic tumor progression 
starting at the melanocyte. Most of these MDAs are
involved in the process of melanin pigment 
production [1]. Remarkably, several well-studied 
MDAs (e.g. tyrosinase [248], gp100 [264], MART- 
1MELAN-A [265] and TRP-1 [237]) have been shown to 
contain epitopes recognized by melanoma reactive 
T cells.
Cancer/testis antigens
These antigens are expressed in histologically 
different types of malignant human tumors and are 
restricted in normal tissues to germ cells of the 
testis, with occasional expression in female 
reproductive organs. For a large number of recently 
found genes with such an expression profile no T 
cell recognized epitopes have been identified yet. 
Therefore, these are cancer/testis-associated genes 
and not yet proven cancer/testis antigens.
Overexpressed antigens
Genes widely expressed in many normal 
tissues can sometimes also give rise to an 
immunological response. By overexpression of 
these proteins in tumors T cell recognition can be 
triggered as a result of the breaking of antigen 
tolerance. Examples described for melanoma are 
PRAM E (preferentially expressed antigen of 
melanoma [266]), p15 [267], sp17 (sperm protein 
17) [268-270] and SART-3 (squamous antigen 
rejecting tumor) [271].
Tumor-specific antigens
Antigens unique to a certain tumor have been 
found based upon specific genetic alterations, lead­
ing to proteins that are recognized as non-self by 
the immune system. In melanoma these have been 
described as a result of point mutation (e.g. ß- 
catenin) [272] or translocation-based gene fusions
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like that of the low-density lipid receptor with GDP 
L-fucose (LDLR/Fut) [273].
A  periodically updated list of tumor antigens is 
maintained at INT tumor institute (www. 
institutotumori.mi.it) [263].
CANCER/TESTIS-ASSOCIATED GENES (CTAs) 
CTA criteria
Criteria for placing genes in the ever growing 
CTA family are based on several characteristic 
features [171,207]: (i) predominant expression in 
(germ cells of the) testis and generally not in other 
normal tissues besides occasional positivity in 
female reproductive organs; (ii) expression in a 
percentage of malignant tumors from different 
histological types; (iii) expression in malignancies 
in a lineage non-specific fashion; (iv ) mapping of 
the gene on the X-chromosome; (v ) presence in 
multigene families. However, for several CTAs 
some exceptions to these criteria have been 
described as w ill be discussed later on.
Though often referred to as cancer/testis anti­
gens the term cancer/testis-associated genes is pref­
erable based on two aspects. First, for many genes 
with a cancer/testis specific profile so far no evi­
dence has been found that they really encode T cell 
recognized epitopes. Secondly, these proteins are 
not antigens in case of expression in testis, since 
testis lacks expression of H LA class I molecules, 
necessary for presentation to and recognition by T 
cells [274]. For this latter reason Boon and co­
workers prefer the term tumor-specific shared 
antigens [275].
Cancer/testis antigens and cancer/testis- 
associated genes have been identified by several 
different approaches:
T-cell epitope cloning
The first CTAs have been discovered by clon­
ing of epitopes recognized by autologous cytotoxic 
T lymphocytes [276]. This cellular, immunology- 
based strategy, extensively applied on melanoma, 
yielded many melanoma-associated antigens [184]. 
Next to several melanoma differentiation antigens 
(e.g. tyrosinase and TRP-1) this approach also 
identified the first CTAs (MAGE [156], GAGE 
[277] and BAGE [165]).
SEREX (serological analysis of 
cDNA expression libraries)
SEREX is based on the fact that there often is an 
integrated reaction against human tumor antigens 
based on CD8+ T cells, CD4+ T cells and B cells 
[278,279]. In this approach novel cDNA cloning 
techniques have been implemented into the 
previously used method of autologous typing
[280]. This screening of recombinantly expressed 
antigens with sera from all kinds of tumor patients 
successfully identified several CTAs (e.g. SSX-2
[167], SCP-1 [171], NY-ESO-1 [158]).
Since the clinical significance of these anti­
tumor antibodies is unknown, the antigens 
recognized by these antibodies can be screened for 
T cell recognition by reverse T cell immunology. 
This is done by loading antigen presenting cells 
either with selected MHC class I binding peptides
[281] or by transfecting them with the cDNA of the 
antigen [279]. A  database of SEREX-identified 
epitopes is maintained at the website of the Ludwig
Identification of CTAs
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Institute for Cancer Research (www.licr.org).
Differential gene expression analysis
Next to the previous two immunological 
methods, identifying real antigens, many CTAs 
have been found based on their specific mRNA ex­
pression profile. Using differential gene expression 
techniques (like representational difference 
analysis (RDA) [66], differential display (DD) [51] 
and suppression subtractive hybridization (SSH) 
[68]) in comparing mRNA pools of tumor versus 
normal or testis versus other tissues, many new 
CTAs were described (e.g. MAGE-C1CT7 [164], 
MAGE-C2CT10 [282], PAGE-1 [169], LAGE-1 [168], 
SPA N X A 11 [185], XAGE-1 [233]).
Bioinformatics
Making use of the huge amount of expression 
data (e.g. SAGE tags and ESTs) present in public 
databases also electronically differentially ex­
pressed genes can and have been identified. 
Moreover, many homologues of previously found 
CTAs were discovered by BLAST alignment. With 
the obtained information specific primers can be 
developed to verify the expression profiles. 
Examples of CTAs detected in such ways include 
MAGE-B5, -B6 and -C3 [227], PAGE-4 [170], CT9 
[222], several XAGEs [219,283] and CT15/16/17 
[284].
CTA genes and families
In Table I a list of human CTAs is given based 
on several CTA reviews and recent papers. Short 
outlines and histories of the CTA genes and 
families are given below:
M AGE
The denominator of the melanoma antigen 
family, MAGE-1, was discovered in 1991 by charac­
terization of a protein and encoded epitope 
recognized by an anti-melanoma T-cell clone 
[156,289]. Since then the number of MAGE 
homologues has been steadily growing. At first a 
cluster of MAGE-A genes was described at Xq28 
[244]. Shortly thereafter, two additional clusters of 
homologues genes were found at Xp21 (MAGE-B 
[176]) and Xq26-27 (MAGE-C [164,227]). MAGE-B 
genes were also identified by analysis of 
autoantibodies in systemic lupus erythematosus 
patients (MAGE-Xp) [290] and in a screening for 
genes involved in the Xp21 sex reversal critical 
region (DAM-6 and -10) [291].
Genes belonging to the MAGE-A, -B and -C 
subfamilies are called type I MAGEs [287]. In these 
type I MAGE genes the full open reading frame 
(ORF) is encoded within the last exon. Moreover, 
besides several pseudogenes like MAGE-A7, they 
all have a cancer/testis-associated expression 
profile at least at mRNA level [232].
Finally, these MAGEs all share a consensus 
sequence of about 170 amino acids in length 
located at the central part of the proteins called the 
MAGE homology domain (MHD) [285,287]. High 
levels of identity found in this part of the proteins 
is suggestive for a conserved function of this 
domain. This assumption is strengthened by the 
fact that based on this MHD also several MAGE 
paralogues have been found in vertebrates (e.g. cat 
[323], dog [324], mouse [232,325,326], rat [327] and 
chicken (Genbank AI980860)), fruit fly [287], 
zebrafish [232] and even in plants [232] and fungi 
[287]. The N-terminal parts of MAGEs, on the other 
hand, are only highly homologous between
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CTA Genes Alternative symbol Chromosome References
Families [207, 232, 263, 285-287]
M AGE:
MAGE-A 15 CT1 1 Xq28 [159, 244, 288, 289]
MAGE-B 17 MAGE-Xp/dam-10; dam-6 Xp21 [175, 176, 227, 290, 291]
MAGE-C 7 CT7; CT10 Xq26-27 [164, 172, 227, 245, 282]
MAGE-D 2 5 NRAGE, magphinin Xp11 [227, 286, 292, 294]
MAGE-E 2 3 Xq13-21 [295, 296]
MAGE-F 2 1 3q26-ter [297]
MAGE-G 1 15q11-14 [232]
MAGE-H 1 Xp11 [232]
MAGE-I 2 Xp11 [232]
MAGE-J 1 Xp11 [232]
MAGE-K 1 Xq24-26 [232]
MAGE-L 2 1 15q11-14 [298]
Necdin 2 1 15q11.2-12 [299]
G AG E/PAG E/XAG E:
GAGE 9 CT3 Xp11.4-11.2 [169, 225, 277]
PAGE 5 CT16; GAGE-B; GAGE-C Xp11.23 [169, 170, 219]
XAGE 5 PLAC6; GAGE-D Xp11.22-11.21 [213, 219, 233, 283, 300]
NY-ESO -1: CT5
NY-ESO-1 1 CTAG-1; CAG-3 Xq28 [158, 173, 301]
LAGE-1 1 CTAG-2; CAM EL Xq28 [168, 302]
S S X 5 HOM-MEL-40; CT4 Xp11.2 [167, 303]
S P A N X 6 CTp11 Xq26.3-27.1 [185-187, 304]
TRAG-3:
TRAG-3 1 Xq28 [305, 306]
CSAGE 1 Xq28 [307]
Non-familial
BAGE CT2 13 [165]
SCP-1 HOM-TES-14; CT6 1p13 [171, 308]
BRDT CT9 1p31.1 [222]
MMA-1 21q22.2 [309]
SAGE CT12 Xq28 [310]
HAGE 6q12-13 [310]
IL13Ralpha Xq24 [311]
OY-TES-1 sp32; CT14 12p13.32 [312]
NY-BR-3 18 [313]
NA88-A - [314]
cTAGE-1 CT13 18p11.2 [315]
TSP50 3p14-12 [316]
HOM-TES-85 CT8 Xq24 [253, 317, 318]
ADAM-2/fertilin CT15 8p11.2 [284]
CT17 CT17 - [284]
HCA661 Xq26.2 [319]
CAGE Xp22 [320]
BORIS 20q13.2 [321]
Table I.
Members of the CTA  fam ily.
1 CT nomenclature proposed by O ld and Chen [322]
2 CTA  without specific CTA  expression profile
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members of the specific subfamilies. These shared 
domains c ould be a result of identical upstream 
regulating elements for these genes [285].
Next to the type I MAGEs with classical CTA 
features, isolation and characterization of the 
MAGE-D subfamily revealed that there are also 
MAGE genes with ubiquitous expression [292,293]. 
The human magphinins, encoded by alternative 
transcripts of the trophinin gene, also belong to the 
MAGE-D subfamily based on chromosomal 
localization (Xp11.22-p11.21) and high level of 
protein homology [286]. Though sharing MHD 
with the type I MAGEs, these type II M AGE genes 
have a different genetic build-up since the corre­
sponding ORFs are split over several exons.
Other type II MAGE genes, like MAGE-E1 and 
MAGE-F1, were identified several years later. 
Tumor-associated gene MAGE-E1, has a similar 
genomic organization as the MAGE-D genes, but is 
normally only expressed in brain and ovary [295]. 
The ORF of MAGE-F1, though again ubiquitously 
expressed, is encoded within a single exon [297]. 
MAGE type II genes do not all resides on the X- 
chromosome. This shows that the group of type II 
MAGEs is much more heterogeneous.
An extensive database search to outline all 
currently deposited MAGE-like sequences by 
Chomez et al. resulted in an excellent overview of 
human (and mouse) MAGEs known to date [232].
GAGE/PAGE/XAGE
Like the first M AGE antigens GAGE was found 
as an antigen on human melanoma cell line MZ2- 
M EL recognized by autologous CTLs [277]. By 
screening of a cDNA library six homologous 
GAGEs were detected, some differing by only one 
amino acid. It is unlikely that some are allelic
variants since the cDNA library was derived from a 
cell line that contained only one X chromosome. 
GAGE-7 was co-identified with GAGE-like gene 
PAGE-1 in a screening for differentially expressed 
genes from prostate cancer cell lines [169]. Further 
screening for GAGEs (GAGE-7B and -8) resulted in 
an alignment and characterization of 9 GAGEs 
known so far [225] However, the GAGE-like PAGE 
family was enlarged by computerized identifica­
tion of PAGE homologues [170,219].
During the search for PAGE-like genes yet an­
other group of GAGE-like cancer/testis-associated 
genes were found: XAGE [219]. Next to XAGE-1, 
which transcripts were described in Ewing's 
sarcoma [213], melanoma [233] and lung carcinoma 
[300], the XAGE family consists of 4 additional 
members (chapters 5 and 6) [283]. XAGE-3 was 
previously annotated as placenta-specific gene 
PLAC-6 [219].
So far the GAGE/PAGE/XAGE superfamily 
seems to consist of at least 19 genes [283]. Unlike in 
most MAGE genes the ORFs present in the GAGE- 
likes are split over the exons present (four to five). 
Nearly all GAGE/PAGE/XAGE transcripts contain 
two relatively large ORFs. In Genbank PAGE and 
XAGE genes are also named GAGE-B, -C and -D. 
Next to the detection of PAGE-5 by our own group 
[283] this gene was recently also identified as CT16 
by database analysis of putative CTA Unigene clus­
ters [284]. XAGE-1, coding for several alternatively 
spliced variants, seems to have incorporated a 
frameshift compared to the other GAGE-likes [283]. 
With lengths of 79 to 146 amino acids these 
putative proteins are relatively small compared to 
the MAGEs (300 to 1300 amino acids). Like the 
MAGE proteins the GAGE-likes have a high 
percentage of charged residues and low pI values
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varying between 3.9 and 4.8 [169,283]. A ll known 
GAGE/PAGE/XAGE genes are X-linked. No 
GAGE-like genes could be identified in databases 
of non-human organisms.
NY-ESO-1
One of the most immunogenic CTAs is NY- 
ESO-1. Product of the CTAG gene [173] this 
putative protein of 180 amino acids was found with 
SEREX screening with sera of esophageal 
squamous cell carcinoma patients [158]. Next to 
expression in testis NY-ESO-1 is also found in 
normal ovary and in many other types of 
malignancies. One year after the discovery of NY- 
ESO-1 a highly homologous gene (84% identity), 
called LAGE-1, was isolated from melanoma by 
RDA [168]. Like NY-ESO-1 it contains 3 exons. 
Alternatively spliced LAGE-1 mRNAs code for 
putative proteins of 180 and 210 amino acids. 
Unlike most MAGEs and members of the GAGE/ 
PAGE/XAGE family, the proteins of NY-ESO-1 and 
LAGE-1 are rather basic (pI between 8.5 and 10.9) 
[168].
Interestingly, T-cell recognized epitopes 
encoded from alternative ORFs of both NY-ESO-1 
and LAGE-1 transcripts have been found: CAMEL 
is an out-of-frame encoded protein of 109 amino 
acids from the LAGE-1 transcript [302], while 
CAG-3 (58 amino acids) is the corresponding 
putative protein of the NY-ESO-1 gene [301]. 
Epitopes of both primary and alternative ORFs of 
NY-ESO-1/LAGE-1 can even be efficiently pre­
sented simultaneously in melanoma [239]. CTL epi­
topes derived from non-primary ORFs, resulting 
from various mechanisms (e.g. cryptic promoters, 
frameshifting), are not exceptional [328].
SSX
SEREX screening of a testicular expression 
library with sera of melanoma patients identified 
antigen HOM-MEL-40 [303]. Antibodies against 
this antigen were found in 10 out of 89 melanoma 
patients tested. Sequence analysis showed HOM- 
MEL-40 to be derived from the SSX-2 gene, 
previously described as fusion partner of SYT in 
t(X;18) translocations associated with sarcoma 
[236]. The multigenic aspect of the SSX family was 
described by the identification of four additional 
highly homologous genes. A ll five SSX genes 
consist of 6 exons and code for putative proteins of 
188 amino acids. These genes, normally only 
expressed in testis, but for SSX-3 were detected in 
melanoma samples [167].
SPANX
Identification of the SPANX family of CTAs 
started with the description of CTp11 isolated from 
a melanoma cell line using mRNA differential 
display (chapter 3) [185]. Next to cell lines, 
SPANXCCTp11 is also expressed in fresh samples of 
malignant melanoma. The corresponding putative 
protein of only 97 amino acids is highly charged 
and is localized in the nucleus. Two highly 
homologous genes, SPANXA and SPANXB, were 
described and characterized from spermatozoa 
[186,187]. Data presented in those studies were 
suggestive for multigenicity of SPANX genes. An 
extensive database search and RT-PCR analyses 
confirmed the existence of at least six human 
SPANX genes (chapter 4) [304], all exclusively 
expressed in testis and/or malignant tumor 
samples. The SPANX genes code for small proteins 
with acidic pIs (4.9 to 6.0) and bipartite nuclear 
localization signals.
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TRAG-3
From melanoma and chondrosarcoma yet 
another two homologous genes were discovered as 
CTAs: TRAG-3 and CSAGE. Both genes were 
isolated by mRNA differential display. TRAG-3 
was expressed in a large number of melanoma 
samples, while in normal tissues it could only be 
found in testis [305]. Originally this gene was 
detected in an ovarian cancer cell line as taxol 
resistance-associated gene 3 [306]. The highly 
homologous CSAGE, also having a CTA expression 
profile, was picked up from a chondrosarcoma cell 
line [307]. Though the CSAGE gene is somewhat 
larger, the last two exons of CSAGE and TRAG-3 
containing the largest ORF, have a high level of 
identity. Both CSAGE and TRAG-3 are X-linked 
genes.
Non-familial CTAs
Next to the CTAs organized in families many 
other antigens or genes with a CTA expression 
profile have been described recently for which so 
far no homologous family members are known. 
The first antigen belonging to this group, BAGE, 
was isolated from the same melanoma cell line that 
rendered MAGE-1 [165]. Though expression of this 
gene is often taken along in studies exploring CTA 
expression, no real further characterizations 
regarding chromosomal and cellular localization or 
putative function of this small 43 amino acid 
protein have been reported.
SCP-1 (synaptonemal complex protein 1) on the 
other hand is one of the best-characterized CTAs. 
This chromosome 1 encoded nuclear protein func­
tions in the pairing of homologous chromosomes 
during meiosis [329]. A  murine SCP1 with high 
homology (suggesting an important function for
these proteins) was later identified [330]. Using 
SEREX with sera of renal cell carcinoma patients 
one of the detected antigens, called HOM-TES-14, 
was a peptide encoded by the human SCP-1 gene 
[171].
CT9, also named BRDT (bromodomain testis- 
specific gene) [331], is another CTA on chromo­
some 1 with clues regarding its function. This 
testis-restricted member of the RING-3 family of 
transcriptional regulators was detected with RT- 
PCR in several tumor samples, but not in 
melanoma [332]. Three other examples of recently 
discovered tumor antigens with testis-specific 
functions are the proacrosin binding protein sp32 
[312] testis-specific protease-like TSP50 [316] and 
BORIS (brother of the regulator of imprinted sites) 
[321].
RDA analysis with a human sarcoma cell line 
co-isolated SAGE and HAGE [310]. The 904 amino 
acid SAGE showed no homology to known 
proteins and is mainly expressed in bladder and 
lung carcinoma. HAGE (648 amino acids), 
expressed in many different types of tumors, is a 
new member of the DEAD-box family of helicases. 
Recent discovery of a second DEAD-box helicase- 
like CTA, called CAGE [320], suggests the existence 
of yet another CTA-family. However, these two 
genes are localized on different chromosomes and 
have different genetic organizations.
Other recently reported CTAs isolated with 
immunological techniques are HOM-TES-85 [318], 
NA88-A [314], cTAGE-1 [315], NW-BR-3 [313] and 
HCA661 [319]. Furthermore, expression profiling 
yielded some other new CTA genes like MMA-1 
[309], IL13Ra [311] and CT15/ADAM2 and 
phospholipase-like CT17 [284].
The list of CTAs presented here w ill
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Figure 1.
Chromosomal localization of CTAs.
The chromosomal representation was obtained from the Genome Database (www.gdb.org/HUGO/chrX) 
1 CTA  without specific CTA  expression profile
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undoubtedly grow further, given the frequency of 
reports on new CTAs in the last few years. 
Furthermore, after more extensive characterization 
some of the recently found CTAs might turn out to 
be misclassified based on expression in normal 
non-testis tissues. The previously reported CTA 
sp17 for instance turned out to have a broader
expression pattern [268-270].
Chromosomal localization of CTAs
One characteristic feature shared by many 
CTAs is their localization on chromosome X. One 
of the first exceptions was SCP-1, which resides on 
chromosome 1. Since then many more non-X CTAs
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have been described as listed in Table I. In Figure 1 
a cartoon of the X-chromosome with the regions in 
which CTAs are localized is given as well as a list 
of CTA localizations on autosomal chromosomes. 
For some genes, like BAGE, no mapping was 
reported, but these could be found via Locuslink of 
the Unigene entry (www.ncbi.nlm.nih.gov).
Most X-linked CTAs are clustered in two 
regions. The Xp11 region contains all members of 
the GAGE/PAGE/XAGE family, SSX and four 
subfamilies of MAGEs. The region on the other arm 
is Xq26-q28, which among others contains the 
SPANX, MAGE-A, MAGE-C, NY-ESO-1 and 
TRAG-3 multigene families. Clustering on auto­
somes is only seen for three members of the MAGE 
superfamily on 15q11. However, though belonging 
to the MAGEs because of their sequence homology 
these are not real CTAs since they are either 
expressed in multiple normal tissues (MAGE-G) or 
are predominantly brain-specific instead of testis- 
specific (Necdin and MAGE-L) [232,285]. All 
MAGEs without real CTA expression profiles, as 
described by Chomez et al, are marked in Figure 1 
[232].
High levels of multigenicity, true for many 
CTAs, is likely caused by gene duplication and 
subsequent divergence. In such a way the original 
gene retains the ancestral function, while the 
additional copies are free to diverge and evolve 
[333]. This w ill eventually lead to homologous 
genes with modification in the promoter and/or 
coding region. These modifications could give 
these genes the ability to vary and optimize the 
structure of the encoded proteins as well as their 
profile of expression. As a result of the multigenic 
nature of CTAs single gene-knockout studies are 
unlikely to sort any effect based on the presence of
many homologous genes with similar and probably 
overlapping functions. A  possible link between the 
presence on chromosome X and expression in 
cancers and testis w ill be discussed later. The high 
number of non-X CTAs however demands the 
localization on X to be seen as an additional hint, 
rather than a criterion to place genes in the family 
of CTAs.
CTA IN  M ELANO M A 
mRNA expression
Since many of the CTAs have been picked up 
from melanoma samples it is obvious that their 
expression in melanoma is well studied. For the 
CTAs discovered in the nineties already several 
papers report on the comparative expression in 
melanoma samples [178,252,254]. A  large sample 
multiple gene analysis for the CTAs highest ex­
pressed in melanoma, together with an overview of 
expression frequencies reported in literature was 
published recently (chapter 7) [234]. MAGE-A 
members with positivities of up to 80% (MAGE-3) 
are most frequently expressed CTAs in melanoma 
metastases. The frequencies of other classical CTAs 
(e.g. SSX-2, NY-ESO-1, MAGE-C1, GAGE-1/2, 
BAGE) roughly vary between 20 and 50% based on 
RT-PCR. Overall more that 95% of melanoma me- 
tastases were positive by RT-PCR for at least one of 
the tested CTAs.
Though less well studied many other CTA 
genes are also expressed in a percentage of mela­
noma samples. MAGE-B1 was found in 22% of 
melanoma lesions (n=36) [175]. Like MAGE-C1, 
MAGE-C2 is also present in a high number of 
melanoma samples (43%, n=70), while several other 
members of the MAGE-B and MAGE-C subfamilies
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were only sporadically detected [227]. LAGE-1 
expression (29%, n=21) seems to be almost perfectly 
co-expressed with the homologous NY-ESO-1
[168]. SCP-1 expression is infrequent in melanoma 
samples (14%, n=28) [171]. SPANX member CTp11 
could only be detected in melanoma with nested 
PCR and not after 30 cycles in the original paper 
(chapter 3) [185], though 19% (n=52) positivity was 
seen with 35 cycles in a later report [200].
Melanoma-associated expression of PAGEs 
was only reported in a few melanoma cell lines. 
PAGE-5, as CT16 [284], was detected in 4 out of 8 
cell lines, while PAGE-1 was found in one 
melanoma cell line tested [169].
Of the more recently discovered CTAs data on 
expression profiles are usually restricted to the 
original papers in which these CTAs are first 
described. Of these genes the most prominently 
expressed in melanoma samples are MMA-1 (33%, 
n=46) [309], HOM-TES-85 (36%, n=22) [318] and 
TRAG-3 (100%, n=4) [305]. Lower frequencies of 
expression were found for SAGE (4%, n=47) and 
HAGE (17%, n=29) [310]. NY-BR-3 was seen in 1 
out of 5 melanoma cell lines [313] BRDT (n=12) 
[222], cTAGE-1 (n=20) [315], CAGE (n=5) [320] and 
both CT15 and CT17 (8 cell lines) [284] were not 
detected in melanoma. No studies on expression in 
melanoma were reported so far for sp32, TSP50, 
HCA661, IL13Ra and NA88-A though the latter 
was identified in a melanoma cell line.
For several CTAs higher levels of expression in 
metastases compared to primary tumors suggest a 
correlation between expression and the level of 
tumor dedifferentiation [279]. This is also the case 
for some of the XAGE transcripts (chapters 5 and 6) 
[233,283]. For SPANXC data are not conclusive. We 
found equal frequencies of expression in primary
and metastatic melanoma lesions (chapter 3) [185]. 
Goydos et al., on the other hand report a prefer­
ential expression in primary melanoma samples 
and almost absence in metastases [200]. Increased 
level of dedifferentiation during tumor progression 
probably lead to derepression of transcriptional 
control resulting in the expression of these cancer- 
specific genes [158].
Protein expression
Immunohistochemical analyses of CTA protein 
expression are far less widespread than studies 
performed on mRNA level with RT-PCR. In fact 
the only immunohistochemical (IHC) data of 
expression in melanoma come from MAGE-A, NY- 
ESO-1, MAGE-C1 and SSX.
Originally raised against MAGE-3 monoclonal 
antibody (mAb) 57B is the most frequently used 
antibody in studying M AGE expression [183,261]. 
More recent studies showed that mAb 57B 
recognizes several members of the MAGE-A 
subfamily and that positive staining correlated best 
with MAGE-A4 expression [258,334]. In normal 
tissues this 57B antibody only stained the 
spermatogenic cells of the testis [260]. In melanoma 
tumors the level of 57B positivity with IHC 
generally correlated with those found by RT-PCR. 
In one study the level of IHC positivity was 
considerably lower [335]. Positivity for MAGE seen 
by IHC in melanocytic tumors was restricted to 
malignant cells and not detected in stromal cells. 
Extensive heterogeneity in the patterns of staining 
were observed for different melanoma samples 
varying between homogeneous, focal and single 
cells. The staining is mainly cytoplasmic with some 
nuclear component [260,261,335].
For NY-ESO-1, similar results as for the MAGE-
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A CTAs have been observed with IHC in two 
independe nt studies with different monoclonal 
antibodies [259,336]. Again primarily cytoplasmic 
staining has been observed in melanoma tumor 
generally with good correlations to RT-PCR. The 
patterns of NY-ESO-1 expression, as true for 
MAGE, were very heterogeneous between tumors. 
In testis NY-ESO-1 staining was restricted to germ 
cell precursors.
In contrast to MAGE-A and NY-ESO-1, SSX 
and MAGE-C1 protein are mainly localized in the 
nucleus. IHC with a monoclonal antibody recogniz­
ing three members of the SSX family was positive 
in 34% (n=101) of melanoma samples tested [215]. 
As true for MAGE-C1 IHC with mAb CT7-33m 
[337]. SSX protein expression correlated well with 
RT-PCR results. For both CTAs distribution in and 
between melanoma lesions was heterogeneous.
CTA AND IM M UNO THERAPY
Over the last years many reviews and opinions 
have been published on the potential use of cancer 
antigens in immunotherapy of tumors [157, 
254,338,339]. Normally, small peptide fragments of 
antigenic proteins are presented on the surface of 
(tumor) cells by major histocompatibility complex 
(MHC) molecules, also called human leukocyte 
antigens (HLA). When these MHC-bound peptides 
are recognized by cytotoxic T cells this might result 
in killing of the cell expressing the antigen.
Vaccinations, with antigens specifically ex­
pressed by the tumor, are aimed at generating a 
specific anti-tumor response by triggering the 
immune system (T cells). The list of human tumor- 
specific antigens and their encoded MHC epitopes, 
both class I and class II HLA-restricted, has been
growing in time [184,263]. Among these antigens 
many epitopes are encoded by CTAs [285]. Because 
of the blood-testis barrier [340] and since germ-line 
cells do not express the classical HLA (class Ia) 
molecules [341,342], these antigens can be 
considered tumor-specific. Next to that MAGE- 
derived epitopes found and used are not encoded 
by the ubiquitously expressed MAGE members 
[232].
The outcome of the first clinical immuno- 
therapeutic trials using tumor antigens performed 
so far are somewhat disappointing [343], including 
trials with MAGE-3 [344] and NY-ESO-1 [345]. 
Though initially several successful responses have 
been observed in patients many tumors seem to be 
unaffected. Possible mechanisms used by tumors to 
escape from the surveillance and attack by the 
immune system include ignorance, loss of antigen 
presentation, immunosuppression, tolerance, and 
apoptotic immune escape [346]:
Ignorance
The immune system may ignore the tumor if T 
cells are not activated by lack of direct contact. This 
can be the case if the tumor grows in an immune- 
privileged site. The infiltration of cells of the 
immune system may also be impaired by down- 
regulation of adhesion molecules or by a physical 
stromal barrier.
Loss of antigen presentation
Many proteins are involved in the successful 
presentation of antigens on the surface of cells. A 
malfunction of one of these proteins may lead to an 
impaired presentation to the immune system and 
hence immune escape. This malfunction of the 
antigen-processing machinery in tumors can be at
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the level of the antigenic protein it self, peptide 
formation by the proteasome, peptide transport to 
the endoplasmic reticulum or assembly of the 
peptide-HLA (and ß2-Microglobulin molecule) in 
the antigen-presentation complex on the surface 
[347]. In melanoma research many reports have 
described such a downregulation or heterogeneous 
expression of antigenic protein [117,215,234,260, 
336], peptide transporters (e.g. TAP-1 [348]) or 
H LA  molecules [265,349,350]. Such downregula- 
tions can even be a direct selection effect of 
immunological pressure present [351] or a result of 
autocrine factors produced by the tumor itself 
[352].
Immunosuppression
Release of immunosuppressive factors like 
TGF-ß or prostaglandins by tumors can prevent the 
activation and differentiation of cells of the 
immune system. These factors might, next to the 
tumors cells, also be produced by cells of stromal 
origin.
Induction of tolerance
Absence of co-stimulatory molecules like B7 
leads to inefficient T cell activation. Tolerance can 
also be achieved by skewing the cellular immune 
process towards a more humoral immune 
response.
Apoptosis-related immune escape
Evasion from CTL-induced apoptosis can be 
achieved by production of anti-apoptotic factors or 
downregulation of pro-apoptotic stimuli. More­
over, tumor cells can also counterattack the 
immune system by expression of CD95L (Fas­
ligand) or other death-receptor ligands. This
putative role of Fas-ligand in counterattack and 
immuneprivilege is widely reported and discussed 
[353,354] and also implicated in melanoma immu­
nology [355,356].
Future immunotherapeutic strategies should 
benefit from the rapid growing molecular 
knowledge of the immune system as well as the 
antigenic profile of tumors. Improvement could 
perhaps be achieved by use of agents that 
upregulate expression of antigens, like 5-aza-2'- 
deoxycytidine [357]. This demethylating agent also 
can upregulate HLA class I expression and co­
stimulatory molecules of the immune system sug­
gesting it would increase immunotherapeutic 
efficiency [358]. However, effects of systemic 
administration of 5-aza-2'-deoxycytidine to non­
tumor tissues have to be investigated before 
allowing use of the drug in immunotherapeutic 
trials.
Efficiencies of immunotherapy may also im­
prove when using multivalent protocols 
addressing more tumor antigens of different HLA- 
restriction (both class I and II epitopes) simulta­
neously. Use of cytokines and co-stimulatory 
molecules might also improve the anti-tumor effect 
[276]. Finally, immune escape may be overcome by 
use of an antigen that is essential in tumorigenesis, 
like hTERT [359]. Whatever the immunothera- 
peutic strategy, patients' antigenic determinants 
should be thoroughly screened prior to inclusion in 
the vaccination protocol.
CTA Review 137
SPERM ATO GENESIS AND CTA EXPRESSIO N
Spermatogenesis
Main function of the testis is the production of 
male gametogenic cells. Formation of spermatozoa 
is performed in the seminiferous tubules, consist­
ing mainly of spermatogenic cells and Sertoli cells. 
The Sertoli cells provide nourishment and struc­
tural support for the developing spermatogenic 
cells. Spermatogenesis starts with spermatogenic 
stem cells at the basal layer and progresses in an 
upward direction towards the lumen of the tubules 
in which the mature spermatozoa are finally 
released (Figure 2A). Spermatogonial stem cells 
originate from the primordial germ cells derived 
from epiblast cells in the embryonic ectoderm [360].
By mitotic division about half of the type A 
spermatogonia produce one exact type A  copy, 
while the other half differentiate into type B 
spermatogonia. After another mitosis the daughter 
cells of the type B spermatogonia differentiate into 
primary spermatocytes, which are the largest 
spermatogenic cells. As a result of a subsequent 
first meiotic division primary spermatocytes (44 
autosomes +X and +Y) are converted to secondary 
spermatocytes (22 autosomes +X or +Y), which then 
quickly undergo a second meiotic division (regular 
mitosis) to produce the first (round) spermatids.
These round spermatids differentiate via 
elongated spermatids into spermatozoa in a 
multistep process called spermiogenesis. Via con­
densation of the nucleus, formation of head-cap 
and tail, aggregation of mitochondria and shedding 
of excess cytoplasm mature male germ cells are 
created and released in the tubular lumen.
Sperm cell-specific gene expression
Striking differences exist between gene 
expression patterns of somatic and spermatogenic 
cells in mammals [361]. In spermatogenic cells 
often transcripts of different length are observed. 
By use of alternative promoter start sites or 
variations in 3'-UTR or 5'-UTR lengths variations 
in mRNA and/or proteins are accomplished. For 
many genes such spermatogenic cell-specific 
transcripts have been reported [361-363]. Many of 
these use TATA-box independent promoters.
Changes in UTRs often include features 
involved in mRNA stability or regulation of 
translation. During spermiogenesis DNA-binding 
histones are replaced by DNA-binding protamines, 
causing massive condensation of chromatin 
thereby disabling transcription since the transcrip­
tional machinery is unable to reach the DNA [364].
To allow protein expression in transcriptionally 
inactive elongated spermatids, the processes of 
transcription and translation are temporally uncou­
pled. mRNAs transcribed in round spermatids are 
stored in free-messenger ribonucleoprotein parti­
cles for translation in later stages of spermiogenesis 
[361]. In spermatogenic stages up to the round 
spermatids gene expression is mainly regulated at 
the transcriptional level, while further maturation 
in spermiogenesis relies more on translational 
regulation [364].
Another factor involved in germ cell-specific 
gene expression is the alternative methylation 
status of genes in spermatogonia, spermatocytes 
and spermatids. A  number of genes have now been 
identified for which the CpG-island containing 
promoters are hypomethylated in meiotic sper- 
matogenic cells. This hypomethylation of promoter 
sequences is associated with increased gene
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expression. Existence of sperm-specific hypomethy- 
lation hot-spot sequences have also been implicated 
in spermatogenesis and even carcinogenesis [365]. 
In fact such demethylation events in specific 
regions of the genome better fit with observed 
heterogeneity of CTA expression than a mere 
global demethylation.
Given the fact that most CTAs are X-linked it is 
interesting to look at the regulation of X chromoso­
mal expression in spermatogenesis. During the 
pachytene prophase of the meiosis the sex body,
consisting of the closely packed X and Y 
chromosome, is formed [366]. This body protects 
the sex chromosomes from double strand break 
mechanisms that initiate recombination between 
chromatids of autosomes. Because this tight 
packaging also prevents transcription of sex chro­
mosomes, inactivation of essential genes on X and 
Y is often compensated by testis-specific expression 
of autosomal isoenzymes [366]. Since only half of 
the spermatids and spermatozoa contain the X 
chromosome one would expect that these would
Figure 2.
CTA  expression during spermatogenesis.
(A ) Stages of spermatogenesis and (B ) expression of CTAs during male germ cell development.
Depicted are m agphinin (1); M AGE-A (2); M AGE-C (3); SSX (4); NY-ESO-1 (5); SCP-1 (6); TSP50 (7); SPA N X  (8); X A G E (9); 
BO R IS (10) and OY-TES-1 (11). W hite bars represent cytoplasmic expression; gray bars represent both nuclear and cyto­
plasmic expression; nuclear specific expression is shown in  black bars. Dotted lines depict low  expression.
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have some difference in gene expression compared 
to Y-bearing sperm cells. This however is not the 
case due to the presence of intercellular bridges 
forming a syncytium that shares protein and 
mRNA between many cells of the spermatogenic 
series. This phenomenon was indeed observed for 
SPANX protein [187]. Moreover, sex chromosomal 
gene expression in haploid post-meiotic spermatids 
is rarely observed. However, some recent studies 
have described X-linked expression in later stages 
of spermiogenesis [366]. Among these are some 
members of the SPANX family of CTAs [186,187].
CTA expression during spermatogenesis
For some members of human CTAs expression 
in testis has been analyzed in more detail by means 
of immunohistochemistry. A ll of these experiments 
showed that expression of CTA is restricted to 
spermatogenic cells. No staining was found in 
other testis-associated cells (e.g. Sertoli cells, 
Leydig cells). This observation fits well with the 
much higher frequency of expression in seminoma 
compared to non-seminoma testis tumors [367]. For 
CTAs various heterogeneous patterns of expression 
during different stages of the spermatogenesis and 
in different cellular compartments have been 
observed in normal testis (Figure 2B).
Most studies on M AGE proteins have been 
performed with monoclonal 57B, which recognizes 
several members of the MAGE-A family [334]. This 
antibody intensely stained nuclei of spermatogonia, 
but also some cytoplasmic staining is observed. 
Expression in spermatocytes was weaker, while 
spermatids were negative for 57B [260,368,369].
Using monoclonal CT7-33 identical patterns of 
expression were observed for MAGE-C1 [337]. 
Again the same stage-specific distribution of
positivity was seen for MAGE-1 with monoclonal 
M454, though this staining was exclusively 
cytoplasmic [370]. With two other antibodies 
against MAGE-1 and MAGE-4 these MAGE-A- 
specific expression patterns were confirmed 
suggesting a role for MAGE-A in the early phases 
of spermatogenesis. Magphinin, another member 
of the M AGE family, was expressed throughout all 
stages of spermatogenesis in the cytoplasm of sper- 
matogenic cells. However, expression of mag- 
phinin was also observed in nuclei of stages 
starting from the secondary spermatocytes [286] 
possibly occurring as functional switch.
NY-ESO-1 expression, both cytoplasmic and 
nuclear, was found in spermatogonia and primary 
spermatocytes but was lacking in all post-meiotic 
spermatogenic cells [336,371].
Immunohistochemical staining with mono­
clonal antibody E3AS, recognizing three members 
of the SSX family, was observed in spermatogonia 
and occasionally also in primary spermatocytes. 
This exclusive nuclear staining was quite hetero­
geneous and only observed in a subset of the 
spermatogonia [215].
Restricted to a specific stage of spermatogene­
sis is expression of SCP-1. This structural protein of 
the synaptonemal complex is only present in the 
prophase (zygotene to diplotene) of the first 
meiotic division [329]. Testis-specific protease 
TSP50 expression was detected in all developing 
stages, but absent in mature spermatozoa [316].
Peculiar is the expression of OY-TES-1 and 
some of the SPANX proteins [186,312]. OY-TES-1 is 
specifically present in mature spermatozoa. 
SPANX proteins are exclusively expressed in 
haploid spermatids and spermatozoa, which is 
only rarely seen for X-linked proteins [366].
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SPANXA and SPANXB proteins were detected in 
both nuclear craters and cytoplasmic droplets of 
about half of both X- and Y-bearing spermatozoa 
[187].
Based on the high frequency of X-linked pre- 
meiotic gene expression the X-chromosome has a 
predominant role in the early stages of mammalian 
spermatogenesis [372]. This observation is not 
completely in line with the fact that not all of the X- 
linked CTAs are expressed in these pre-meiotic 
stages. Therefore, there does not seem to be a 
general mechanisms of transcriptional regulation 
for X-linked genes during spermatogenesis.
REG ULATIO N  OF CTA EXPRESSIO N
Methylation of DNA is the epigenetic 
modification of the genome by adding a methyl 
group to the cytosine of CpG dinucleotides [373]. 
Such CpG sequences are often clustered in so- 
called CpG islands. These are DNA regions larger 
than 200 bp with a G+C content over 50% and an 
observed/expected presence of CpG > 0.6 [374]. 
CpG islands account for about 1% of the genome 
and are often associated with the 5' regulatory 
sequences of genes [205].
Alteration in gene transcription is frequently 
associated with a changed pattern of CpG island 
methylation [374]. Transcriptional silencing is 
accomplished by methyl binding proteins that bind 
to methylated regions in the genome, recruit 
histone deacetylases and thereby deacetylate his- 
tones in the promoter region [375]. Deacetylation 
leads to a tighter packing of the DNA, inhibiting 
the binding of transcription factors and thus 
transcription [373].
Next to its function in transcription, DNA
methylation is also important in processes like 
chromatin remodeling, X-chromosome inactivation, 
imprinting and DNA repair. In tumors two 
methylation-related phenomena are described. The 
first is the hypermethylation of specific regions. 
Such a hypermethylation of promoter regions of 
tumor suppressor genes is believed to be a primary 
event in tumorigenesis [373]. Secondly, global 
hypomethylation is often encountered in cancers. 
This demethylation of up to 60% less methylation 
than normal can cause chromosome instability, loss 
of imprinting and illegitimate transcription [376].
In normal tissues CpG-island-methylation of 
promoters, associated with gene silencing, can be 
found for imprinted genes, X-chromosome 
inactivated genes, tissue-specific genes and germ- 
line specific genes [376]. For male germ cell-specific 
CTAs (e.g. MAGE-A1) high levels of promoter 
methylation in normal somatic tissues have indeed 
been shown [205].
As already mentioned CTAs are expressed in 
multiple tumor samples of different origin. Using 
the demethylating agent 5' -aza-2-deoxycytidine 
expression of several CTAs in cultured tumor cell 
lines can be induced or upregulated [358]. This 5' - 
aza-2-deoxycytidine traps DNA methyltransferases 
in a complex with DNA and leads to progressive 
loss of DNA methylation, thereby releasing 
transcriptional blockage [373]. Such an upregulated 
expression induced by 5' -aza-2-deoxycytidine has 
been reported for several MAGE members [175, 
205,377-379], LAGE-1 [168,205], SSX-2 [215,358], 
CAGE [320] and NY-ESO-1 and GAGE [358]. 
Expression levels of MAGE-1 indeed correlated 
with the methylation status of MAGE-1 promoter 
elements like the Ets binding sequence [223, 
226,378].
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In a recent demethylation experiment (of our 
own group) using several human melanoma cell 
lines, described in chapter 5, we could confirm 
upregulated expression of MAGE-1, GAGE-1/2 and 
NY-ESO-1, but we did not observe an induction of 
SSX-2 expression. Analysis of SPANXC and XAGE- 
1 expression only revealed a poor induction for 
XAGE-1 in 1 out of 4 melanoma cell lines [233]. For 
MAGE-A1 demethylation was necessary and suffi­
cient for gene expression suggesting demethylation 
to be the primary mechanism of transcription 
control [205]. This implies that both normal and 
cancer cells posses the crucial transcription factors. 
The authors suggest a common mechanism of 
expression-regulation for MAGE, GAGE and LAGE 
since they have a high correlation of expression.
Interesting regarding regulation of expression 
of CTAs by demethylation is the recent discovery 
of CTA BORIS which has a key function in 
regulation of DNA methylation. BORIS is a sperm 
cell-specific protein with a 11-zinc-finger domain 
also present in CTCF, which functions in X- 
chromosome inactivation and expression of 
imprinted genes by means of methylation 
regulation [321].
BORIS and CTCF have inversely correlated 
expressions during male germ cell development. 
Erasure of methylation during male germ cell
development is associated with upregulation of 
BORIS and downregulation of CTCF. The authors 
also report that BORIS is activated in a wide variety 
of cancers and therefore can be qualified as CTA. 
Detailed analysis of BORIS-expression in tumors 
might reveal if BORIS is also involved in the 
epigenetic reprogramming in cancer cells.
Several lines of evidence indicate that not all 
CTAs are purely dependent on global demethyla- 
tion for their expression, but that other 
transcriptional mechanisms and players are 
involved. Strongest arguments come from co­
expression studies of CTAs in tumors. These 
analyses, mostly performed in melanoma, show a 
large heterogeneity of expression [178.234,252,254].
Additionally, the CTA rich region in Xp11.21- 
22 (e.g. SSX, MAGE-B) has been described to 
escape X-chromosomal inactivation but these are 
normally not expressed in females [380]. Moreover, 
while global hypomethylation is common in colo­
rectal cancer [341] few CTAs have ever been 
reported to be expressed in this type of cancer. 
Non-methylation dependent induction of MAGE 
expression has also been shown at hypertonicity 
[381]. In conclusion, regulation of methylation is a 
key player, but not the only factor involved in 
expression of CTAs during spermatogenesis and 
tumorigenesis.
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General discussion

FUNCTIO NS OF CTA FROM  LITERATURE
Data on function and precise cellular 
localization of CTAs are severely lagging behind to 
the information on their expression and immuno- 
genicity. The only CTA proteins functionally estab­
lished in gametogenesis are SCP-1, involved in 
chromosome pairing during meiosis [171], OY-TES- 
1 which functions in acrosin packaging in the 
acrosome of sperm heads [312] and BORIS, which 
is involved in erasure of imprinting by epigenetic 
reprogramming during the final round of mitosis 
in spermatogenesis [321].
The role of these functional testis-specific 
proteins in tumorigenesis remains elusive. 
However, SCP-1 expression in tumors is not cell 
cycle restricted, while it is rapidly degraded after 
the meiotic prophase in spermatocytes. This 
aberrant expression of SCP-1 might lead to 
additional chromosomal instability in tumors [171].
BORIS expression in cancer is likely to induce 
expression of certain methylation-controlled 
tumor-associated genes. Given the moment of 
BORIS expression during spermatogenesis com­
pared to the earlier expression of several other 
CTAs it is however unlikely that BORIS is a major 
CTA inducing factor.
For the majority of CTAs most clues regarding 
putative function come from homology to well 
studied proteins or protein domains. Both CAGE 
[320] and HAGE [310] code for proteins with heli- 
case-like features. Likewise, enzyme resemblance 
has been found for protease-like TSP50 [316], 
phospholipase-like CT17 and metalloproteinase- 
like CT15 [284]. CTAs with a possible function in 
transcription are the TFDP1-like HCA661 [319] and 
BRDT that contains bromodomains implicated in
transcriptional regulation [222]. The HOM-TES-85 
protein seems to have myc oncogene-like features 
[318]. However, for confirmation of such activities 
functional studies are indispensable.
Suggestions on the role of MAGEs with a CTA 
expression profile mainly depend on studies on 
their ubiquitously expressed family members (e.g. 
Necdin, MAGE-D1, NRAGE, Dlxin-1). Overall 
these data point to a role for MAGEs in cell cycle 
control and apoptosis via transcriptional regulation 
[286,287,382,383]. The high level of homology 
(especially the central domain) between members 
of the MAGE family, both mouse and human, 
suggests important and common functions in testis 
and cancer [285].
Functional studies on NY-ESO-1 are largely 
lacking though it is one of the most immunogenic 
and promising CTAs known. Based on the high pI 
value (about 10) compared to those of MAGE-likes 
(about 5) it is likely that members of the NY-ESO-1 
family exert different functions compared to most 
MAGE-likes.
Since members of the SSX family, next to being 
CTAs, are also involved in a specific translocation 
in most synovial sarcomas (SYT-SSX) they have 
been subject of relatively many functional studies. 
SSX genes code for relatively small nuclear proteins 
(188 amino acids) with a high percentage of 
charged residues (36%; 68 out of 188 residues for 
SSX-2) [167]. Many of the acidic residues are 
located at the C-terminus. In transactivation studies 
this acidic domain, called SSXRD (SSX repressor 
domain), was a strong repressor of transcription 
and even more potent than the N-terminal KRAB- 
like repressor domain [231].
In the nucleus both diffuse and speckled 
localizations have been reported for SSX proteins
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[162 ,230]. This nuclear presence and granular 
pattern was depending on the C-terminal SSXRD 
[230]. The speckled pattern suggests that SSX may 
be a component of one of the many known nuclear 
bodies that are often associated with transcriptional 
and posttranscriptional processes [229,384]. Co­
localization with protein-components of some of 
these nuclear bodies showed that SSX coincides 
with polycomb-group nuclear bodies that are 
associated with transcriptional repression [230,385]. 
SSX was not localized in coiled bodies, SC35 
splicing granules or PM L bodies [162].
Outcome of these studies on SSX proteins have 
some resemblances with the data obtained in this 
thesis on mainly SPANXC and XAGE-1 (chapters 3 
and 5) [185,233]. As true for SSX both SPANX and 
XAGE are small and highly charged proteins (33% 
and 27% charged residues for SPANXC and XAGE- 
1b respectively) containing a bipartite nuclear 
localization signal. While most acidic amino acids 
of XAGE-1b are C-terminally localized this was not 
as striking as the C-terminal acidic stretch of 
SPANXC, which resembles a GAL4 transcriptional 
activation domain [36].
Transient transfection studies with fusion 
constructs of XAGE-1b and green fluorescent 
protein revealed an almost exclusive localization in 
distinct nuclear dots. Unlike SSX these speckles co­
localized with SC35 pre-mRNA splicing factor 
containing bodies. These SC35 domains, next to the 
storage of splicing factors, have been implicated in 
the dynamic recruitment of transcription factors 
[384,386]. HOM-TES-85, believed to be involved in 
transcriptional regulation, was also present in 
nuclear foci containing U1 snRNP and SC35 [318].
XAGE-1B AND SPANXC IN TERACTIN G  
PRO TEINS
In order to get more information about the 
possible functions of the CTAs described in this 
thesis Yeast-Two-Hybrid analyses with XAGE-1b 
and SPANXC were performed using multiple types 
of human cDNA prey libraries (data not shown). 
For XAGE-1b this resulted in 15 possible interac­
tants of which about half were known genes.
Based on the fact that in order to interact, 
proteins must be in each others vicinity we selected 
three putative interacting proteins that were 
expressed in testis and located in the nucleus: 
topoisomerase IIa (topoIIa) (cDNA library from 
fetal liver), repressor/activator protein 1 (RAP1) 
(cDNA library from fetal brain) and XRCC5, better 
known as the Ku p80 autoantigen (testis library). 
SPANXC Yeast-Two-Hybrid analyses only re­
vealed three candidates, from which one is 
localized in nuclei of testis. Interestingly, this was 
the Ku p70 autoantigen (also known as G22P1), 
detected in a cDNA testis library.
Topoisomerase IIa
DNA topoisomerases are enzymes with key 
roles in the high order structure of DNA [387]. 
Type I topoisomerases introduce transient single 
strand breaks in DNA and regulate relaxation 
versus supercoiling status of DNA. Type II 
enzymes regulate the untangling of DNA by 
making double strand breaks, passing intact DNA 
strands and rejoining of the broken strand.
Functions of topoisomerases are crucial in 
many nuclear processes like DNA replication, 
DNA recombination, DNA repair and transcription 
[388]. Another recently found activity of topoIIa is
146 Chapter 9
cleavage of telomeric repeat sequences (5'- 
TTAGG*G-3') [389]. It was suggested that this 
activity might be necessary in the untangling of 
sister chromatids during mitosis, a process in 
which topoIIa is involved in yeast [390]. In fact 
topoIIa is one of the major non-histone proteins 
associated with metaphase chromosome scaffolds 
[391].
Topoisomerases are the targets of many anti­
cancer chemotherapeutic drugs (e.g. etiposide, 
doxorubicin, mitoxantrone) [388]. These drugs in­
tercalate the DNA next to topoisomerase binding 
sites, stabilize the DNA-enzyme complex and 
prevent rejoining of the DNA breaks. High 
expression of topoIIa, a marker of cell proliferation 
in both normal and malignant tissues, has been 
shown to correlate with poor outcome in several 
tumor types. During melanocytic tumor progres­
sion topoIIa expression increases with advanced 
stage from about 50% immunoreactivity in nevi to 
around 90% positivity in melanoma metastases 
[388].
Repressor/activator protein-1
The hRAP-1 protein is the ortholog of the yeast 
telomeric protein scRAP-1p [392]. This telomeric 
scRAP-1p functions in transcriptional regulation, 
replication and telomere structure and function. 
Recent studies reveal that scRAP-1p also functions 
in chromatin opening and meiotic recombination 
[393]. While scRAP-1p can directly bind to 
telomeric DNA via its two Myb domains hRAP-1, 
lacking one of these Myb domains, is recruited to 
telomeres by TRF2 (telomeric repeat factor 2).
Immunohistochemical analyses indeed 
showed a telomeric concentration of hRAP-1 
throughout the cell cycle and presence in TRF-
containing speckles in interphase nuclei [392]. 
Another difference in human RAP-1 compared to 
its yeast ortholog is that it misses the transcrip­
tional activation domain. One may speculate that 
binding of XAGE-1b (with transcription regulation­
like features) to hRAP-1 might restore some of the 
transcriptional functions. Not unlikely such an 
interaction could be involved during meiosis in 
male gametogenesis where both proteins are 
present.
RAP-1 proteins contain a BRCT domain 
involved in protein-protein interaction. This 
domain is found in many proteins that are linked to 
DNA repair, of which several have been shown to 
be associated with the telomeric nucleoprotein 
complex [394-396]. RAP-1 is suggested to act as a 
negative regulator of telomere length based on a 
counting mechanism of RAP-1 C-terminal domains 
at the chromosome ends [392].
Ku p70 and p80 autoantigens
Ku is the major autoantigen recognized by sera 
from patients suffering from several types of auto­
immune diseases (e.g. systemic lupus erythemato­
sus, Sjögren's syndrome, scleroderma- 
polymyositis) [397,398]. The Ku autoantigen is a 
heterodimer of p70 and p80 phosphoproteins, 
which form a DNA binding complex. This evolu­
tionary conserved nuclear complex has a high 
affinity for DNA ends but also binds DNA at nicks, 
gaps, hairpins and telomeres. Ku also displays an 
ATP-dependent helicase activity [398] and is the 
regulatory subunit of DNA-dependent protein 
kinase (DNA-PK) that phosphorylates many key 
proteins (e.g. p53, SV40 large T, topoisomerases, 
hsp90) and transcription factors (e.g. c-jun, c-fos, c- 
myc, oct-1, sp-1, TFIID).
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Given this broad substrate range it is not sur­
prising that DNA-PK is a multifunctional protein 
involved in many processes like dsDNA break 
repair (via non homologous end joining (NHEJ)), V 
(D)J recombination, DNA replication, transcrip­
tional regulation, cell cycle control and heat shock 
response. Furthermore, DNA-PK is also associated 
with a function in telomere maintenance, possibly 
by the access-control of nucleases and recombi- 
nases [399].
Ku heterodimers, expressed throughout the cell 
cycle, are not always associated with the large 
catalytic subunit of DNA-PK (DNA-PKcs). For 
instance the DNA-PKcs, unlike the p70/p80 
heterodimer, is not localized at the periphery of 
condensed chromosomes during mitosis [400]. It 
therefore is likely that Ku p70/p80 also functions 
beyond its association with DNA-PK. Mutation of 
yeast Ku DNA resulted in abnormally short 
telomeres [401] and disrupts the subnuclear 
organization of telomeres [402]. Next to that the 
granular pattern of scRAP-1p was changed into a 
diffuse localization in the nucleoplasm.
From knockout studies in mice it was 
concluded that Ku p80 suppresses chromosomal 
aberration and malignant transformation [403]. Ku, 
therefore, seems to have a caretaker function in the 
maintenance of chromosomal integrity. Ku p70, 
essential in NHEJ, interacts with NHEJ-associated 
protein MRE11 that also functions in homologous 
recombination during meiosis [404].
Analysis of Ku expression during melanocytic 
tumor progression showed a downregulation of 
expression in the early phases of melanoma 
progression. This decreased expression in primary 
melanoma correlated with a decreased patient 
survival [405].
Given the small number of possible interacting 
clones found and the relatively high percentage of 
telomere function-associated proteins among them 
we speculate on a role of XAGE-1b and possibly 
also SPANXC in telomere maintenance.
TELO M ERIC  NUCLEOPRO TEIN  COM PLEX
Telomeres are the protective ends of 
chromosomes, consisting of a number of repeat se­
quences (in mammals TTAGGG). These telomeres 
have two main functions. First they circumvent the 
replication problem of DNA ends, mainly 
regulated by telomerase [406]. Secondly, telomeres 
protect the DNA ends from activities of the dsDNA 
break repair system and exonucleases. Telomere 
homeostasis is thought to be achieved by the 
switching between telomere capping, involving the 
high-order telomeric DNA-protein complex, and 
telomere uncapping activating telomerase [407].
Focussing on the protective function regulated 
by the telomeric nucleoprotein complex (to which 
more and more proteins have been shown to be 
associated) in Figure 1 a schematic representation 
of the telomeric complex is given adapted from 
recent reviews on the subject [395,396,407]. 
Included in this figure are the Yeast-Two-Hybrid 
results on putative interactions with XAGE-1b and 
SPANXC.
The protection of chromosome ends depends 
mainly on the telomere binding proteins TRF-1 and 
TRF-2. TRF-2 is a key factor in the formation of a 
protective telomeric loop (t-loop) [396]. T-loops are 
formed by the annealing of the 3'-overhang (several 
hundred nucleotides of single stranded TTAGGG) 
back into the duplex telomeric repeat, resembling 
processes involved in homologous recombination,
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Figure 1.
Telomeric nucleoprotein complex.
Putative interactions are depicted w ith arrows.
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hiding them from the DNA damage detection 
machinery. Severe telomere dysfunction can cause 
telomere fusion between chromosomes, cell 
senescence and apoptosis as shown by TRF-2 
inhibition and depletion studies in yeast [395,396].
After binding to the telomere, TRF proteins can 
recruit many telomeric proteins with a role in 
telomeric signaling and maintenance [407]. Proven 
TRF-2 binding partners are hRAP-1, the MRE11 
complex (MRE11/NBS/RAD50), and Ku p70/p80 
[394,408,409]. Interestingly, both Ku p80 and hRAP- 
1 are putative interactants of XAGE-1b, while Ku 
p70 may be associated with SPANXC. Other 
telomeric proteins are TIN-2 (associated with TRF-
1), Pot-1 which binds and protects the 3'-overhang 
and tankyrase [407]. Telomeric proteins can often 
be visualized in telomeric nuclear foci [394]. In 
yeast telomeric foci, Ku p80 co-localized with 
scRAP-1p [410]. The meiotic telomere complex is 
similar to its somatic counterpart and contains 
many of the same proteins [411].
CO NCLUSIVE REM ARKS
Taken together the data point to a role for 
SPANX and XAGE proteins in transcriptional 
regulation, which seems to be the case for the 
majority of CTAs. However, like SSX, SPANX and
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XAGE lack known DNA binding domains and are 
thus for a putative function in transcriptional 
regulation dependent on binding to chromatin- 
associated proteins or complexes. Speculative, the 
putative association with proteins like Ku and 
RAP1 might enable XAGE (and SPANX) to 
perform such a transcriptional function.
Alternatively, interaction with these telomeric 
proteins might also be important for non- 
transcriptional functions in telomeric maintenance. 
Many of the telomere-associated proteins also have 
a role in DNA break signaling. Not fully 
understood yet is how these proteins distinguish 
between the mechanisms of telomere-protection 
and break repair. Regarding the association of 
SPANX and XAGE with the Ku autoantigen it 
would be interesting to see if they can be 
phosphorylated by DNA-PK.
Main questions regarding CTAs is the role of 
their presence in gametogenic cells and tumor cells. 
Are they functional in spermatogenesis and tu- 
morigenesis or is their presence an epiphenome- 
non? The answer to this question, nicely discussed 
upon by Old in 2001 [207], is still uncertain.
Most of the CTAs w ill have certain 
programmed functions in testis based on their
stage specific expression, as already shown several 
CTAs (e.g. SCP-1). Aberrant CTA expression in 
tumors (caused by deregulation and genomic 
instability) however, unwantingly could give these 
cells spermatogenic features supporting tumor pro­
gression. Such parallels between spermatogenesis 
and tumorigenesis have also been described for 
oncogenes (e.g. c-myc, c-fos, c-jun), present in 
highly proliferative spermatogonia and tumor 
suppressor genes (e.g. p53, BRCA-1), expressed in 
spermatocytes during meiosis because of their role 
in DNA recombination and repair [412].
Main factor arguing against an initiating and 
crucial role for CTAs in tumorigenesis is their 
heterogeneous expression pattern, resulting from a 
tight interplay of DNA accessibility (methylation- 
status and nuclear localization) and presence of 
transcription factors both temporally and spatially. 
This variation in expression (inter- and intra- 
tumoral) also is the main impeding factor in use of 
these genes in cancer immunotherapy or in anti­
function strategies.
Future studies on CTA expression and their 
molecular interactants in testis and tumors might 
yield a better view on the links that exist between 
spermatogenesis and tumorigenesis.
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ISummary
Human cutaneous melanoma, the cancer origi­
nating from the melanocyte, the pigment produc­
ing cell in the skin, is one of the most aggressive 
types of tumors due to its early dissemination. The 
best therapy against melanoma is complete surgical 
removal of the primary lesion. Once melanoma 
cells have disseminated and spread to other parts 
of the body survival rates are poor.
The progression of melanoma surpasses several 
stages from common nevi to metastatic tumors. For 
diagnostic and clinical purposes it is crucial to have 
a set of marker genes that can distinguish between 
these different stages of melanocytic tumor pro­
gression. This thesis describes the identification of 
three differentially expressed genes during melano- 
cytic tumor progression using two methods of 
differential gene expression analysis.
At the start of this thesis a general introduction 
(Chapter 1) is given on the origin, classification and 
progression of human cutaneous melanoma. Addi­
tionally, chapter 1 gives an overview of the meth­
ods available for the detection of differential gene 
expression. Two of these methods have been used 
in the research described in this thesis: mRNA 
differential display (Chapters 2 and 3) and suppres­
sion subtractive hybridization (Chapter 4).
Using mRNA differential display on a panel of 
human melanoma cell lines with different metas­
tatic capacities after subcutaneous injection in im­
mune compromised nude mice, we detected sev­
eral differentially expressed genes. Two of these 
genes have been analyzed in more detail in this
thesis.
Chapter 2 describes the isolation and partial 
characterization of TM7XN1. This new member of 
the secretin subfamily of seven transmembrane 
receptors contains a large extracellular domain 
without any homologies to known protein do­
mains. Expression of TM7XN1, localized on chro­
mosome 16q13, is markedly downregulated in 
highly metastatic melanoma cell lines. TM7XN1 
could be detected in a variety of normal tissues and 
cell types. Database searches for TM7XN1-like 
genes resulted in the outlining of a group of seven 
transmembrane proteins with large extracellular 
domains: LN-TM7.
Chapter 3 deals with the isolation and charac­
terization of a gene that was only present in the 
highly metastatic melanoma cell lines. Expression 
analyses in fresh normal tissues and lesions of the 
melanocytic tumor progression lineage revealed a 
so-called cancer/testis-associated expression pro­
file. During melanocytic tumor progression expres­
sion was only detected in the malignant stages. 
Moreover, several other types of tumor cell lines 
and tumor samples expressed this transcript. This 
chromosome X-linked gene, called CTp11 
(cancer/testis protein of 11 kD), codes for a small 
highly charged protein with a bipartite nuclear 
localization signal and an acidic GAL4 transcrip­
tion activation-like C-terminus.
Transfection studies with eGFP-CTp11 fusion 
proteins showed that the nuclear localization signal 
was functional. Based on later reports of two sperm
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cell-specific genes with high homology, CTp11 was 
renamed SPANXC. SPANX genes, located as a 
gene cluster on chromosome Xq26.3-27.1, are one of 
few X-linked genes that are post-meiotically ex­
pressed.
In chapter 4 an overview of the SPANX multi­
gene family (consisting of at least 6 genes, as de­
tected by database analyses and RT-PCR) is given. 
Based on the presence or absence of a 6 amino acid 
insert in the encoded proteins these genes can be 
subdivided into two subfamilies: SPANXA-likes 
and SPANXB-likes. The SPANXA-like subfamilies 
contain transcripts with a cancer/testis-associated 
expression profile, while the SPANXB-likes seem 
specifically expressed in the germ cells (and precur­
sors) of the testis. Southern blotting and database 
analyses reveal an exclusive presence of SPANX 
genes in higher primates, suggesting that these 
genes emerged late in evolution.
Identified in a suppression subtractive hybridi­
zation experiment comparing expression profiles of 
human metastatic melanoma versus common nevo- 
cellular nevi, chapter 5 describes another can­
cer/testis-associated transcript: XAGE-1b. Northern 
blotting and RT-PCR analyses showed that XAGE- 
1b is the major transcript of the XAGE-1 gene, pre­
viously identified from Ewing's sarcoma. In normal 
tissues XAGE-1b is mainly expressed in testis and 
only sporadically in placenta and brain. Regarding 
human tumors and human tumor cell lines highest 
frequencies of XAGE-1b expression are found in 
Ewing's sarcoma and cutaneous melanoma. During 
melanocytic tumor progression XAGE-1b is exclu­
sively expressed in metastatic samples.
The putative XAGE-1b protein shares many 
features with the earlier described SPAN-Xc. Next 
to the nuclear localization it also is a highly
charged protein encode by an X-chromosome 
linked gene. Interesting is the localization in dis­
tinct nuclear speckles. The XAGE-1 gene is a mem­
ber of a multigene family on Xp11.22-21 as de­
scribed in chapter 6. High levels of homology of 
XAGEs to the GAGE and PAGE families of can­
cer/testis-associated genes (CTAs) outline a GAGE/ 
PAGE/XAGE superfamily of at least 19 genes. Re­
markably most of these genes contain a large alter­
native open reading frame. This chapter also de­
scribes the genomic organization and expression 
profiling of the first three XAGE genes. Of the 
XAGE-1 gene four splice variants (XAGE-1a to -1d) 
were detected and analyzed.
Their characteristic expression patterns qualify 
cancer/testis-associated genes as candidate antigens 
for anti-tumor immunotherapeutic strategies. In 
chapter 7 we compared expression profiles of three 
melanoma differentiation antigens with those of 
eight CTAs in melanoma metastases. These data 
show that CTAs can indeed increase the number of 
lesions positive for putative target antigens in im­
munotherapy. Moreover, efficacy of eventual poly­
valent immunotherapeutic strategies may benefit 
from the use of both differentiation antigens and 
CTAs simultaneously.
Chapter 8 outlines the large family of CTAs 
known so far. In this chapter the various tech­
niques used for CTA discovery, their chromosomal 
localization and their expression in melanoma 
(both on mRNA and protein level) are reviewed. 
Next to that the potential use of CTAs in immuno­
therapy and their role and regulation of expression 
during spermatogenesis are discussed.
The last chapter (chapter 9) of this thesis dis­
cusses the known and putative functions of various 
CTAs in testis and cancer. Many CTAs seem to
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have a role in transcriptional and cell cycle regula­
tion. In this general discussion preliminary results 
on putative interactants of XAGE-1b and SPAN-Xc, 
found by Yeast-Two-Hybrid analyses, are included. 
These data point to a possible role of XAGE-1b and 
SPAN-Xc in telomere-associated functions.
In conclusion, CTA expression in tumors may
be the result of an aberrant activation of testis- 
specific genes. Unraveling the functional role of 
CTAs and their possible use in immunotherapy 
against tumors depends on future in-depth studies. 
Such efforts may clarify the link CTAs seem to 
represent between gametogenesis and tumorigene- 
sis.
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ISamenvatting
Het melanoom van de huid, een kwaadaardige 
ontsporing van de pigment producerende melano- 
cyten in de huid, is één van de meest agressieve 
vormen van kanker. De beste therapie is 
chirurgische verwijdering van de tumor. Zodra de 
melanoomcellen zich losgemaakt hebben van de 
primaire tumor en uitzaaien naar andere plaatsen 
in het lichaam, daalt het percentage patiënten dat 
uiteindelijk overleefd dramatisch.
De ontwikkeling van het huidmelanoom 
doorloopt diverse stadia, beginnende met een 
onschuldige moedervlek tot uiteindelijk een 
uitzaaiing elders. Om een goed onderscheid te 
kunnen maken tussen de verschillende stadia van 
deze huidkanker is het van groot belang de 
beschikking te hebben over een aantal stadium- 
specifieke merkers.
Dit proefschrift beschrijft een drietal genen die 
verschillend tot expressie komen gedurende het 
verloop van de ziekte. Voor het opsporen van deze 
genen is gebruik gemaakt van twee verschillende 
technieken.
De inleiding van dit proefschrift (Hoofdstuk 1) 
beschrijft het ontstaan en het groeiproces van het 
huidmelanoom. Tevens wordt ingegaan op de 
classificatie van melanocytaire tumoren zoals die 
momenteel gehanteerd wordt. Tot slot geeft 
hoofdstuk 1 een overzicht van de vele voor handen 
zijnde methoden om genexpressie te bestuderen. 
Twee van deze methoden zijn gebruikt in het in dit 
proefschrift beschreven onderzoek: "mRNA 
differential display" (Hoofdstukken 2 and 3) en
"su p p re ss io n  su b trac tiv e  h y b rid iz a tio n "  
(Hoofdstuk 4).
Allereerst is er met behulp van "mRNA 
differential display" gekeken naar expressie- 
verschillen in een serie van diverse humane mela- 
noomcellijnen. Deze gekweekte tumorcellen 
hebben verschillende mate van agressiviteit na 
onderhuids inspuiten in muizen met een verzwakte 
afweer. Twee, met behulp van deze techniek 
gevonden, verschillend tot expressie komende 
genen zijn verder geanalyseerd en beschreven in 
dit proefschrift.
H oofdstuk 2 beschrijft de ontdekking en 
gedeeltelijke karakterisatie van TM7XN1. Dit gen 
bleek een nieuw lid van de secretine subfamilie van 
zeven-transmembraan eiwitten in de celwand. Dit 
eiwit heeft een voor deze familie opmerkelijk lange 
uitwendige staart. De functie van deze staart is nog 
onbekend.
In ons panel van humane melanoomcellijnen 
bleek de aanwezigheid van TM7XN1 aanzienlijk 
minder in de cellijnen met een hoge mate van 
agressiviteit. Bestudering van TM7XN1 liet 
aanwezigheid zien in diverse typen normale cellen 
en weefsels. In het genoom (DNA) is TM7XN1 
gelocaliseerd op chromosoom 16q13. Databank 
analyses voor TM7XN1-achtige genen resulteerde 
in een aantal homologe zeven-transmembraan 
genen m et lange u itw endige gebieden, 
samengevoegd onder de naam LN-TM7.
In H oofdstuk 3 wordt de isolatie en 
gedeeltelijke karakterisatie van een gen beschreven
Samenvatting 175
dat uitsluitend voorkomt in de melanoomcellijnen 
die vaak u itzaaien (in het muizenmodel). Analyse 
van de aanwezigheid in allerlei normale weefsels 
en in diverse typen tumoren toont een specifiek 
kanker/testis profiel. In de ontwikkeling van 
humane melanocytaire tumoren komt dit gen 
alleen voor in de kwaadaardige stadia. Dit gen, 
gelegen op chromosoom X, kreeg van ons de naam 
CTp11 ("cancer/testis-protein" van 11 kD groot).
CTp11 bleek een klein, sterk geladen eiwit met 
een kernsignaal en een negatief geladen staart die 
lijkt op een GAL4 domein. Zo'n GAL4 domein kan 
andere genen aanzetten tot activiteit. Studies met 
een fusie eiwit van CTp11 en een groen 
fluorescerend eiwit (eGFP) lieten inderdaad zien 
dat dit eiwit zich in de kern bevindt. Naar 
aanleiding van de publicatie van twee zaadcel- 
specifieke genen die sterk lijken op CTp11 is deze 
later hernoemd tot SPANX type C.
SPANX genen, gelegen naast elkaar in een 
gencluster op chromosoom Xq26.3-27.1, behoren 
tot de weinige genen van het X-chromosoom die na 
de meiose (een bepaalde delingsfase in de 
productie van voortplantingscellen) tot expressie 
komen.
H oofdstuk 4 beschrijft de SPANX familie die 
volgens allerlei analyses bestaat uit tenminste 6 
genen. De SPANX familie kan op basis van aan- of 
afwezigheid van 6 extra aminozuren in de bijbe­
horende eiwitten worden ingedeeld in twee sub­
families: SPANXA-achtigen en SPANXB. De 
SPANXA subfamilie bevat eiwitten met een 
kanker/testis profiel. SPANXB lijkt alleen voor te 
komen in spermacellen (en enkele van hun 
voorloperstadia) in de testis.
Aanwezigheid van SPANX genen, bepaald met 
behulp van DNA en databank analyses, lijkt
specifiek voor mensapen, wat suggereert dat deze 
genen laat in de evolutie zijn verschenen.
Naast tumor cellijnen is ook gebruik gemaakt 
van verse humane huidtumoren voor het opsporen 
kankergenen. Met behulp van "suppression 
subtractive hybridization" zijn de aanwezig- 
heidsprofielen van genen in uitzaaiingen ver­
geleken met die van moedervlekken.
H oofdstuk 5 beschrijft een ander nieuw 
kanker/testis-specifiek gen dat werd gevonden met 
deze studie: XAGE-1b. Analyse van aanwezigheid 
(van expressie) laten zien dat XAGE-1b het 
voornaamste deel is van het XAGE-1 gen, 
oorspronkelijk gevonden in een ander type kanker 
(Ewing's sarcoom). Met betrekking tot normale 
weefsels komt XAGE-1b voornamelijk voor in 
testis, en sporadisch in placenta en hersenen. In 
tumoren en tumor cellijnen komt XAGE-1b het 
meest frequent voor in Ewing's sarcoom en 
melanoom. In melanocytaire tumoren is XAGE-1b 
alleen aantoonbaar in uitzaaiingen.
Het XAGE-1b eiwit toont sterke overeen­
komsten met het eerder beschreven SPANX type C. 
Naast localisatie in de celkern zijn beide eiwitten 
sterk geladen en zijn beide genen gelegen op 
chromosoom X. Opvallend is het gespikkelde 
patroon van XAGE-1b in de kern.
Het XAGE-1 gen behoort tot een genfamilie 
gelegen op Xp11.22-21 zoals beschreven in 
hoofdstuk 6. Sterke homologie van de XAGE 
genen met de GAGE en PAGE families van 
kanker/testis genen rechtvaardigt de vorming van 
een GAGE/PAGE/XAGE superfamilie bestaande 
uit tenminste 19 genen. Opvallend is dat bijna alle 
genen behorende tot deze superfamilie naast hun 
langste eiwitcode ook voor een vrij alternatief eiwit 
kunnen coderen.
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Hoofdstuk 6 behandelt ook de genomische 
organisatie en een eerste aanwezigheidprofiel van 
de eerste drie XAGE genen. Van het XAGE-1 gen 
zijn vier varianten (XAGE-1a t/m -1d) gevonden en 
bekeken.
Gezien hun specifieke profiel zijn de 
kanker/testis genen goede kandidaatgenen voor 
gebruik in antitumor strategieën met name in 
immuuntherapie. In hoofdstuk 7 hebben we de 
aanwezigheid van drie pigmentcel-specifieke 
genen met die van acht kanker/testis genen 
vergeleken in een uitgebreide serie melanoom- 
uitzaaiingen. Uit deze gegevens blijkt dat 
kanker/testis genen het aantal tumoren kan 
vergroten dat positief is voor deze eiwitten, die 
mogelijk doelwit zijn van anti-tumor strategieën 
gebaseerd op immuuntherapie. Tevens zou de 
effectiviteit van de therapie gebaat kunnen zijn bij 
een aanpak waarbij zowel pigment-cel als 
kanker/testis genen tegelijk worden aangevallen.
H oofdstuk 8 geeft een overzicht van de familie 
van kanker/testis genen die tot nu toe zijn 
beschreven. Dit hoofdstuk behandelt de technieken 
die zijn gebruikt voor het opsporen van 
kanker/testis genen en beschrijft de chromosomale 
localisatie van de genen en hun aanwezigheid in 
melanoom huidkanker. Verder wordt de potentie
van deze genen voor gebruik in immuuntherapie 
besproken en wordt aandacht besteed aan hun 
mogelijke rol in de regulatie van zaadcel produktie.
Het laatste hoofdstuk (hoofdstuk 9) van dit 
proefschrift gaat in op bekende en mogelijke 
functies van enkele kanker/testis eiwitten in testis 
en tumoren. Veel van deze eiwitten lijken een rol te 
spelen in regulatie van de celcyclus. Tevens wordt 
aandacht besteed aan de voorlopige resultaten van 
"Yeast-Two-Hybrid" analyse op eiwitten die 
binden aan XAGE-1b en SPAN-XC. Deze gegevens 
wijzen op een mogelijke rol voor XAGE-1b en 
SPAN-XC in processen aan de uiteinden van 
chromosomen (telomeren).
Samenvattend lijkt de aanwezigheid van 
kanker/testis genen in kanker een gevolg te zijn van 
een oneigenlijke activatie van testis-specifieke 
genen. Voor de verdere bestudering omtrent de 
functionele rol van deze genen in tumoren, 
alsmede de potentie van het gebruik in anti-tumor 
immuuntherapie zijn aanvullende studies nood­
zakelijk. Naar alle waarschijnlijkheid zullen deze 
studies inzicht geven in het verband dat 
kanker/testis genen lijken te leggen tussen het 
proces van voortplantingscel productie en de 
ontwikkeling van kanker.
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IColour plates
Figure 6. Chapter 3 page 52
Fluorescence microscopy of COS-1 cells transfected with a construct containing only eGFP (A, B, C) or the full-length 
CTp11 cDNA/eGFP fusion-construct (D, E, F). DAPI-images show cell nuclei. (A, D), while GFP-images show eGFP (B) and 
cDNA-eGFP (E) distribution. Finally, the merged images of A and B (C) and D and E (F) are represented.
**,
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Figure 7. Chapter 5 page 87
Fluorescence microscopy of COS-1 cells transfected with constructs containing ORFs for eGFP (a, e, i), XAGE-1b/eGFP (b, 
f, j, m), DsRed (c, g, k), XAGE-1b/DsRed (d, h, l), eGFP/XAGE-1b (n), XAGE-1a/eGFP (o), eGFP/XAGE-1a (p), and XAGE- 
1a/eGFP in combination with XAGE-1b/DsRed (q-s). DAPI images show nuclei (a-d), eGFP-derived fluorescence is shown 
in green (e, f, i, j, m-p, q, s), while red coloring represents fluorescence of the DsRed (g, h, k, l, r, s). In images m-p eGFP- 
derived fluorescences are merged with the corresponding DAPI recordings. Other merged images are derived of a and e 
(i), b and f (j), c and g (k), d and h  (l), and q and r (s).
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